{"$schema":"https:\/\/assets.cochrane.org\/schema\/v1\/studies.schema.json","review-level-concepts":{"characteristic-definitions":[{"name":"Notes"},{"name":"Outcomes"},{"name":"Interventions"},{"name":"Participants"},{"name":"Methods"}],"covariate-definitions":[],"interventions":[{"name":"Probiotic","description":""},{"name":"No probiotic","description":""},{"name":"Synbiotics","description":""},{"name":"No synbiotics","description":""}],"outcomes":[{"name":"Cow's milk protein allergy by 2 years","description":"","type":"DICHOTOMOUS"},{"name":"Asthma by 10 years","description":"","type":"DICHOTOMOUS"},{"name":"Allergic rhinitis by 10 years","description":"","type":"DICHOTOMOUS"},{"name":"Eczema by 10 years","description":"","type":"DICHOTOMOUS"},{"name":"Eczema by 2 years","description":"","type":"DICHOTOMOUS"},{"name":"Asthma by 2 years","description":"","type":"DICHOTOMOUS"},{"name":"Food allergy by 2 years","description":"","type":"DICHOTOMOUS"},{"name":"Allergic rhinitis by 2 years","description":"","type":"DICHOTOMOUS"}],"risk-of-bias-domains":[{"name":"Bias arising from the randomization process","study-level":true},{"name":"Bias due to deviations from intended interventions","study-level":false},{"name":"Bias due to missing outcome data","study-level":false},{"name":"Bias in measurement of the outcome","study-level":false},{"name":"Bias in selection of the reported result","study-level":false},{"name":"Overall bias","study-level":false}]},"studies":[{"name":"Kopp 2008","year":"2008","data-source":"PUB","identifiers":[{"name":"CRS","value":"2621304"}],"references":[{"reference-type":"JOURNAL_ARTICLE","primary":true,"authors":"Kopp MV, Hennemuth I, Heinzmann A, Urbanek R","title":"Randomized, double-blind, placebo-controlled trial of probiotics for primary prevention: no clinical effects of Lactobacillus GG supplementation","original-title":"","source":"Pediatrics","publication-date":"2008","volume":"121","issue":"4","pages":"e850-6","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"2621306"},{"name":"DOI","value":"10.1542\/peds.2007-1492"},{"name":"PUBMED","value":"18332075"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Kopp MV, Goldstein M, Dietschek A, Sofke J, Heinzmann A, Urbanek R","title":"Lactobacillus GG has in vitro effects on enhanced interleukin-10 and interferon-gamma release of mononuclear cells but no in vivo effects in supplemented mothers and their neonates","original-title":"","source":"Clinical and Experimental Allergy","publication-date":"2008","volume":"38","issue":"4","pages":"602-10","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"2621305"},{"name":"DOI","value":"10.1111\/j.1365-2222.2007.02911.x"},{"name":"PUBMED","value":"18167121"}]}],"characteristics":[{"name":"Notes","value":"<p><b>Sponsor: <\/b>supported by the University of Freiburg and by Infectopharm, Heppenheim, Germany.<\/p>\n<p><b>Declaration: <\/b>not reported.<\/p>"},{"name":"Methods","value":"<p>Double-blind, randomised, placebo-controlled prospective trial.<\/p>"},{"name":"Participants","value":"<p><b>Inclusion criteria: <\/b>pregnant women with:<\/p>\n<ul>\n <li>an uneventful pregnancy;<\/li>\n <li>absence of underlying chronic disease; and<\/li>\n <li>a family history of atopic disease: 1 family member (mother, father, or older sibling) with AD, allergic rhinitis, or asthma and a confirmed allergic sensitisation against an inhalant allergen.<\/li>\n<\/ul>\n<p><b>Exclusion critiera<\/b>: none stated.<\/p>"},{"name":"Interventions","value":"<p><b>Treatment (n = 54):<\/b> L. rhamnosus GG (ATCC 53103) containing 5 x 10<sup>9<\/sup> cfu daily for 4 – 6 weeks before expected delivery. Capsules taken post-natally for 6 months. Directly after delivery, breastfeeding mothers took the capsules; otherwise, children received the agents (n = 2 in the LGG group, n = 3 in the placebo group). After 3 months, capsules were given only to the neonates.<\/p>\n<p><b>Control (n = 51): <\/b>placebo (microcrystalline cellulose).<\/p>\n<p>Duration of breastfeeding: median treatment 9 months, control 8 months.<\/p>"},{"name":"Outcomes","value":"<p><b>Primary outcome:<\/b> prevention of atopic diseases during the first 2 years of life.<\/p>\n<p><b>Other outcomes:<\/b> severity of atopic dermatitis, the cumulative incidence of atopic dermatitis, the incidence of recurrent (5 episodes) wheezing bronchitis, total immunoglobulin E (IgE) and the number of children with sensitisation to an inhalant allergen at the age of 2 years.<\/p>\n<p><br><b>Definitions: <\/b>questionnaires and blinded physician examination. Physicians underwent standardised training program.<br>\n Eczema confirmed by pruritus, facial or extensor involvement, or both, and chronic relapsing course by using United Kingdom Working Party criteria (William 1994). The criterion (quote:) “chronic relapsing course” fulfilled if child had eczema for 1 month. The severity scoring of atopic dermatitis (Scoring Atopic Dermatitis Index) was used to assess eczema severity.<br>\n Skin prick tests, sensitisation to inhalant allergens and total IgE performed at 2 years reported for all infants.<\/p>"}],"covariates":[],"arms":[{"name":"No probiotics","description":"","intervention":"No probiotic"},{"name":"Probiotics","description":"","intervention":"Probiotic"}],"results":[{"outcome":"Eczema by 2 years","arm-level-result":{"dichotomous-data-rows":[{"arm":"No probiotics","cases":12,"sample-size":44},{"arm":"Probiotics","cases":14,"sample-size":50}],"risk-of-bias":[{"domain":"Bias due to deviations from intended interventions","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>Placebo used (microcrystalline cellulose). LGG and placebo capsules were made identical in appearance, taste, smell and packing. The physicians who conducted the physical examinations and diagnoses of atopic disease were unaware of the contents of the capsules until the end of the study.<\/p><p>Per-protocol analysis.<\/p>"},{"domain":"Bias due to missing outcome data","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>11\/105 (10.5%) withdrew from the study during the follow-up or were excluded from the analysis because of major protocol violation. No details for the reason of drop-out were detailed.&nbsp;<\/p>"},{"domain":"Bias in measurement of the outcome","judgement":"LOW_RISK","support-for-judgement":"<p>The primary end point was the manifestation of an atopic disease at the age of 2 years. Specific definitions for allergy reported. Primary outcomes were measured by validated and appropriate methods.&nbsp;<\/p>"},{"domain":"Bias in selection of the reported result","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>No pre-specified analysis plan. UKF00505.<\/p>"},{"domain":"Overall bias","judgement":"HIGH_RISK","support-for-judgement":"<p>The study is judged to have some concerns for multiple domains in a way that substantially lowers confidence in the result.<\/p>"}]}}],"risk-of-bias":[{"domain":"Bias arising from the randomization process","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>Blocks of 4 according to a computerised randomisation list. Computer randomised and blinded. Allocation concealment was not described.<\/p><p>No significant differences at baseline between groups in family history of atopy.<\/p>"}]},{"name":"Niers 2009","year":"2009","data-source":"PUB","identifiers":[{"name":"CRS","value":"2621320"}],"references":[{"reference-type":"JOURNAL_ARTICLE","primary":true,"authors":"Niers L, Martin R, Rijkers G, Sengers F, Timmerman H, van Uden N, et al","title":"The effects of selected probiotic strains on the development of eczema (the PandA study)","original-title":"","source":"Allergy","publication-date":"2009","volume":"64","issue":"9","pages":"1349-58","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"23696210"},{"name":"DOI","value":"10.1111\/j.1398-9995.2009.02021.x"},{"name":"PUBMED","value":"19392993"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Kim HK, Rutten NB, Besseling-van der Vaart I, Niers LE, Choi YH, Rijkers GT, et al","title":"Probiotic supplementation influences faecal short chain fatty acids in infants at high risk for eczema","original-title":"","source":"Beneficial Microbes","publication-date":"2015","volume":"6","issue":"6","pages":"783-90","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958454"},{"name":"DOI","value":"10.3920\/BM2015.0056"},{"name":"PUBMED","value":"26565082"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Rutten NB, Gorissen DM, Eck A, Niers LE, Vlieger AM, Besseling-van der Vaart I, et al","title":"Long term development of gut microbiota composition in atopic children: impact of probiotics","original-title":"","source":"PLOS One","publication-date":"2015","volume":"10","issue":"9","pages":"e0137681","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958456"},{"name":"DOI","value":"10.1371\/journal.pone.0137681"},{"name":"PUBMED","value":"26378926"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Gorissen DM, Rutten NB, Oostermeijer CM, Niers LE, Hoekstra MO, Rijkers GT, et al","title":"Preventive effects of selected probiotic strains on the development of asthma and allergic rhinitis in childhood. The Panda study","original-title":"","source":"Clinical and Experimental Allergy","publication-date":"2014","volume":"44","issue":"11","pages":"1431-3","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958453"},{"name":"DOI","value":"10.1111\/cea.12413"},{"name":"PUBMED","value":"25227163"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Niers L, Martín R, Rijkers G, Sengers F, Timmerman H, van Uden N, et al","title":"Correction for: Niers et al. The effects of selected probiotic strains on the development of eczema (the PandA study)","original-title":"","source":"Allergy","publication-date":"2020","volume":"75","issue":"","pages":"2719","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"23696211"},{"name":"DOI","value":"10.1111\/all.14312"}]}],"characteristics":[{"name":"Methods","value":"<p>Double-blind, randomised, placebo-controlled trial.<\/p>"},{"name":"Participants","value":"<p><b>Inclusion criteria: <\/b>pregnant women and their families were included at least 2 months before expected delivery (n = 156).<\/p>\n<p>Families with a positive family history of allergic disease, i.e. atopic eczema, food allergy, asthma or allergic rhinitis in either the mother, or the father plus an older sibling with a history of allergic disease.<\/p>\n<p><b>Exclusion criteria: <\/b>if their mother received antibiotic treatment during the last 2 weeks of pregnancy, child born before 37 weeks' gestation, children received antibiotic treatment in the first 2 weeks of life, if ingestion of the study product was difficult because of vomiting or feeding problems in general for longer than 3 weeks from birth, or if the children had other major medical problems.<\/p>"},{"name":"Interventions","value":"<p>Probiotic bacteria were prenatally administered to the pregnant mothers during the last 6 weeks of pregnancy and postnatally for 12 months to their offspring. The intervention was mixed with at least 10 ml of water, breast milk or infants' formula, depending on the choice of feeding by the parents, and ingested as a suspension.<\/p>\n<p><b>Intervention group (n = 78): <\/b>once daily 3 x 10<sup>9<\/sup> cfu (1 x 10<sup>9<\/sup> cfu of each: B. bifidum W23, Bifidobacterium lactis W52 (previously classified as Bifidobacterium infantis), and Lc lactis W58) freeze-dried powder of the probiotic mixture.<\/p>\n<p><b>Control group (n = 78):<\/b> placebo consisting of the carrier of the probiotic product, i.e. rice starch and maltodextrin. Breastfeeding treatment group 84%, control group 79%). Mean duration of breastfeeding treatment group 7.0 months, control group 7.2 months.<\/p>"},{"name":"Outcomes","value":"<p><b>Primary outcome: <\/b>development of eczema during the first 2 years of life, and the initial effects on early microbial colonisation and immune responses. Symptoms indicative of food allergy, eczema, asthma and allergic rhinitis at age of 3, 12 and 24 months were evaluated.<\/p>\n<p><b>Other outcome:<\/b> compliance and problems experienced with the daily administration of the study product. 6 year follow-up study included the preventative effect of probiotics on the prevalence of asthma, allergic rhinitis and eczema in these high risk children.&nbsp;<\/p>\n<p><b>Definitions: <\/b>Parental reported eczema from diaries completed weekly.<\/p>\n<p>Physician diagnosed eczema was defined as eczema reported by the parents and diagnosed as eczema by the family doctor or consulted physician.<br>\n Eczema was defined as non-infectious dermatitis with typical features (redness, dryness, oedema, oozing and itching (scratching)) and distribution.<\/p>\n<p>Atopic eczema was defined as eczema plus sensitisation, i.e. detectable (&gt; 0.35 IU\/ml) allergen specific IgE antibodies or a positive SPT.<\/p>\n<p>6 year follow-up study included diagnosed allergic diseases from the treating family doctor, complete physical examinations, blood sampling and lung function testing.&nbsp;<br>\n Asthma was defined as at least 1 of the following 4 criteria: doctors diagnosed asthma active in the past 12 months, parental reported wheezing in the past 12 months, use of asthma medication in the past 12 months or an at least 9% reversibility in the forced expiratory volume in half a second (FEV 0.5) or in one second (FEV1).<br>\n Allergic rhinitis was defined according to the ARIA guidelines (Bousquet 2008).&nbsp;<br>\n Food allergy was defined as doctor diagnosed food allergy, combined with sensitisation to food allergens.&nbsp;<br>\n Eczema was defined according to the Williams UK Working Party's criteria (William 1994).<\/p>"},{"name":"Notes","value":"<p><b>Sponsor: <\/b>declared independent study. 1 &nbsp;author employee of probiotic manufacturer (Winclove Bio Industries B.V., Amsterdam).&nbsp;<\/p>\n<p>Outcomes of allergic disease at 6 years of age included in analysis under childhood incidence.<\/p>\n<p><b>Declaration of interests:<\/b> HT was an employee of Winclove Bio Industries and the University Medical Centre Utrecht. All of the other authors declared that they had no conflict of interest.<\/p>"}],"covariates":[],"arms":[{"name":"No probiotics","description":"","intervention":"No probiotic"},{"name":"Probiotics","description":"","intervention":"Probiotic"}],"results":[{"outcome":"Eczema by 2 years","arm-level-result":{"dichotomous-data-rows":[{"arm":"No probiotics","cases":33,"sample-size":48},{"arm":"Probiotics","cases":27,"sample-size":50}],"risk-of-bias":[{"domain":"Bias due to deviations from intended interventions","judgement":"LOW_RISK","support-for-judgement":"<p>Placebo consisted of the carrier of the probiotic bacteria mixture - rice starch and maltodextrin. Both supplements were dispensed as a stable powder in identical individually packed sachets containing 3 g of material.<\/p><p>Double Blind (Participant, Caregiver, Investigator, Outcomes Assessor).<\/p>"},{"domain":"Bias due to missing outcome data","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>58\/156 (37%) post-randomisation losses - 54 exclusion criteria, 21 parental requests, 8 (all control group) excluded due to non-compliance. Completed study at 2 years: probiotic group 50\/78 (64%); placebo group 48\/78 (62%). 83 participants of the former P and A study participated in the follow-up study at the age of 6 years: probiotic group 39, placebo group 44. High drop-out right, although described to not be related to study intervention.<\/p>"},{"domain":"Bias in measurement of the outcome","judgement":"LOW_RISK","support-for-judgement":"<p>Primary outcomes: Incidence and severity of atopic disease at the age of 2 years. Incidence and prevalence of eczema at 2 years. Specific definitions for allergic disease or food hypersensitivity, or both, reported. Not all infants with parental reported eczema examined by physician.<\/p>"},{"domain":"Bias in selection of the reported result","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>No prespecified analysis plan. NCT00200954.<\/p>"},{"domain":"Overall bias","judgement":"HIGH_RISK","support-for-judgement":"<p>The study is judged to have some concerns for multiple domains in a way that substantially lowers confidence in the result.<\/p>"}]}}],"risk-of-bias":[{"domain":"Bias arising from the randomization process","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>Block randomisation with a block size of 10 was used. Method of sequence generation not reported. Statistically significant imbalance between groups in frequency of pets at home.<\/p><p>Study investigators ensured that randomisation was successful with placebo and intervention groups being equal with respect to potential risk factors and confounders. Allocation concealment method not described. 54\/156 excluded after randomisation as met exclusion criteria.<\/p>"}]},{"name":"Rautava 2006","year":"2006","data-source":"PUB","identifiers":[{"name":"CRS","value":"2621324"}],"references":[{"reference-type":"JOURNAL_ARTICLE","primary":true,"authors":"Rautava S, Arvilommi H, Isolauri E","title":"Specific probiotics in enhancing maturation of IgA responses in formula-fed infants","original-title":"","source":"Pediatric Research","publication-date":"2006","volume":"60","issue":"2","pages":"221-4","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"2621325"},{"name":"DOI","value":"10.1203\/01.pdr.0000228317.72933.db"},{"name":"PUBMED","value":"16864708"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Rautava S, Salminen S, Isolauri E","title":"Specific probiotics in reducing the risk of acute infections in infancy – a randomised, double-blind, placebo-controlled study","original-title":"","source":"British Journal of Nutrition","publication-date":"2009","volume":"101","issue":"11","pages":"1722-6","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"2621326"},{"name":"PUBMED","value":"18986600"},{"name":"DOI","value":"10.1017\/S0007114508116282"}]}],"characteristics":[{"name":"Notes","value":"<p><b>Sponsor: <\/b>funded by the Microbes and Man Research Program, Academy of Finland, and the Sigrid Juselius Foundation.<\/p>\n<p><b>Declaration of interest: <\/b>not reported.<\/p>"},{"name":"Outcomes","value":"<p><b>Primary outcomes:<\/b> effects of probiotic supplementation in reducing the risk of infectious disease in infants devoid of the recommended 6 months of exclusive breast-feeding.<\/p>\n<p><br><b>Other outcomes:<\/b> clinical examination at 3, 7, and 12 months. Skin prick test performed at ages 7 and 12 months.&nbsp;<br>\n &nbsp;<\/p>\n<p><b>Definitions<\/b><\/p>\n<p>Atopic eczema: criteria introduced by Hanifin and Rajka (Hanifin 1980).<br>\n Cow’s milk hypersensitivity: Confirmed by double-blind, placebo-controlled cow’s milk challenge. CMA confirmed by SPTs at the ages of 7 and 12 months.<\/p>"},{"name":"Interventions","value":"<p>81 infants randomised to receive infant formula (Enfamil, Mead Johnson Nutritionals, Evansville, IN) supplemented with either:<br><b>Treatment (n = 38): <\/b>1 x 10<sup>10<\/sup> colony-forming units of Lactobacillus rhamnosus (Lactobacillus GG, American type culture collection 53103, Valio Ltd., Helsinki, Finland) and Bifidobacterium lactis Bb-12 (Chr. Hansen, Hoersholm, Denmark) daily until the age of 12 months; or<\/p>\n<p><br><b>Control (n = 43): <\/b>Placebo (microcrystalline cellulose).<br>\n The intervention was commenced when the need for artificial feeding arose and the supplemented formula was to be used as the sole infant formula during the study period.&nbsp;<\/p>"},{"name":"Participants","value":"<p><b>Inclusion criteria: <\/b>need for artificial feeding before the age of 2 months. Intervention commenced when the need for artificial feeding arose and the supplemented formula was to be used as the sole infant formula. Not selected on basis of risk of allergy.<\/p>\n<p><br><b>Exclusion criteria: <\/b>infants with chronic disease.<\/p>"},{"name":"Methods","value":"<p>Randomised, double-blind, placebo-controlled clinical trial.<\/p>"}],"covariates":[],"arms":[{"name":"No probiotics","description":"","intervention":"No probiotic"},{"name":"Probiotics","description":"","intervention":"Probiotic"}],"results":[{"outcome":"Cow's milk protein allergy by 2 years","arm-level-result":{"dichotomous-data-rows":[{"arm":"No probiotics","cases":1,"sample-size":40},{"arm":"Probiotics","cases":0,"sample-size":32}],"risk-of-bias":[{"domain":"Bias due to deviations from intended interventions","judgement":"LOW_RISK","support-for-judgement":"<p>Placebo (microcrystalline cellulose).<\/p><p>All investigations were performed double-blind; the code was opened after all the infants had completed the study and data had been edited.<\/p>"},{"domain":"Bias due to missing outcome data","judgement":"LOW_RISK","support-for-judgement":"<p>Losses to follow up: 9\/81 (11%). Excluded infants discontinuing treatment. Probiotic group n = 6 loss to follow up - 2 discontinued due to gastrointestinal complaints, 1 for arduousness of study, 1 found formula inconvenient and 2 lost to follow up; placebo group n = 3 lost contact - 1 discontinued due to gastrointestinal complaints, 1 because of arduousness of study and 1 lost contact. Drop outs were not described to be due to study intervention.&nbsp;<\/p>"},{"domain":"Bias in measurement of the outcome","judgement":"LOW_RISK","support-for-judgement":"<p>Allergy outcomes not reported to be prespecified. Primary outcomes including IgA secreting cells and serum levels were measured using appropriate validated clinical methods.<\/p>"},{"domain":"Bias in selection of the reported result","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>No pre-specified analysis plan. No clinical trial registry number found.<\/p>"},{"domain":"Overall bias","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.<\/p>"}]}},{"outcome":"Eczema by 2 years","arm-level-result":{"dichotomous-data-rows":[{"arm":"No probiotics","cases":8,"sample-size":40},{"arm":"Probiotics","cases":4,"sample-size":32}],"risk-of-bias":[{"domain":"Bias due to deviations from intended interventions","judgement":"LOW_RISK","support-for-judgement":"<p>Placebo (microcrystalline cellulose).<\/p><p>All investigations were performed double-blind; the code was opened after all the infants had completed the study and data had been edited.<\/p>"},{"domain":"Bias due to missing outcome data","judgement":"LOW_RISK","support-for-judgement":"<p>Losses to follow up: 9\/81 (11%). Excluded infants discontinuing treatment. Probiotic group n = 6 loss to follow up - 2 discontinued due to gastrointestinal complaints, 1 for arduousness of study, 1 found formula inconvenient and 2 lost to follow up; placebo group n = 3 lost contact - 1 discontinued due to gastrointestinal complaints, 1 because of arduousness of study and 1 lost contact. Drop outs were not described to be due to study intervention.&nbsp;<\/p>"},{"domain":"Bias in measurement of the outcome","judgement":"LOW_RISK","support-for-judgement":"<p>Allergy outcomes not reported to be prespecified. Primary outcomes including IgA secreting cells and serum levels were measured using appropriate validated clinical methods.<\/p>"},{"domain":"Bias in selection of the reported result","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>No pre-specified analysis plan. No clinical trial registry number found.<\/p>"},{"domain":"Overall bias","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.<\/p>"}]}}],"risk-of-bias":[{"domain":"Bias arising from the randomization process","judgement":"LOW_RISK","support-for-judgement":"<p>Block randomisation with individual codes. Random allocation was generated independently from the investigators by the manufacturer of the capsules.<\/p><p>Assessed for eligibility then randomised. Random allocation was generated by independent personnel - allocation was concealed from participants and researchers.<\/p>"}]},{"name":"Ortiz-Andrellucchi 2008","year":"2008","data-source":"PUB","identifiers":[{"name":"CRS","value":"2621322"}],"references":[{"reference-type":"JOURNAL_ARTICLE","primary":true,"authors":"Ortiz-Andrellucchi A, Sanchez-Villegas A, Rodriguez-Gallego C, Lemes A, Molero T, Soria A, et al","title":"Immunomodulatory effects of the intake of fermented milk with Lactobacillus casei DN114001 in lactating mothers and their children","original-title":"","source":"British Journal of Nutrition","publication-date":"2008","volume":"100","issue":"4","pages":"834-45","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"2621323"},{"name":"DOI","value":"10.1017\/S0007114508959183"},{"name":"PUBMED","value":"18341756"}]}],"characteristics":[{"name":"Methods","value":"<p>Randomised, controlled, double-blind intervention study with parallel groups.<\/p>"},{"name":"Participants","value":"<p><b>Inclusion criteria: <\/b>pregnant women aged 18 – 40 years in good general health, low obstetric risk with a normal delivery of a healthy baby.<\/p>\n<p><b>Exclusion criteria:<\/b> participants &nbsp;with pre-existing conditions such as diabetes, hypertension, autoimmune diseases, asthma, allergy, renal diseases, hepatic diseases, antecedents of viral, bacterial or protozoan infection, multiple pregnancy, high-risk pregnancy, anaemia with Hb below 10·5% and those who smoked &gt; 10 cigarettes\/d.<\/p>"},{"name":"Interventions","value":"<p><b>Treatment (n = 59):<\/b> milk fermented with L. casei DN-114001 consumed 3 times\/day for 6 weeks, or<\/p>\n<p><b>Control (n = 45):<\/b> placebo (killed L. casei).<\/p>\n<p>Breastfed: probiotic group 92·6%, control group 81·6%.<\/p>\n<p>The administration of the study products consisted of consumption 3 times per day during 6 weeks. Initiation of the fermented milk intake occurred on the day following the first extraction of blood and breast milk samples.<\/p>"},{"name":"Outcomes","value":"<p><b>Primary outcomes:<\/b> to determine if probiotic modulated immune system in women who had recently delivered and were breast-feeding; role of probiotic intake on cytokines in maternal milk and on newborn health variables was also ascertained.<\/p>\n<p><br><b>Other outcomes: <\/b>antropometry, respiratory episodes (cold, otitis, pharyngitis, laryngitis, bronchitis, pneumonia), gastrointestinal symptoms (oral candidiasis, regurgitation, diarrhoea, colic, constipation)<\/p>\n<p><b>Definitions: <\/b>evaluated dermatitis and allergic episodes at 2 and 6 months. Definition of dermatitis (communication from author) does not meet review definition for eczema (dermatitis&nbsp;defined as erythematous&nbsp;lesions, with pruritus, presence of cradle cap, peeling and flaking (scaliness or desquamation).<\/p>\n<p>Cow's milk allergy was confirmed by serological test and clinical diagnosis.<\/p>"},{"name":"Notes","value":"<p><b>Sponsor: <\/b>Danone SA through research contract with the University Foundation of Las Palmas. One author worked for Danone S. A.<\/p>\n<p><b>Declaration of interests:<\/b> J.C worked for Danone. None of the other authors had a conflict of interest.<\/p>"}],"covariates":[],"arms":[{"name":"No probiotics","description":"","intervention":"No probiotic"},{"name":"Probiotics","description":"","intervention":"Probiotic"}],"results":[{"outcome":"Cow's milk protein allergy by 2 years","arm-level-result":{"dichotomous-data-rows":[{"arm":"Probiotics","cases":2,"sample-size":51},{"arm":"No probiotics","cases":2,"sample-size":37}],"risk-of-bias":[{"domain":"Bias due to deviations from intended interventions","judgement":"LOW_RISK","support-for-judgement":"<p>Placebo was same product used for the intervention group but subjected to a beta radiation process. The dose of the radiation was 4·5 kGy.<\/p><p>Investigators did not have access to the allocation sequence until the database was closed.<\/p>"},{"domain":"Bias due to missing outcome data","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>Losses to follow-up: 16\/104 (15%). Lost to follow-up prior to completion of study n = 11; 2 in control group and 3 in intervention group were for reasons of lack of adherence. Reason for drop out for other participants were not described.<\/p>"},{"domain":"Bias in measurement of the outcome","judgement":"LOW_RISK","support-for-judgement":"<p>Unclear if allergy outcome definitions prespecified. The outcomes were measured using standard, validated techniques such as flow cytometry and ELISA.<\/p>"},{"domain":"Bias in selection of the reported result","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>No pre-specified analysis plan. No clinical trial registry number was found.<\/p>"},{"domain":"Overall bias","judgement":"HIGH_RISK","support-for-judgement":"<p>The study is judged to be at high risk of bias in at least one domain for this result.<\/p>"}]}},{"outcome":"Eczema by 2 years","arm-level-result":{"dichotomous-data-rows":[{"arm":"Probiotics","cases":11,"sample-size":51},{"arm":"No probiotics","cases":14,"sample-size":37}],"risk-of-bias":[{"domain":"Bias due to deviations from intended interventions","judgement":"LOW_RISK","support-for-judgement":"<p>Placebo was same product used for the intervention group but subjected to a beta radiation process. The dose of the radiation was 4·5 kGy.<\/p><p>Investigators did not have access to the allocation sequence until the database was closed.<\/p>"},{"domain":"Bias due to missing outcome data","judgement":"HIGH_RISK","support-for-judgement":"<p>Losses to follow-up: 16\/104 (15%). Lost to follow-up prior to completion of study n = 11; 2 in control group and 3 in intervention group were for reasons of lack of adherence. Reason for drop out for other participants were not described.<\/p>"},{"domain":"Bias in measurement of the outcome","judgement":"LOW_RISK","support-for-judgement":"<p>Unclear if allergy outcome definitions prespecified. The outcomes were measured using standard, validated techniques such as flow cytometry and ELISA.<\/p>"},{"domain":"Bias in selection of the reported result","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>No pre-specified analysis plan. No clinical trial registry number was found.<\/p>"},{"domain":"Overall bias","judgement":"HIGH_RISK","support-for-judgement":"<p>The study is judged to be at high risk of bias in at least one domain for this result.<\/p>"}]}}],"risk-of-bias":[{"domain":"Bias arising from the randomization process","judgement":"LOW_RISK","support-for-judgement":"<p>Computer generated randomisation sequence in 4 strata: primiparous age 18 – 24 years, primiparous age 25 – 40 years, multiparous age 18 – 24 years or multiparous age 25 – 40 years.<\/p><p>Baseline characteristics were similar between groups.<br>Randomisation procedure after birth conducted by external collaborator. All the participants identified with an alphanumeric code.<\/p>"}]},{"name":"Savino 2010","year":"2010","data-source":"PUB","identifiers":[{"name":"CRS","value":"2621328"}],"references":[{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Savino F, Cordisco L, Tarasco V, Palumeri E, Calabrese R, Oggero R, et al","title":"Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial","original-title":"","source":"Pediatrics","publication-date":"2010","volume":"126","issue":"3","pages":"e526-33","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"2621329"},{"name":"DOI","value":"10.1542\/peds.2010-0433"},{"name":"PUBMED","value":"20713478"}]}],"characteristics":[{"name":"Methods","value":"<p>Randomised, controlled, double-blind study.<\/p>"},{"name":"Participants","value":"<p><b>Inclusion criteria: <\/b>breastfed infants diagnosed with infantile colic according to modified Wessel’s criteria (Wessel 1954), episodes of fussy crying that lasted 3 hours a day and for 3 days in the 1 week before enrolment.) All were born at term, birth weight: 2500 – 4000 g and aged 2 to 16 weeks.<\/p>\n<p><b>Exclusion criteria: <\/b>chronic illness or gastrointestinal disorders, any intake of probiotics or antibiotics in the week preceding recruitment, and any formula-feeding.<\/p>"},{"name":"Interventions","value":"<p>5 drops, once a day, 30 minutes before the feed in the morning for 21 days:<\/p>\n<p><b>Treatment (n = 25): <\/b>L reuteri 10<sup>8<\/sup> live bacteria\/day in sunflower oil and medium-chain triglyceride oil.<\/p>\n<p><b>Control (n = 25): <\/b>placebo (sunflower oil and medium-chain triglyceride oil).<\/p>"},{"name":"Outcomes","value":"<p><b>Primary outcome:<\/b> reduction in average crying time to &lt; 3 hours a day on day 21<\/p>\n<p>Other outcomes: the number of responders in each group on days 7, 14, 21. Intestinal microflora of the infants and any adverse effects.<\/p>\n<p><b>Definitions:<\/b> not given.<\/p>\n<p>Adverse events reported included rhinitis and eczema.<\/p>\n<p>Parents recorded diary. Paediatricians assessed baseline and day 21.<\/p>"},{"name":"Notes","value":"<p><b>Sponsor: <\/b>funded by BioGaia AB (Stockholm, Sweden).<\/p>\n<p><b>Declaration of interests: <\/b>not reported.<\/p>"}],"covariates":[],"arms":[{"name":"No probiotics","description":"","intervention":"No probiotic"},{"name":"Probiotics","description":"","intervention":"Probiotic"}],"results":[{"outcome":"Allergic rhinitis by 2 years","arm-level-result":{"dichotomous-data-rows":[{"arm":"Probiotics","cases":1,"sample-size":25},{"arm":"No probiotics","cases":1,"sample-size":25}],"risk-of-bias":[{"domain":"Bias due to deviations from intended interventions","judgement":"LOW_RISK","support-for-judgement":"<p>Bottles were coded and blinded by the study statistician for both the participants and for the physicians, and the code was revealed to the investigators once recruitment, data collection, and all laboratory and statistical analyses were complete.<\/p><p>Follow-up visits performed by the same paediatrician.<\/p><p>Parental interviews, with the aid of a study diary, was used to assess adverse events', such as illness.<\/p><p>Faecal samples collected directly from sample or anus and samples (blinded) were stored (refrigerated) until analysed.<\/p>"},{"domain":"Bias due to missing outcome data","judgement":"LOW_RISK","support-for-judgement":"<p>Loss to follow-up: 4\/50 (8%). 0\/25 treatment and 4\/25 controls excluded post-randomisation - 2 controls excluded due to adverse events (hay fever, gastrointestinal symptoms), 2 excluded due to failure of completing the diary. Cause of missing data were similar across both groups.<\/p>"},{"domain":"Bias in measurement of the outcome","judgement":"LOW_RISK","support-for-judgement":"<p>Primary outcomes measured using parental questionnaires and secondary outcomes measured through appropriate validated methods.<\/p>"},{"domain":"Bias in selection of the reported result","judgement":"LOW_RISK","support-for-judgement":"<p>Pre-specified analysis plan, no deviation from pre-specified analysis plan described. NCT00893711.<\/p>"},{"domain":"Overall bias","judgement":"LOW_RISK","support-for-judgement":"<p>The study is judged to be at low risk of bias for all domains for this result.<\/p>"}]}},{"outcome":"Eczema by 2 years","arm-level-result":{"dichotomous-data-rows":[{"arm":"Probiotics","cases":0,"sample-size":25},{"arm":"No probiotics","cases":1,"sample-size":21}],"risk-of-bias":[{"domain":"Bias due to deviations from intended interventions","judgement":"LOW_RISK","support-for-judgement":"<p>Bottles were coded and blinded by the study statistician for both the participants and for the physicians, and the code was revealed to the investigators once recruitment, data collection, and all laboratory and statistical analyses were complete.<\/p><p>Follow-up visits performed by the same paediatrician.<\/p><p>Parental interviews, with the aid of a study diary, was used to assess adverse events', such as illness.<\/p><p>Faecal samples collected directly from sample or anus and samples (blinded) were stored (refrigerated) until analysed.<\/p>"},{"domain":"Bias due to missing outcome data","judgement":"LOW_RISK","support-for-judgement":"<p>Loss to follow-up: 4\/50 (8%). 0\/25 treatment and 4\/25 controls excluded post-randomisation - 2 controls excluded due to adverse events (hay fever, gastrointestinal symptoms), 2 excluded due to failure of completing the diary. Cause of missing data were similar across both groups.<\/p>"},{"domain":"Bias in measurement of the outcome","judgement":"LOW_RISK","support-for-judgement":"<p>Primary outcomes measured using parental questionnaires and secondary outcomes measured through appropriate validated methods.<\/p>"},{"domain":"Bias in selection of the reported result","judgement":"LOW_RISK","support-for-judgement":"<p>Pre-specified analysis plan, no deviation from pre-specified analysis plan described. NCT00893711.<\/p>"},{"domain":"Overall bias","judgement":"LOW_RISK","support-for-judgement":"<p>The study is judged to be at low risk of bias for all domains for this result.<\/p>"}]}}],"risk-of-bias":[{"domain":"Bias arising from the randomization process","judgement":"LOW_RISK","support-for-judgement":"<p>Computer generated randomisation list created by an independent statistician.<\/p><p>Baseline difference (placebo compared with probiotic group) in caesarean delivery rate 25%; compared with 52%; potentially clinically significant although not statistically significant.<\/p><p>Used 2-treatment randomisation scheme with random block of varying size. Paediatrician allocated the next available product on entry into the trial. Allocations were concealed in sealed envelopes for each site.<\/p>"}]},{"name":"Scalabrin 2009","year":"2009","data-source":"PUB","identifiers":[{"name":"CRS","value":"2621330"}],"references":[{"reference-type":"JOURNAL_ARTICLE","primary":true,"authors":"Scalabrin DM, Johnston WH, Hoffman DR, P'Pool VL, Harris CL, Mitmesser SH","title":"Growth and tolerance of healthy term infants receiving hydrolyzed infant formulas supplemented with Lactobacillus rhamnosus GG: randomized, double-blind, controlled trial","original-title":"","source":"Clinical Pediatrics","publication-date":"2009","volume":"48","issue":"7","pages":"734-44","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"2621331"},{"name":"DOI","value":"10.1177\/0009922809332682"},{"name":"PUBMED","value":"19264721"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Scalabrin D, Harris C, Johnston WH, Berseth CL","title":"Long-term safety assessment in children who received hydrolyzed protein formulas with Lactobacillus rhamnosus GG: a 5-year follow-up","original-title":"","source":"European Journal of Pediatrics","publication-date":"2017","volume":"176","issue":"2","pages":"217-24","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958466"},{"name":"DOI","value":"10.1007\/s00431-016-2825-4"},{"name":"PUBMED","value":"27975116"}]}],"characteristics":[{"name":"Methods","value":"<p>Double-blind, randomised, controlled, parallel, prospective study.<\/p>"},{"name":"Participants","value":"<p><b>Inclusion criteria: <\/b>eligible infants were healthy, term infants 38 to 42 weeks' gestational age, with birth weight ≥ 2500 g and solely formula-fed at least 24 hours prior to randomisation.<\/p>\n<p><b>Exclusion criteria: <\/b>history of underlying disease or congenital malformation likely to interfere with normal growth and development or participant evaluation, formula intolerance, weight at 14 days of age &lt; 98% of birth weight, large for gestational age born from a mother diabetic at childbirth, immunodeficiency, fever at randomisation, systemic antibiotic use within 7 days of randomisation, systemic steroid use any time since birth, LGG-supplemented diet any time since birth (including infants breast-fed when mother consumed dietary LGG), and diarrhoea within 24 hours prior to randomisation.<\/p>"},{"name":"Interventions","value":"<p>Randomised to receive through 120 days of age:<\/p>\n<p><b>Control (n = 94): <\/b>extensively hydrolysed (EH) casein formula (Nutramigen LIPIL, Mead Johnson &amp; Company, Evansville, IN);<\/p>\n<p><b>Treatment 1 (n = 94): <\/b>same formula supplemented with LGG 10<sup>8<\/sup> cfu per gram of formula powder; or<\/p>\n<p><br><b>Treatment 2 (n = 98): <\/b>partially hydrolysed whey: casein (60:40) formula supplemented with LGG 10<sup>8<\/sup> cfu per gram of formula powder.<\/p>\n<p>A subset of infants continued to receive study formula through 150 days of age.<\/p>\n<p>All formulas supplemented with 0.64% arachidonic acid and 0.32% docosahexaenoic acid of total FAs.<\/p>"},{"name":"Outcomes","value":"<p><b>Primary outcome: <\/b>to evaluate the effect on growth and tolerance in healthy, term infants from 14 to 120 days of age.<\/p>\n<p><b>Other outcomes:<\/b> to analyse the incidence of allergies and infections as well as allergic sensitisation and antibody response to routine vaccinations in a subset of infants who received study formula up to 150 days of age. Reported percentages of allergy-related events.<\/p>\n<p><b>Definitions:<\/b> not given for allergy-related events.<\/p>\n<p>Performed total IgE and specific IgE to cow milk protein by fluorescent EIA. Definitions of allergy-related adverse events not provided in 5 year follow-up study.<\/p>"},{"name":"Notes","value":"<p><b>Sponsor: <\/b>study was supported by Mead Johnson Nutrition.<\/p>\n<p>Adverse events categorised as allergy-related (EHF, 10%; EHF-LGG, 18%; PHF-LGG, 15%). Data not included in meta-analysis.<\/p>\n<p>Allergy-related adverse event through year 5 included in analysis under childhood incidence.<\/p>\n<p><b>Declaration of interests: <\/b>DS, CLH and CLB were all employees of Mead Johnson Nutrition at the time of the study. WJ received research support from Mead Johnson Nutrition. No other conflict of interest to disclose.<\/p>"}],"covariates":[],"arms":[],"results":[],"risk-of-bias":[{"domain":"Bias arising from the randomization process","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>Study sponsor created a computer-generated, gender-stratified randomisation schedule, provided in sealed consecutively numbered envelopes, for each study site. On infant enrolment, study formula was assigned by opening the next sequential envelope from the appropriate set at the study site. Demographics and characteristics including family history of allergy were similar for infants in all groups at enrollment.<\/p><p>Parents or guardians provided written informed consent prior to enrolment. Details of allocation concealment not provided.<\/p>"}]},{"name":"Soh 2009","year":"2009","data-source":"PUB","identifiers":[{"name":"CRS","value":"2621332"}],"references":[{"reference-type":"JOURNAL_ARTICLE","primary":true,"authors":"Soh SE, Aw M, Gerez I, Chong YS, Rauff M, Ng YP, et al","title":"Probiotic supplementation in the first 6 months of life in at risk Asian infants – effects on eczema and atopic sensitization at the age of 1 year","original-title":"","source":"Clinical and Experimental Allergy","publication-date":"2009","volume":"39","issue":"4","pages":"571-8","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"2621337"},{"name":"PUBMED","value":"19134020"},{"name":"DOI","value":"10.1111\/j.1365-2222.2008.03133.x"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Soh SE, Aw M, Gerez I, Lee BW, Chong YS, Rauff M, et al","title":"Influence of probiotic supplementation on the primary prevention of eczema and allergen sensitization in at risk Asian infants: a randomized double-blind placebo controlled trial","original-title":"","source":"Journal of Allergy and Clinical Immunology","publication-date":"2008","volume":"21","issue":"Suppl 1","pages":"S33","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"2621338"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Yap GC, Chee KK, Hong PY, Lay C, Satria CD, Sumadiono, et al","title":"Evaluation of stool microbiota signatures in two cohorts of Asian (Singapore and Indonesia) newborns at risk of atopy","original-title":"","source":"BMC Microbiology","publication-date":"2011","volume":"11","issue":"","pages":"193","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958474"},{"name":"DOI","value":"10.1186\/1471-2180-11-193"},{"name":"PUBMED","value":"21875444"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Quah P, Huang C, Shek P, Aw M, Chua K, Lee B, et al","title":"Chemokines, soluble receptors and mediators of cord blood mononuclear cells and atopic sensitization at 2 years of age in at risk infants participating in a probiotic supplementation clinical trial","original-title":"","source":"Journal of Allergy and Clinical Immunology","publication-date":"2012","volume":"129","issue":"2","pages":"AB54","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958471"},{"name":"DOI","value":"10.1016\/j.jaci.2011.12.699"}]},{"reference-type":"OTHER","primary":false,"authors":"NCT00826189","title":"Influence of probiotics on atopy with focus on respiratory allergic diseases – follow-up to 7 years","original-title":"A follow-up study to 7 years of a randomized, double-blinded, placebo-controlled study on the influence of probiotics on atopy with focus on respiratory allergic diseases","source":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00826189","publication-date":"(first received 22 January 2009)","volume":"","issue":"","pages":"","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"2621334"}]},{"reference-type":"OTHER","primary":false,"authors":"NCT00318695","title":"Influence of probiotics on prevention of atopy, atopic disease and immunological responses","original-title":"Influence of probiotics on prevention of atopy, atopic disease and immunological responses- a randomized double-blind placebo controlled trial","source":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00318695","publication-date":"(first received 27 April 2006)","volume":"","issue":"","pages":"","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"2621336"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Mah KW, Chin VI, Wong WS, Lay C, Tannock GW, Shek LP, et al","title":"Effect of a milk formula containing probiotics on the fecal microbiota of Asian infants at risk of atopic diseases","original-title":"","source":"Pediatric Research","publication-date":"2007","volume":"62","issue":"6","pages":"674-9","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958469"},{"name":"DOI","value":"10.1203\/PDR.0b013e31815991d5"},{"name":"PUBMED","value":"17957155"}]},{"reference-type":"OTHER","primary":false,"authors":"NCT00365469","title":"Influence of probiotics on atopy, immunological responses and gut microflora – follow-up to 5 years","original-title":"A follow-up study to 5 years of a randomized, double-blinded, placebo-controlled study on the influence of probiotics on atopy, immunological responses and gut microflora","source":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00365469","publication-date":"(first received 17 August 2006)","volume":"","issue":"","pages":"","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"2621335"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Quah PL, Loo EX, Lee GN, Kuo IC, Gerez I, Llanora GV, et al","title":"Clinical phenotype and allergen sensitization in the first 2 years as predictors of atopic disorders at age 5 years","original-title":"","source":"World Allergy Organization Journal","publication-date":"2015","volume":"8","issue":"1","pages":"33","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958472"},{"name":"DOI","value":"10.1186\/s40413-015-0082-z"},{"name":"PUBMED","value":"26664574"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Hong PY, Lee BW, Aw M, Shek LP, Yap GC, Chua KY, et al","title":"Comparative analysis of fecal microbiota in infants with and without eczema","original-title":"","source":"PLOS One","publication-date":"2010","volume":"5","issue":"4","pages":"e9964","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958467"},{"name":"DOI","value":"10.1371\/journal.pone.0009964"},{"name":"PUBMED","value":"20376357"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Oh S, Yap GC, Hong PY, Huang CH, Aw MM, Shek LP, et al","title":"Immune-modulatory genomic properties differentiate gut microbiota of infants with and without eczema","original-title":"","source":"PLOS One","publication-date":"2017","volume":"12","issue":"10","pages":"e0184955","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958470"},{"name":"DOI","value":"10.1371\/journal.pone.0184955"},{"name":"PUBMED","value":"29049378"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Soh SE, Ong DQ, Gerez I, Zhang X, Chollate P, Shek LP, et al","title":"Effect of probiotic supplementation in the first 6 months of life on specific antibody responses to infant Hepatitis B vaccination","original-title":"","source":"Vaccine","publication-date":"2010","volume":"28","issue":"14","pages":"2577-9","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958473"},{"name":"DOI","value":"10.1016\/j.vaccine.2010.01.020"},{"name":"PUBMED","value":"20105426"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Loo EX, Llanora GV, Lu Q, Aw M, Lee BW, Shek LP","title":"Supplementation with probiotics in the first 6 months of life did not protect against eczema and allergy in at-risk Asian infants: a 5-year follow-up","original-title":"","source":"International Archives of Allergy and Immunology","publication-date":"2014","volume":"163","issue":"1","pages":"25-8","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958468"},{"name":"PUBMED","value":"24247661"},{"name":"DOI","value":"10.1159\/000356338"}]}],"characteristics":[{"name":"Methods","value":"<p>Double-blind, placebo-controlled randomised clinical trial.<\/p>"},{"name":"Participants","value":"<p>Families with a history of allergic disease were recruited from the antenatal clinics.<\/p>\n<p><b>Inclusion criteria: <\/b>first-degree relative with doctor diagnosis of asthma, allergic rhinitis or eczema and a positive SPT to Dust mites; gestational age &gt;35 weeks; birth weight &gt; 2 kg.<\/p>\n<p><b>Exclusion criteria: <\/b>no major congenital malformation or illness. Parents who chose to breast-feed exclusively were not considered for the study.<\/p>"},{"name":"Interventions","value":"<p>Participants received at least 60 mL (9.26 g) a day of commercially available cow’s milk-based infant formula with:<\/p>\n<p><b>Treatment (n = 127): <\/b>probiotic supplementation B. longum BL999 (ATCC: BAA-999 designation BB536, Morinaga, Japan) 1x10<sup>7<\/sup> cfu\/g and L. rhamnosus LPR (CGMCC 1.3724) 2 x 10<sup>7<\/sup> cfu\/g initiated within 12 hours for the first 6 months of life; or<\/p>\n<p><b>Control (n = 126):<\/b> formula without probiotics.<\/p>\n<p>Mothers were free to decide whether to make up the remainder of the baby feeds with either the trial formula, or to supplement with breast milk, or another infant formula. Weaning to solids was allowed at between 4 and 6 months of age according to local practices, but parents were advised to avoid potentially allergenic foods including eggs, shellfish, and peanuts until after the first birthday.&nbsp;<\/p>"},{"name":"Outcomes","value":"<p><b>Primary outcome:<\/b> prevention of eczema and allergic sensitisation in the first year of life in Asian infants at risk of allergic disease.<\/p>\n<p><b>Other outcomes<\/b>: Paediatrician evaluation at 1, 3, 6 and 12 months which involved a detailed history, recording of anthropometric data and clinical examination. Questionnaires are administered at these visits to record clinical disease and environmental exposures. Biweekly phone calls performed for the first 6 months, after which monthly phone contacts were carried out.<\/p>\n<p><b>Definitions<\/b><\/p>\n<p>Eczema defined as a pruritic rash over the face or extensors with a chronic relapsing course criteria of Hanifin and Rajka (Hanifin 1980), or both physician diagnosed at 12 months, SCORAD index used.<\/p>\n<p>Sensitisation: SPTs and specific IgE at 12 months. A weal &gt; 3 mm in diameter above the negative control was considered positive.&nbsp;<\/p>"},{"name":"Notes","value":"<p><b>Sponsor: <\/b>National Medical Research Council, Singapore. The study milk formula was sponsored by Nestles, Vevey, Switzerland.<\/p>\n<p>Infant incidence of cow's milk sensitisation\/hypersensitivity unable to be included in analysis due to probiotic n = 0 and placebo n = 0. Incidence of atopic disease up to 5 years included in analysis under childhood incidence. Food allergy since year 3 included in analysis under childhood prevalence.<\/p>\n<p><b>Declaration of interests: <\/b>not reported.<\/p>"}],"covariates":[],"arms":[{"name":"No probiotics","description":"","intervention":"No probiotic"},{"name":"Probiotics","description":"","intervention":"Probiotic"}],"results":[{"outcome":"Allergic rhinitis by 2 years","arm-level-result":{"dichotomous-data-rows":[{"arm":"Probiotics","cases":2,"sample-size":124},{"arm":"No probiotics","cases":3,"sample-size":121}],"risk-of-bias":[{"domain":"Bias due to deviations from intended interventions","judgement":"LOW_RISK","support-for-judgement":"<p>The formula feeds (test and control) tasted and appeared identical.<br>Mothers (caregivers), doctors, nurses and statisticians involved in the trial were blinded to milk formula allocation.<\/p>"},{"domain":"Bias due to missing outcome data","judgement":"LOW_RISK","support-for-judgement":"<p>8\/253 withdrew before follow-up. 10 participants dropped out (probiotic group = 2, placebo group = 8). Analysed at 1 year: probiotic group n = 124, placebo group n = 121). Loss to follow-up: 18\/253 (7%). 220\/253 (87%) participants completed follow-up until 5 years. Small number of drop outs.&nbsp;<\/p>"},{"domain":"Bias in measurement of the outcome","judgement":"LOW_RISK","support-for-judgement":"<p>Primary clinical outcome measure was the incidence of eczema in 1st year; secondary outcome measure allergen sensitisation. Specific definitions for allergy reported.<\/p>"},{"domain":"Bias in selection of the reported result","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>Pre-specified analysis plan was not found for follow up at 1yr. Pre-specified analysis plan available for follow up at 5 and 7 years, although no indication of whether there was any deviation from pre-specified plan. NCT00318695, NCT00365469, NCT00826189.<br>A large number of participants (208\/266) continued to consume probiotics of their own accord in the form of milk formula\/food\/supplements with probiotics. The investigators noted that this was statistically associated with a reduced incidence of asthma and allergic rhinitis at the age of 5 years.<\/p>"},{"domain":"Overall bias","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.<\/p>"}]}},{"outcome":"Asthma by 2 years","arm-level-result":{"dichotomous-data-rows":[{"arm":"Probiotics","cases":11,"sample-size":124},{"arm":"No probiotics","cases":11,"sample-size":121}],"risk-of-bias":[{"domain":"Bias due to deviations from intended interventions","judgement":"LOW_RISK","support-for-judgement":"<p>The formula feeds (test and control) tasted and appeared identical.<br>Mothers (caregivers), doctors, nurses and statisticians involved in the trial were blinded to milk formula allocation.<\/p>"},{"domain":"Bias due to missing outcome data","judgement":"LOW_RISK","support-for-judgement":"<p>8\/253 withdrew before follow-up. 10 participants dropped out (probiotic group = 2, placebo group = 8). Analysed at 1 year: probiotic group n = 124, placebo group n = 121). Loss to follow-up: 18\/253 (7%). 220\/253 (87%) participants completed follow-up until 5 years. Small number of drop outs.&nbsp;<\/p>"},{"domain":"Bias in measurement of the outcome","judgement":"LOW_RISK","support-for-judgement":"<p>Primary clinical outcome measure was the incidence of eczema in 1st year; secondary outcome measure allergen sensitisation. Specific definitions for allergy reported.<\/p>"},{"domain":"Bias in selection of the reported result","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>Pre-specified analysis plan was not found for follow up at 1yr. Pre-specified analysis plan available for follow up at 5 and 7 years, although no indication of whether there was any deviation from pre-specified plan. NCT00318695, NCT00365469, NCT00826189.<br>A large number of participants (208\/266) continued to consume probiotics of their own accord in the form of milk formula\/food\/supplements with probiotics. The investigators noted that this was statistically associated with a reduced incidence of asthma and allergic rhinitis at the age of 5 years.<\/p>"},{"domain":"Overall bias","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.<\/p>"}]}},{"outcome":"Eczema by 2 years","arm-level-result":{"dichotomous-data-rows":[{"arm":"Probiotics","cases":27,"sample-size":124},{"arm":"No probiotics","cases":30,"sample-size":121}],"risk-of-bias":[{"domain":"Bias due to deviations from intended interventions","judgement":"LOW_RISK","support-for-judgement":"<p>The formula feeds (test and control) tasted and appeared identical.<br>Mothers (caregivers), doctors, nurses and statisticians involved in the trial were blinded to milk formula allocation.<\/p>"},{"domain":"Bias due to missing outcome data","judgement":"LOW_RISK","support-for-judgement":"<p>8\/253 withdrew before follow-up. 10 participants dropped out (probiotic group = 2, placebo group = 8). Analysed at 1 year: probiotic group n = 124, placebo group n = 121). Loss to follow-up: 18\/253 (7%). 220\/253 (87%) participants completed follow-up until 5 years. Low drop out at 1 year follow up and unrelated to study intervention.<\/p>"},{"domain":"Bias in measurement of the outcome","judgement":"LOW_RISK","support-for-judgement":"<p>Primary clinical outcome measure was the incidence of eczema in 1st year; secondary outcome measure allergen sensitisation. Specific definitions for allergy reported.<\/p><p>A large number of participants (208\/266) continued to consume probiotics of their own accord in the form of milk formula\/food\/supplements with probiotics. The investigators noted that this was statistically associated with a reduced incidence of asthma and allergic rhinitis at the age of 5 years.<\/p>"},{"domain":"Bias in selection of the reported result","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>Pre-specified analysis plan was not found for follow up at 1yr. Pre-specified analysis plan available for follow up at 5 and 7 years, although no indication of whether there was any deviation from pre-specified plan. NCT00318695, NCT00365469, NCT00826189.<\/p>"},{"domain":"Overall bias","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.<\/p>"}]}}],"risk-of-bias":[{"domain":"Bias arising from the randomization process","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>Sequential computerised randomisation in blocks of 6. Allocation concealment was not specified.&nbsp;<\/p><p>Well balanced groups after randomisation. No significant differences in the baseline demographics and family history of allergic disease between the participants who completed follow-up and those who were lost to follow-up. Participants in the probiotic group and placebo group that completed the 5 year follow-up did not differ significantly in environmental factors.<\/p><p>Allocation concealment not specified.&nbsp;<\/p><p>A large number of participants (208\/266) continued to consume probiotics of their own accord in the form of milk formula\/food\/supplements with probiotics. The investigators noted that this was statistically associated with a reduced incidence of asthma and allergic rhinitis at the age of 5 years.<\/p>"}]},{"name":"Taipale 2011","year":"2011","data-source":"PUB","identifiers":[{"name":"CRS","value":"2621340"}],"references":[{"reference-type":"JOURNAL_ARTICLE","primary":true,"authors":"Taipale T, Pienihakkinen K, Isolauri E, Larsen C, Brockmann E, Alanen P, et al","title":"Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in infancy","original-title":"","source":"British Journal of Nutrition","publication-date":"2011","volume":"105","issue":"3","pages":"409-16","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"2621341"},{"name":"DOI","value":"10.1017\/S0007114510003685"},{"name":"PUBMED","value":"20863419"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Taipale T, Pienihakkinen K, Salminen S, Jokela J, Soderling E","title":"Bifidobacteriumanimalis subsp. lactis BB-12 administration in early childhood: a randomized clinical trial of effects on oral colonization by mutans streptococci and the probiotic","original-title":"","source":"Caries Research","publication-date":"2012","volume":"46","issue":"1","pages":"69-77","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"2621342"},{"name":"DOI","value":"10.1159\/000335567"},{"name":"PUBMED","value":"22327347"}]}],"characteristics":[{"name":"Methods","value":"<p>Randomised double-blind, placebo-controlled study.<\/p>"},{"name":"Participants","value":"<p>Newborn 1-month-old infants were recruited.<\/p>\n<p><b>Inclusion criteria:<\/b> the child was healthy, parents were willing to use the novel slow release pacifier and the child started to receive the tablet before the age of 2 months age.<\/p>\n<p><b>Exclusion criteria:<\/b> not specified<\/p>"},{"name":"Interventions","value":"<p>Children were given 2 &nbsp;probiotic tablets per day via a novel slow-release pacifier. Each tablet contained 5 x 10<sup>9<\/sup> cfu of BB-12. Until 6 - 8 months of age, children received the tablet via a small pacifier, thereafter via a large pacifier.<\/p>\n<p><b>Treatment (n = 55):<\/b> probiotic Bifidobacterium animalis BB-12 containing xylitol tablet administered to the infants twice a day (daily dose BB-12 10 x 10<sup>9<\/sup> cfu) from age 1 – 2 months to 8 months.<\/p>\n<p><b>Control (n = 54):<\/b> control xylitol tablet.<\/p>\n<p>Exclusive breastfeeding (months - mean (SD)): treatment: 3·4 (1·7); control 3·8 (1·9). The families were encouraged not to use any other pacifier besides the slow-release pacifier twice a week. If families wanted to use a regular pacifier as well, they were offered the pouch-free version of the slow-release pacifier.&nbsp;<\/p>"},{"name":"Outcomes","value":"<p><b>Primary outcome: <\/b>reported cumulative incidence of acute respiratory infections and doctor-diagnosed<b> <\/b>acute otitis media before age of 8 months. Caries occurrence to 4 years.<\/p>\n<p><br><b>Other outcomes<\/b>: acute infectious diseases to 2 years. Successful intestinal passage of BB-12. Oral microbial colonisation.<\/p>\n<p>Parents reported atopic diseases or allergic sensitisation to 8 months.<\/p>\n<p><b>Definitions: <\/b>not reported.<\/p>"},{"name":"Notes","value":"<p><b>Sponsor: <\/b>grants from Emil Aaltonen and Sohlberg Foundations, Finnish Dental Society Apollonia and Finnish Dental Association. Chr. Hansen A\/S (Hoersholm, Denmark) donated the BB-12 for the probiotic tablets and helped in carrying out the faecal analysis of BB-12. The tablets were manufactured by Oy Karl Fazer Ab (Vantaa, Finland). The pacifiers manufactured by Mekalasi Oy (Konnevesi, Finland). Neither Hansen, Fazer nor Mekalasi provided financial support.<\/p>\n<p><b>Declaration of interests: <\/b>T.T had no conflicts of interest. No other conflict of interest reported.<\/p>"}],"covariates":[],"arms":[{"name":"No probiotics","description":"","intervention":"No probiotic"},{"name":"Probiotics","description":"","intervention":"Probiotic"}],"results":[{"outcome":"Cow's milk protein allergy by 2 years","arm-level-result":{"dichotomous-data-rows":[{"arm":"Probiotics","cases":2,"sample-size":34},{"arm":"No probiotics","cases":1,"sample-size":35}],"risk-of-bias":[{"domain":"Bias due to deviations from intended interventions","judgement":"LOW_RISK","support-for-judgement":"<p>All study personnel and participants were blinded to treatment assignment for the duration of the study.<\/p>"},{"domain":"Bias due to missing outcome data","judgement":"HIGH_RISK","support-for-judgement":"<p>69% (75\/109) started administration, 38\/55 received BB-12 and 37\/54 xylitol control. 31% (34\/109) were excluded. 69\/109 (63%) completed follow-up. Reasons for drop-out was not described. Potentially clinically important differences between groups as analysed after substantial losses.<\/p>"},{"domain":"Bias in measurement of the outcome","judgement":"LOW_RISK","support-for-judgement":"<p>Primary outcomes were assessed using standardised clinical measures.<\/p><p>Breastfeeding habits, pacifier use, dietary habits, medications, and all signs and symptoms of acute infections were registered in diaries by parents and in questionnaires by trained professionals.<\/p>"},{"domain":"Bias in selection of the reported result","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>Allergic disease was not described as an outcome on pre-specified analysis plan. NCT00638677.<\/p>"},{"domain":"Overall bias","judgement":"HIGH_RISK","support-for-judgement":"<p>The study is judged to be at high risk of bias in at least one domain for this result.<\/p>"}]}}],"risk-of-bias":[{"domain":"Bias arising from the randomization process","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>Computer generated blocks of three. Placebo used. Participants were blinded to treatment assignment. No clear allocation concealment described.<\/p>"}]},{"name":"Taylor 2006","year":"2006","data-source":"PUB","identifiers":[{"name":"CRS","value":"2621343"}],"references":[{"reference-type":"JOURNAL_ARTICLE","primary":true,"authors":"Taylor AL, Dunstan JA, Prescott SL","title":"Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in high-risk children: a randomized controlled trial","original-title":"","source":"Journal of Allergy and Clinical Immunology","publication-date":"2007","volume":"119","issue":"1","pages":"184-91","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"2621347"},{"name":"DOI","value":"10.1016\/j.jaci.2006.08.036"},{"name":"PUBMED","value":"17208600"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Taylor A, Hale J, Wiltschut J, Lehmann H, Dunstan JA, Prescott SL","title":"Evaluation of the effects of probiotic supplementation from the neonatal period on innate immune development in infancy","original-title":"","source":"Clinical and Experimental Allergy","publication-date":"2006","volume":"36","issue":"10","pages":"1218-26","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"2621346"},{"name":"DOI","value":"10.1111\/j.1365-2222.2006.02552.x"},{"name":"PUBMED","value":"17014428"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Jensen MP, Meldrum S, Taylor AL, Dunstan JA, Prescott SL","title":"Early probiotic supplementation for allergy prevention: long-term outcomes","original-title":"","source":"Journal of Allergy and Clinical Immunology","publication-date":"2012","volume":"130","issue":"5","pages":"1209-21.e5","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958475"},{"name":"DOI","value":"10.1016\/j.jaci.2012.07.018"},{"name":"PUBMED","value":"22958946"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Martino DJ, Currie H, Taylor A, Conway P, Prescott SL","title":"Relationship between early intestinal colonization, mucosal immunoglobulin A production and systemic immune development","original-title":"","source":"Clinical and Experimental Allergy","publication-date":"2008","volume":"38","issue":"1","pages":"69-78","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"2621344"},{"name":"DOI","value":"10.1111\/j.1365-2222.2007.02856.x"},{"name":"PUBMED","value":"17976218"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Taylor AL, Hale J, Wiltschut J, Lehmann H, Dunstan JA, Prescott SL","title":"Effects of probiotic supplementation for the first 6 months of life on allergen- and vaccine-specific immune responses","original-title":"","source":"Clinical and Experimental Allergy","publication-date":"2006","volume":"36","issue":"10","pages":"1227-35","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"2621349"},{"name":"DOI","value":"10.1111\/j.1365-2222.2006.02553.x"},{"name":"PUBMED","value":"17014429"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Prescott SL, Wiltschut J, Taylor A, Westcott L, Jung W, Currie H, et al","title":"Early markers of allergic disease in a primary prevention study using probiotics: 2.5-year follow-up phase","original-title":"","source":"Allergy","publication-date":"2008","volume":"63","issue":"11","pages":"1481-90","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"2621345"},{"name":"DOI","value":"10.1111\/j.1398-9995.2008.01778.x"},{"name":"PUBMED","value":"18925885"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Taylor AL, Hale J, Hales BJ, Dunstan JA, Thomas WR, Prescott SL","title":"FOXP3 mRNA expression at 6 months of age is higher in infants who develop atopic dermatitis, but is not affected by giving probiotics from birth","original-title":"","source":"Pediatric Allergy and Immunology","publication-date":"2007","volume":"18","issue":"1","pages":"10-9","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"2621348"},{"name":"Other","value":" 10.1111\/j.1399-3038.2006.00483.x"},{"name":"PUBMED","value":"17295794"}]}],"characteristics":[{"name":"Notes","value":"<p><b>Sponsor: <\/b>National Health and Medical Research Council of Australia and Probiomics as an industry partner. The study and all of the analyses were conducted independently of the commercial entity.<\/p>\n<p>Clinical and sensitisation characteristics of the study population at 1 year included in analysis under infant incidence. Clinical and sensitisation at 2.5 years of age included in analysis under childhood incidence. All outcomes described in the 5 year follow-up study refer to \"recent\" symptoms (in the preceding 12 months) unless stated otherwise; thus included in analysis under childhood prevalence.&nbsp;<\/p>\n<p><b>Declaration of interests: <\/b>not reported.<\/p>"},{"name":"Outcomes","value":"<p><b>Primary outcomes: <\/b>clinical assessment of atopic dermatitis at 6 and 12 months of age. Incidence of atopic dermatitis, food allergy, and sensitisation at 12 months and 2.5 years of age.r Primary allergy prevention in a population of Australian children at high risk of allergic disease.<br><br><b>Other outcomes:<\/b> detailed history and examination collected at 12 months and 2.5 years by the same paediatric allergist. Other symptoms based on parental record; all parents who noted (quote:) 'noisy breathing' of any kind were asked to give detail descriptions of this to the paediatrician. Doctor diagnosed gastrointestinal infections were recorded. Assessment of the expression of T-regulatory phenotype.<\/p>\n<p><b>Definitions:&nbsp;<\/b><br>\n Atopic dermatitis: typical skin lesions responsive to topical steroids. The severity determined using the severity score of atopic dermatitis (SCORAD).<br>\n IgE-mediated food allergy: History of immediate symptoms after contact with or ingestion of food and a positive SPT to the implicated food. Symptoms of acute food allergy include skin reactions (hives, rash or swelling) or respiratory symptoms (cough, wheeze, stridor) or gastrointestinal symptoms (abdominal pain, vomiting, loose stools) or cardiovascular symptoms (collapse).<\/p>\n<p>Asthma: defined as recurrent wheezing (3 or more episodes, at least 1 confirmed by a paediatrician or general practitioner) with evidence of responsiveness to bronchodilator therapy.<\/p>"},{"name":"Interventions","value":"<p><b>Treatment (n = 115): <\/b>3 x 10<sup>9<\/sup> \/ L acidophilus LAVRI-A1 in maltodextrin (Probiomics, Sydney, Australia). Supplements supplied as stable freeze-dried powder, dissolved in 1 to 2 mL sterile water and administered orally daily from birth to 6 months.<\/p>\n<p><br><b>Control (n = 111): <\/b>maltodextrin alone.<\/p>\n<p><br>\n Intervention commenced within 48 hours of delivery and was given only to the baby, independent of feeding method.<\/p>"},{"name":"Participants","value":"<p><b>Inclusion criteria:<\/b> pregnant, atopic women. Maternal atopy defined as doctor-diagnosed clinical history of asthma, allergic rhinitis, or eczema plus a positive SPT to 1 or more common allergens.<\/p>\n<p><br><b>Exclusion criteria:<\/b> women excluded if smoked, had other medical problems or pregnancy complications, delivered before 37 weeks' gestation, or already taking probiotic supplements.<\/p>"},{"name":"Methods","value":"<p>Randomised, double-blind, placebo-controlled trial.<\/p>"}],"covariates":[],"arms":[{"name":"No probiotics","description":"","intervention":"No probiotic"},{"name":"Probiotics","description":"","intervention":"Probiotic"}],"results":[{"outcome":"Eczema by 2 years","arm-level-result":{"dichotomous-data-rows":[{"arm":"Probiotics","cases":38,"sample-size":88},{"arm":"No probiotics","cases":34,"sample-size":87}],"risk-of-bias":[{"domain":"Bias due to deviations from intended interventions","judgement":"LOW_RISK","support-for-judgement":"<p>Placebo supplements were image-matched, and participants, research scientists, and paediatrician remained blinded for the duration of the study. Randomisation and allocation of supplements occurred at a separate area from participant recruitment. Supplements were dispensed to participants by persons independent from the allocation process.<\/p>"},{"domain":"Bias due to missing outcome data","judgement":"LOW_RISK","support-for-judgement":"<p>Losses to follow up: 8\/226 withdrew prior to receiving allocation. 40\/226 discontinued intervention: 2 due to non-compliance\/found study too demanding, 4 due to colic or apparent abdominal discomfort in the baby, 2 due to postnatal depression, 4 due to unrelated infant health problems, 2 due to infant refusing to take supplement. 178\/226 analysed at 6 and 12 months (probiotic group n = 89, placebo group n = 89) with 48\/226 (21%) loss to follow-up\/discontinued at 12 months. Additional control infant not reported for atopic eczema. 153\/226 analysed at 2.5-year assessment with 73\/226 (32%) loss to follow-up at 2.5 years. 123\/226 analysed at 5-year assessment (probiotic group n = 66, placebo group n = 57) with 103\/226 (45%) loss to follow-up.&nbsp;<\/p><p>Dropout rate was similar across both groups and no indication that missing data was related to health outcomes.<\/p>"},{"domain":"Bias in measurement of the outcome","judgement":"LOW_RISK","support-for-judgement":"<p>Primary outcome atopic dermatitis and food allergy at 6 and 12 months and evidence of allergen sensitisation at 12 months age. Children were clinically evaluated at 5 years of age, including a detailed history, allergy skin prick testing and physical examinations. Specific definitions for allergy reported. Clinical outcomes were evaluated by the same paediatrician at 5 years of age as at the earlier visits (Prof SL Prescott).<\/p>"},{"domain":"Bias in selection of the reported result","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>No pre-specified analysis plan found. No clinical trial registry number found.<\/p>"},{"domain":"Overall bias","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.<\/p>"}]}},{"outcome":"Food allergy by 2 years","arm-level-result":{"dichotomous-data-rows":[{"arm":"Probiotics","cases":14,"sample-size":88},{"arm":"No probiotics","cases":9,"sample-size":87}],"risk-of-bias":[{"domain":"Bias due to deviations from intended interventions","judgement":"LOW_RISK","support-for-judgement":"<p>Placebo supplements were image-matched, and participants, research scientists, and paediatrician remained blinded for the duration of the study. Randomisation and allocation of supplements occurred at a separate area from participant recruitment. Supplements were dispensed to participants by persons independent from the allocation process.<\/p>"},{"domain":"Bias due to missing outcome data","judgement":"LOW_RISK","support-for-judgement":"<p>Losses to follow up: 8\/226 withdrew prior to receiving allocation. 40\/226 discontinued intervention: 2 due to non-compliance\/found study too demanding, 4 due to colic or apparent abdominal discomfort in the baby, 2 due to postnatal depression, 4 due to unrelated infant health problems, 2 due to infant refusing to take supplement. 178\/226 analysed at 6 and 12 months (probiotic group n = 89, placebo group n = 89) with 48\/226 (21%) loss to follow-up\/discontinued at 12 months. Additional control infant not reported for atopic eczema. 153\/226 analysed at 2.5-year assessment with 73\/226 (32%) loss to follow-up at 2.5 years. 123\/226 analysed at 5-year assessment (probiotic group n = 66, placebo group n = 57) with 103\/226 (45%) loss to follow-up.&nbsp;<\/p><p>Dropout rate was similar across both groups and no indication that missing data was related to health outcomes.<\/p>"},{"domain":"Bias in measurement of the outcome","judgement":"LOW_RISK","support-for-judgement":"<p>Primary outcome atopic dermatitis and food allergy at 6 and 12 months and evidence of allergen sensitisation at 12 months age. Children were clinically evaluated at 5 years of age, including a detailed history, allergy skin prick testing and physical examinations. Specific definitions for allergy reported. Clinical outcomes were evaluated by the same paediatrician at 5 years of age as at the earlier visits (Prof SL Prescott).<\/p>"},{"domain":"Bias in selection of the reported result","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>No pre-specified analysis plan found. No clinical trial registry number found.<\/p>"},{"domain":"Overall bias","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.<\/p>"}]}}],"risk-of-bias":[{"domain":"Bias arising from the randomization process","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>Computerised randomisation schedule with allocation and dispensing by pharmacy. Groups were stratified and block-randomised according to maternal allergy (asthma compared with other allergies); parity (first child compared with 2 or more children); and paternal allergy (allergy compared with no allergy).<\/p><p>Recruitment before randomisation. Allocation completed by external personnel, independent from the investigators. Significant differences were seen with birth length (P = 0.013) and birth head circumference (P = 0.023) between the 2 groups as analysed. Other baseline characteristics between groups were balanced with no significant differences reported.<\/p>"}]},{"name":"Vlieger 2009","year":"2009","data-source":"PUB","identifiers":[{"name":"CRS","value":"2621350"}],"references":[{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Vlieger AM, Robroch A, van Buuren S, Kiers J, Rijkers G, Benninga MA, et al","title":"Tolerance and safety of Lactobacillus paracasei ssp. paracasei in combination with Bifidobacterium animalis ssp. lactis in a prebiotic-containing infant formula: a randomised controlled trial","original-title":"","source":"British Journal of Nutrition","publication-date":"2009","volume":"102","issue":"6","pages":"869-75","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"2621351"},{"name":"DOI","value":"10.1017\/S0007114509289069"},{"name":"PUBMED","value":"19331702"}]}],"characteristics":[{"name":"Methods","value":"<p>Randomised controlled trial.<\/p>"},{"name":"Participants","value":"<p><b>Inclusion criteria: <\/b>pregnant mothers, who intended to bottle-feed infants born &gt; 37 weeks' gestation and &lt; 7 days at enrolment (N = 159).<\/p>\n<p><b>Exclusion criteria:<\/b> use of antibiotics in the first week, congenital illnesses or malformations and insufficient Dutch language.<\/p>"},{"name":"Interventions","value":"<p>Infants fed to 3 months with a pre-biotic containing starter formula supplemented with L. paracasei ssp paracasei and B. animalis ssp. lactis or the same formula without probiotics. Parents of the first 80 infants who completed the first part of the study were asked to continue the use of the study formula for another 3 months. Parents received the assigned infant formula with written instructions for its preparation and were advised to feed infants ad libitum during the study period. Solid foods were introduced at the age of 4 months.<\/p>\n<p><b>Treatment (n = 69): <\/b>standard milk-based powder formula with GOS 2.4 g\/L with B. animalis 1 x 10<sup>7<\/sup> cfu\/g and L. paracasei 1 x 10<sup>7<\/sup> cfu\/g;<\/p>\n<p><b>Control (n = 64): <\/b>standard milk-based powder formula with GOS 2.4g\/L.<\/p>"},{"name":"Outcomes","value":"<p><b>Primary outcome: <\/b>differences in growth parameters at 3 months of age.<\/p>\n<p><b>Other outcomes:<\/b> differences in growth parameters at the age of 6 months, differences in stool characteristics (consistency and frequency), crying (h\/d), the number of upper respiratory tract infections and gastrointestinal tract infections as diagnosed by the parents, the number of antibiotics and visits to the general practitioner. Adverse effects were recorded including vomiting, diarrhoea, constipation, colic and rash or eczema. Recorded in participant diaries.<\/p>\n<p><b>Definitions:<\/b> definitions not specified. In case of serious adverse events, 1 of the paediatricians was contacted to assess the adverse event.<\/p>"},{"name":"Notes","value":"<p><b>Sponsor: <\/b>Financed by Friesland Foods, Leeuwarden, The Netherlands.<\/p>\n<p>Did not report data for allergy. Included data for adverse effects which combines rash with eczema.<\/p>\n<p><b>Declaration of interests: <\/b>J. K and R. t. B were employed by the sponsor (Friesland Foods) at the time of the study. All other authors declared that they had no conflict of interest.&nbsp;<\/p>"}],"covariates":[],"arms":[{"name":"No probiotics","description":"","intervention":"No probiotic"},{"name":"Probiotics","description":"","intervention":"Probiotic"}],"results":[{"outcome":"Eczema by 2 years","arm-level-result":{"dichotomous-data-rows":[{"arm":"Probiotics","cases":10,"sample-size":41},{"arm":"No probiotics","cases":7,"sample-size":38}],"risk-of-bias":[{"domain":"Bias due to deviations from intended interventions","judgement":"LOW_RISK","support-for-judgement":"<p>Both formulas had similar taste, smell and colour. Diaries and growth charts were analysed by authors who were all blinded to the treatment arm.&nbsp;<\/p><p>Compliance was monitored and no major deviations from the protocol were reported.<\/p>"},{"domain":"Bias due to missing outcome data","judgement":"LOW_RISK","support-for-judgement":"<p>159 mothers enrolled. 133 infants allocated to treatment. 7\/133 (5%) at 3 months; 33\/133 (25%) at 6 months. Unclear timing of exclusions in relation to randomisation. Reasons for drop out include colic, regurgitation, constipation and practical regions. Reasons for drop out and incidence of adverse events were similar in both groups.<\/p><p>Dropout were not related to health outcomes related to the intervention.<\/p>"},{"domain":"Bias in measurement of the outcome","judgement":"LOW_RISK","support-for-judgement":"<p>Recorded adverse events; primary outcomes were pre-specified and analyses followed a planned approach.<\/p><p>Parental-reported episodes of upper respiratory tract infections and gastrointestinal tract infections, number of antibiotics and general practitioner visits were recorded by parents.<\/p>"},{"domain":"Bias in selection of the reported result","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>No pre-specified analysis plan was available. ISRCTN78225533.<\/p>"},{"domain":"Overall bias","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.<\/p>"}]}}],"risk-of-bias":[{"domain":"Bias arising from the randomization process","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>Computerised random-number generator. Allocation concealment and sequence not reported.<\/p><p>Baseline characteristics, including birth weight, gestational age, and mode of delivery, were similar between the probiotic and control groups. Fewer infants were born by caesarean section in the probiotic group.<\/p>"}]},{"name":"West 2008","year":"2008","data-source":"PUB","identifiers":[{"name":"CRS","value":"2621352"}],"references":[{"reference-type":"JOURNAL_ARTICLE","primary":true,"authors":"West CE, Gothefors L, Granstrom M, Kayhty H, Hammarstrom ML, Hernell O","title":"Effects of feeding probiotics during weaning on infections and antibody responses to diphtheria, tetanus and Hib vaccines","original-title":"","source":"Pediatric Allergy and Immunology","publication-date":"2008","volume":"19","issue":"1","pages":"53-60","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"2621353"},{"name":"DOI","value":"10.1111\/j.1399-3038.2007.00583.x"},{"name":"PUBMED","value":"18086218"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"West CE, Hammarström ML, Hernell O","title":"Probiotics in primary prevention of allergic disease – follow-up at 8–9 years of age","original-title":"","source":"Allergy","publication-date":"2013","volume":"68","issue":"8","pages":"1015-20","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958477"},{"name":"DOI","value":"10.1111\/all.12191"},{"name":"PUBMED","value":"23895631"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"West CE, Hammarstrom ML, Hernell O","title":"Probiotics during weaning reduce the incidence of eczema","original-title":"","source":"Pediatric Allergy and Immunology","publication-date":"2009","volume":"20","issue":"5","pages":"430-7","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958476"},{"name":"DOI","value":"10.1111\/j.1399-3038.2009.00745.x"},{"name":"PUBMED","value":"19298231"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"West CE, Rydén P, Lundin D, Engstrand L, Tulic MK, Prescott SL","title":"Gut microbiome and innate immune response patterns in IgE-associated eczema","original-title":"","source":"Clinical and Experimental Allergy","publication-date":"2015","volume":"45","issue":"9","pages":"1419-29","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958478"},{"name":"DOI","value":"10.1111\/cea.12566"},{"name":"PUBMED","value":"25944283"}]}],"characteristics":[{"name":"Methods","value":"<p>Double-blind, placebo controlled, randomised intervention trial<\/p>"},{"name":"Participants","value":"<p><b>Inclusion criteria: breastfed<\/b> healthy, term infants (gestational age 37 – 42 weeks), birthweight &gt; 2500 g, vaginally delivered, had no allergic manifestation or medication.<\/p>\n<p><b>Exclusion criteria:<\/b> atopic manifestation or medication that could affect gut microbiota, i.e. antibiotics, or prior probiotic intake.<\/p>\n<p>Infants at high risk of allergy: probiotic group 66%, placebo 61%.<\/p>"},{"name":"Interventions","value":"<p><b>Treatment (n = 89):<\/b> cereals (containing milk proteins) supplemented with Lactobacillus paracasei F19 (one serving contained 1x10<sup>8<\/sup> cfu); or<\/p>\n<p><b>Control (n = 90): <\/b>Same cereals without LF19 from 4 to 13 months of age. The recommended intake was at least 1 &nbsp;serving of cereals daily until 13 months of age.<\/p>\n<p>Parents were asked to avoid feeding the infant other products with probiotics. There was no interference with dietary habits in other respects.<\/p>"},{"name":"Outcomes","value":"<p><b>Primary outcome: <\/b>daily breastfeedings as long as the infant was breastfed, and any symptoms from the skin or airway. Any allergy or asthmatic symptoms, doctor's diagnosis and prescription and use of any drug or supplement. Days with infectious symptoms, antibiotic prescriptions and IgG antibody responses to Haemophilus influenza type b (Hib), diphtheria and tetanus vaccines. Reported to 13 months.<\/p>\n<p><b>Definitions:<\/b><\/p>\n<p>Eczema defined on the basis of questionnaires and diaries as an itchy rash for at least 2 weeks with typical distribution and dry skin or &nbsp;doctors diagnosis of eczema, or both.<\/p>\n<p>Asthma and allergic rhino-conjunctivitis: Only doctor diagnosis of asthma or allergic rhino-conjunctivitis were defined as asthma and allergic rhino-conjunctivitis.<\/p>\n<p>Cow milk protein allergy was diagnosed by a physician by an oral food challenge (blinding not reported).<\/p>"},{"name":"Notes","value":"<p><b>Sponsor:<\/b> Semper AB, Sweden, Swedish Research Council for Environment, Agricultural Science and Spatial Planning (FORMAS); Swedish Agency for Innovation Systems (VINNOVA); Swedish Research Council, Medicine; the county of Vasterbotten; Ronald McDonald Fund; Swedish Nutrition Foundation; and Oskarfonden.<\/p>\n<p>Follow-up study data at 8 - 9 years of age included in analysis under childhood prevalence.&nbsp;<\/p>\n<p><b>Declaration of interests: <\/b>none of the researchers had any financial or personal interest in the organisations and companies that sponsored the trial.<\/p>"}],"covariates":[],"arms":[{"name":"No probiotics","description":"","intervention":"No probiotic"},{"name":"Probiotics","description":"","intervention":"Probiotic"}],"results":[{"outcome":"Allergic rhinitis by 2 years","arm-level-result":{"dichotomous-data-rows":[{"arm":"No probiotics","cases":0,"sample-size":87},{"arm":"Probiotics","cases":1,"sample-size":84}],"risk-of-bias":[{"domain":"Bias due to deviations from intended interventions","judgement":"LOW_RISK","support-for-judgement":"<p>Placebo used. Cereals supplemented with LF19 or the same cereals without LF19.<\/p><p>Parents and investigators were blinded as to which carton contained LF19 until laboratory analyses were completed.<\/p>"},{"domain":"Bias due to missing outcome data","judgement":"LOW_RISK","support-for-judgement":"<p>Losses to follow up: 9\/179 (5%) at 13 month follow-up. Probiotic group n = 89, placebo group n = 90. 121 completed follow-up at 8 - 9 years of age, loss to follow-up: 50\/179 (30%). 8 - 9 year follow-up: probiotic group n = 59, placebo group n = 62. Small number of drop outs during follow up at 13 months.&nbsp;<\/p>"},{"domain":"Bias in measurement of the outcome","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>Primary outcome measure was the cumulative incidence of eczema at 13 months. Specific definitions for allergy reported. Primary outcomes measured using appropriate and validated methods.&nbsp;<\/p>"},{"domain":"Bias in selection of the reported result","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>No pre-specified analysis plan found. NCT00894816.<\/p>"},{"domain":"Overall bias","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.<\/p>"}]}},{"outcome":"Asthma by 2 years","arm-level-result":{"dichotomous-data-rows":[{"arm":"No probiotics","cases":5,"sample-size":87},{"arm":"Probiotics","cases":2,"sample-size":84}],"risk-of-bias":[{"domain":"Bias due to deviations from intended interventions","judgement":"LOW_RISK","support-for-judgement":"<p>Placebo used. Cereals supplemented with LF19 or the same cereals without LF19.<\/p><p>Parents and investigators were blinded as to which carton contained LF19 until laboratory analyses were completed.<\/p>"},{"domain":"Bias due to missing outcome data","judgement":"LOW_RISK","support-for-judgement":"<p>Losses to follow up: 9\/179 (5%) at 13 month follow-up. Probiotic group n = 89, placebo group n = 90. 121 completed follow-up at 8 - 9 years of age, loss to follow-up: 50\/179 (30%). 8 - 9 year follow-up: probiotic group n = 59, placebo group n = 62. Small number of drop outs during follow up at 13 months.&nbsp;<\/p>"},{"domain":"Bias in measurement of the outcome","judgement":"LOW_RISK","support-for-judgement":"<p>Primary outcome measure was the cumulative incidence of eczema at 13 months. Specific definitions for allergy reported. Primary outcomes measured using appropriate and validated methods.&nbsp;<\/p>"},{"domain":"Bias in selection of the reported result","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>No pre-specified analysis plan found. NCT00894816.<\/p>"},{"domain":"Overall bias","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.<\/p>"}]}},{"outcome":"Eczema by 2 years","arm-level-result":{"dichotomous-data-rows":[{"arm":"No probiotics","cases":19,"sample-size":87},{"arm":"Probiotics","cases":9,"sample-size":84}],"risk-of-bias":[{"domain":"Bias due to deviations from intended interventions","judgement":"LOW_RISK","support-for-judgement":"<p>Placebo used. Cereals supplemented with LF19 or the same cereals without LF19. Parents and investigators were blinded as to which carton contained LF19 until laboratory analyses were completed.<\/p>"},{"domain":"Bias due to missing outcome data","judgement":"LOW_RISK","support-for-judgement":"<p>Losses to follow up: 9\/179 (5%) at 13 month follow-up. Probiotic group n = 89, placebo group n = 90. 121 completed follow-up at 8 - 9 years of age, loss to follow-up: 50\/179 (30%). 8 - 9 year follow-up: probiotic group n = 59, placebo group n = 62.<\/p><p>Low risk at 13 month follow-up.&nbsp;<\/p>"},{"domain":"Bias in measurement of the outcome","judgement":"LOW_RISK","support-for-judgement":"<p>Primary outcome measure was the cumulative incidence of eczema at 13 months. Specific definitions for allergy reported.<\/p>"},{"domain":"Bias in selection of the reported result","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>No pre-specified analysis plan found. NCT00894816.<\/p>"},{"domain":"Overall bias","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.<\/p>"}]}}],"risk-of-bias":[{"domain":"Bias arising from the randomization process","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>Reported to be randomised but method not reported. Written and oral information was provided before enrolment and written consent was signed by parents. Allocation concealment is not described.<\/p><p>Well balanced groups after randomisation.<\/p>"}]},{"name":"Wickens 2008","year":"2008","data-source":"MIX","identifiers":[{"name":"CRS","value":"2621355"}],"references":[{"reference-type":"JOURNAL_ARTICLE","primary":true,"authors":"Wickens K, Black PN, Stanley TV, Mitchell E, Fitzharris P, Tannock GW, et al; Probiotic Study Group","title":"A differential effect of 2 probiotics in the prevention of eczema and atopy: a double-blind, randomized, placebo-controlled trial","original-title":"","source":"Journal of Allergy and Clinical Immunology","publication-date":"2008","volume":"122","issue":"4","pages":"788-94","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958486"},{"name":"PUBMED","value":"18762327"},{"name":"DOI","value":"10.1016\/j.jaci.2008.07.011"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Wickens K, Barthow C, Mitchell EA, Kang J, van Zyl N, Purdie G, et al","title":"Effects of Lactobacillus rhamnosus HN001 in early life on the cumulative prevalence of allergic disease to 11 years","original-title":"","source":"Pediatric Allergy and Immunology","publication-date":"2018","volume":"29","issue":"8","pages":"808-14","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958484"},{"name":"DOI","value":"10.1111\/pai.12982"},{"name":"PUBMED","value":"30430649"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Prescott SL, Wickens K, Westcott L, Jung W, Currie H, Black PN, et al; Probiotic Study Group","title":"Supplementation with Lactobacillus rhamnosus or Bifidobacterium lactis probiotics in pregnancy increases cord blood interferon-gamma and breast milk transforming growth factor-beta and immunoglobin A detection","original-title":"","source":"Clinical and Experimental Allergy","publication-date":"2008","volume":"38","issue":"10","pages":"1606-14","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958483"},{"name":"DOI","value":"10.1111\/j.1365-2222.2008.03061.x"},{"name":"PUBMED","value":"18631345"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Crane J, Wickens K, Stanley T, Mitchell E, Barthow C, Fitzharris P, et al","title":"Staphylococcal colonisation and atopy","original-title":"","source":"Internal Medicine Journal","publication-date":"2010","volume":"40","issue":"","pages":"6","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958479"},{"name":"CENTRAL","value":"CN-00789280"},{"name":"DOI","value":"10.1111\/j.1445-5994.2010.02322.x"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Murphy R, Morgan XC, Wang XY, Wickens K, Purdie G, Fitzharris P, et al","title":"Eczema-protective probiotic alters infant gut microbiome functional capacity but not composition: sub-sample analysis from a RCT","original-title":"","source":"Beneficial Microbes","publication-date":"2019","volume":"10","issue":"1","pages":"5-17","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958482"},{"name":"DOI","value":"10.3920\/BM2017.0191"},{"name":"PUBMED","value":"30574802"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Wickens K, Fitzharris P, Stanley T, Mitchell E, Crane J","title":"Does delaying the introduction of food in infancy increase the risk of atopic sensitisation?","original-title":"","source":"Allergy","publication-date":"2011","volume":"94","issue":"","pages":"47-8","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958487"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Morgan AR, Han DY, Wickens K, Barthow C, Mitchell EA, Stanley TV, et al","title":"Differential modification of genetic susceptibility to childhood eczema by two probiotics","original-title":"","source":"Clinical and Experimental Allergy","publication-date":"2014","volume":"44","issue":"10","pages":"1255-65","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958481"},{"name":"DOI","value":"10.1111\/cea.12394"},{"name":"PUBMED","value":"25146491"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Wickens K, Black P, Stanley TV, Mitchell E, Barthow C, Fitzharris P, et al","title":"A protective effect of Lactobacillus rhamnosus HN001 against eczema in the first 2 years of life persists to age 4 years","original-title":"","source":"Clinical and Experimental Allergy","publication-date":"2012","volume":"42","issue":"7","pages":"1071-9","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958485"},{"name":"DOI","value":"10.1111\/j.1365-2222.2012.03975.x"},{"name":"PUBMED","value":"22702506"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Wickens K, Stanley TV, Mitchell EA, Barthow C, Fitzharris P, Purdie G, et al","title":"Early supplementation with Lactobacillus rhamnosus HN001 reduces eczema prevalence to 6 years: does it also reduce atopic sensitization?","original-title":"","source":"Clinical and Experimental Allergy","publication-date":"2013","volume":"43","issue":"9","pages":"977-1090","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958489"},{"name":"DOI","value":"10.1111\/cea.12154"},{"name":"PUBMED","value":"23957340"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Dekker JW, Wickens K, Black PN, Stanley TV, Micthell EA, Fitzharris P, et al","title":"Safety aspects of probiotic bacterial strains Lactobacillus rhamnosus HN001 and Bifidobacterium animalis subsp. lactis HN019 in human infants aged 0 to 2 years","original-title":"","source":"International Dairy Journal","publication-date":"2009","volume":"19","issue":"3","pages":"149-54","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958480"},{"name":"CENTRAL","value":"CN-00838403"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Wickens K, Stanley T, Mitchell E, Barthow C, Fitzharris P, Purdie G, et al","title":"Early supplementation with Lactobacillus rhamnosus HN001 reduces eczema prevalence to 6 years: does it also reduce atopic sensitisation?","original-title":"","source":"Clinical and Translational Allergy","publication-date":"2014","volume":"4","issue":"Suppl 1","pages":"O9","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958488"},{"name":"DOI","value":"10.1186\/2045-7022-4-S1-O9"}]},{"reference-type":"OTHER","primary":false,"authors":"ACTRN12607000518460","title":"A trial of the effect of probiotics on the development of atopy and eczema in children","original-title":"","source":"https:\/\/anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?ACTRN=ACTRN12607000518460","publication-date":"(first posted 9 October 2007)","volume":"","issue":"","pages":"","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"28372294"}]}],"characteristics":[{"name":"Methods","value":"<p>Double-blind, randomised placebo-controlled trial.<\/p>"},{"name":"Participants","value":"<p><b>Inclusion criteria: <\/b>pregnant women - the woman or infant’s biological father had a history of treated for asthma, hay fever, or eczema.<\/p>\n<p><b>Exclusion criteria:<\/b> planned to move from the study centre during the 2 years study period, delivered &lt; 37 weeks' gestation or had not taken the study probiotic for ≥ 2 weeks pre-birth, already taking probiotic supplements or intended to use these in the child, if infants were &lt; 3rd percentile for weight, had congenital anomalies, infant admission to neonatal unit for more than 48 hours or mother receiving less than 2 weeks of treatment prior to giving birth.<\/p>"},{"name":"Interventions","value":"<p>Women were randomised to receive daily supplements of either:<\/p>\n<p><b>Treatment 1 (n = 170): <\/b>6 x 10<sup>9<\/sup> cfu\/day L. rhamnosus HN001; or<\/p>\n<p><b>Treatment 2 (n = 171): <\/b>9 x 10<sup>9<\/sup> cfu\/day B. animalis (spp lactis HN019); or<\/p>\n<p><b>Control (n = 171): <\/b>placebo (dextran, salt and a yeast extract).<\/p>\n<p>Intervention commenced 2 – 5 weeks before delivery, supplementation was continued in the postnatal period for the mother for up to 6 months if breastfeeding and for the baby, independent of feeding methods, for 2 years. Infants started the intervention between 2 and 16 days post-birth, given undiluted to the infant or mixed with water, breast milk, or formula and given via a teaspoon or syringe until solid food was started.<\/p>\n<p>Over 95% breastfed. Mean duration breast feeding 9 months.<\/p>"},{"name":"Outcomes","value":"<p><b>Primary outcome: <\/b>eczema prevalence and severity from birth to 2 years. Skin prick test assessed at 24 months.<\/p>\n<p><b>Other outcomes: <\/b>faecal samples collected soon after birth and at 3, 12, and 24 months of age; safety outcomes and standard morphometric measures, frequency and reason for any adverse effects, antibiotic use by the infants over the treatment period<\/p>\n<p><b>Definitions: <\/b>eczema prevalence was assessed using a modified version of the UK Working Party’s Diagnostic Criteria (William 1994), for atopic dermatitis at 3, 6, 12, 18 and 24 months via questionnaire and assessment of visible atopic dermatitis. IgE-associated eczema was defined as eczema plus a positive SPT response, and non-IgE associated eczema as eczema plus a negative SPT response.<br>\n Atopy was assessed at 24 months using SPTs and defined as any mean wheal diameter &gt; 3 mm.<br>\n Allergic disease development (eczema, asthma, rhinoconjunctivitis, and atopic sensitisation) was assessed using SPT, total and serum-specific IgE (ssIgE), to age 6 years.<\/p>"},{"name":"Notes","value":"<p><b>Sponsor:<\/b> Health Research Council of New Zealand and Fonterra Co-operative Group (Auckland, New Zealand).<\/p>\n<p>In this review, infant incidence reports analyses eczema and allergic disease at 2 years of age. Childhood incidence analyses the cumulative prevalence of eczema and allergic disease at 6 years of age. Childhood prevalence analyses the current health outcomes at 6 years. Prevalence of allergic disease measured at 11 years included in analysis under adolescent allergic disease.<\/p>\n<p><b>Declaration of interests: <\/b>Wickens received research funding from the Health Research Council and Fonterra Co-operative Group. P.N Black has received research funding from the Health Research Council of New Zealand, the Child Health Research Foundation and Boehringer-Ingelheim T. V. Stanley has received research funding from the Health Research Council of New Zealand and Washington Medical Research Foundation. E. Mitchell has received research funding from the Child Health Research Foundation and the National Heart Foundation of New Zealand and has served as trustee in the past year for the Wilson &amp; Sweet Trust and the Child Health Research Foundation. P. Fitzharris has received research funding from the Marsden Fund and the Foundation for Research, Science &amp; Technology. G. W. Tannock has received research support from the Marsden Fund and the Foundation for Research, Science and Technology. G. Purdie has received research funding from the Health Research Council of New Zealand and the Ministry of Health. J. Crane has received research funding from the Health Research Council of New Zealand, Rex Medical and Asthma and Respiratory Foundation of New Zealand, and the National Institute of Environmental Health Sciences.<\/p>"}],"covariates":[],"arms":[{"name":"No probiotics","description":"","intervention":"No probiotic"},{"name":"Probiotics","description":"","intervention":"Probiotic"}],"results":[{"outcome":"Eczema by 2 years","arm-level-result":{"dichotomous-data-rows":[{"arm":"No probiotics","cases":41,"sample-size":159},{"arm":"Probiotics","cases":59,"sample-size":315}],"risk-of-bias":[{"domain":"Bias due to deviations from intended interventions","judgement":"LOW_RISK","support-for-judgement":"<p>All study nurses and participants were blind to treatment assignment for the duration of the study. To evaluate the efficacy of the blinding, the final questionnaire asked participants to indicate whether they believed they were in a probiotic or placebo group.<\/p>"},{"domain":"Bias due to missing outcome data","judgement":"LOW_RISK","support-for-judgement":"<p>Losses to follow up: 66\/512 (13%). Loss to follow-up prebirth n = 7, not meeting birth criteria n = 31, lost to follow-up n = 28. 35 discontinuation of intervention. 422\/512 participants responded to the 6 year follow up (loss to follow up: 90\/512 (18%)); L. rhamnosus group n = 134, B. lactis group n = 144, placebo group n = 144. 342\/512 participants completed questionnaire at 11 year follow up (loss to follow up: 170\/512 (33%); L. rhamnosus group n = 109, B. lactis group n = 118, placebo group n = 115.<\/p><p>Loss to follow-up and drop out were due to sickness in mother, infant, time management, relocation, unable to be contacted, opposed capsules or declined contact. Reasons were not related to health outcomes measured.&nbsp;<\/p>"},{"domain":"Bias in measurement of the outcome","judgement":"LOW_RISK","support-for-judgement":"<p>Primary outcome cumulative prevalence of eczema by 2 years. Specific definitions for eczema and allergic disease reported.<\/p><p>The research staff were trained in determining eczema by using an internationally recognised training manual for defining atopic eczema (SCORAD). This occurred for all participants regardless of whether they had been diagnosed with eczema. Allergy testing was performed by the study nurse, using a panel of allergens shown to detect 90% of atopic children at 15 months.<\/p>"},{"domain":"Bias in selection of the reported result","judgement":"LOW_RISK","support-for-judgement":"<p>Pre-specified analysis plan provided. ACTRN12607000518460.<\/p>"},{"domain":"Overall bias","judgement":"LOW_RISK","support-for-judgement":"<p>The study is judged to be at low risk of bias for all domains for this result.<\/p>"}]}}],"risk-of-bias":[{"domain":"Bias arising from the randomization process","judgement":"LOW_RISK","support-for-judgement":"<p>Performed by clinical trials pharmacist, stratified by study centre and performed in blocks of 15 according to a computer-generated randomisation list.<\/p><p>Well-balanced after randomisation. Differences in participation rates at 11 years by outcomes at 6 years were not significant between study groups.<\/p><p>At enrollment assigned to next sequential study number. Allocation of supplements were performed by external personnel not associated with participants.<\/p>"}]},{"name":"Rozé 2012","year":"2012","data-source":"PUB","identifiers":[{"name":"CRS","value":"22958464"}],"references":[{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Rozé JC, Barbarot S, Butel MJ, Kapel N, Waligora-Dupriet AJ, De Montgolfier I, et al","title":"An α-lactalbumin-enriched and symbiotic-supplemented v. a standard infant formula: a multicentre, double-blind, randomised trial","original-title":"","source":"British Journal of Nutrition","publication-date":"2012","volume":"107","issue":"11","pages":"1616-22","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958465"},{"name":"DOI","value":"10.1017\/S000711451100479X"},{"name":"PUBMED","value":"22079177"}]}],"characteristics":[{"name":"Methods","value":"<p>Double-blind randomised controlled trial.&nbsp;<\/p>"},{"name":"Participants","value":"<p><b>Inclusion criteria:<\/b> gestational age &gt; 37 weeks, a postnatal age less than 3 days, fed from birth with probiotic- and prebiotic-free infant formula, and without human milk before inclusion. 4 &nbsp;centres participated in the trial (Mother-and-Children Hospital, Nates, France; Children's Hospital Angers, France; Hospital Saint-Vincent de Paul and HospitalSalpetriere, Paris, France).<\/p>\n<p><b>Exclusion criteria: <\/b>infant presenting a metabolic, nervous, digestive or organic disease able to interfere with study, evidence of cow's milk protein allergy, infant presenting lactose intolerance.<\/p>"},{"name":"Interventions","value":"<p><b>Treatment (n = 48): <\/b>the experimental formula was characterised by the presence of 2 &nbsp;strains of probiotics (Lactobacillus rhamnosus LCS-742 and Bifidobacterium longum subsp infantis M63) and by the addition of prebiotics: 96% galacto-oligosaccharides and 4% short-chain fructo-oligosaccharides. This formula was also enriched with bovinea-lactalbumin, using a native whey protein concentrate with high a-lactalbu-min concentration (34% of soluble proteins) obtained using careful fractionation techniques (ultrafiltration).&nbsp;<\/p>\n<p><b>Control (n = 49):<\/b> standard infant formula.<\/p>\n<p>The intervention ended at 6 months of age.&nbsp;<\/p>"},{"name":"Outcomes","value":"<p><b>Primary outcomes: <\/b>antropometric measurements such as weight, length, BMI, and cranial perimeter. Dermatological examination and scoring atopic dermatitis (SCORAD) index calculation, sleeping time and general well-being using structured interviews.&nbsp;<\/p>\n<p><b>Other outcomes:<\/b> formula intake for each meal, bowel habits and stool consistency over the 3 d before each visit were also collected from a home diary kept by the parents.&nbsp;<\/p>\n<p><b>Definitions:<\/b> atopic dermatitis utilised the UK Working Party's diagnostic criteria (William 1994), and SCORAD index was calculated to assess severity.&nbsp;<\/p>"},{"name":"Notes","value":"<p><b>Sponsor:<\/b> study was supported by grants from Sodliac, France. Ordesa Group provided scientific support.<\/p>\n<p><b>Declaration of interests:<\/b> J.-C R. and C. D. received consulting fees from Sodilac, France. No other conflicts of interest reported.<\/p>"}],"covariates":[],"arms":[],"results":[],"risk-of-bias":[{"domain":"Bias arising from the randomization process","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>Random sequence generation not discussed. Each product (experimental formula and control formula) was identified by a number randomly allocated using a software. No statistical perinatal characteristics were observed.<\/p><p>After inclusion, infants were randomly assigned to the experimental or control formula.<\/p>"}]},{"name":"Abrahamsson 2007","year":"2007","data-source":"PUB","identifiers":[{"name":"CRS","value":"2621274"}],"references":[{"reference-type":"JOURNAL_ARTICLE","primary":true,"authors":"Abrahamsson TR, Jakobsson T, Bottcher MF, Fredrikson M, Jenhalm MC, Björkstén B, et al","title":"Probiotics in prevention of IgE-associated eczema: a double blind randomised, placebo-controlled trial","original-title":"","source":"Journal of Allergy and Clinical Immunology","publication-date":"2007","volume":"119","issue":"5","pages":"1174-80","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"2621276"},{"name":"DOI","value":"10.1016\/j.jaci.2007.01.007"},{"name":"PUBMED","value":"17349686"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Forsberg A, Abrahamsson TR, Björkstén B, Jenmalm MC","title":"Pre- and postnatal administration of Lactobacillus reuteri decreases TLR2 responses in infants","original-title":"","source":"Clinical and Translational Allergy","publication-date":"2014","volume":"4","issue":"1","pages":"21","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958404"},{"name":"DOI","value":"10.1186\/2045-7022-4-21"},{"name":"PUBMED","value":"25002964"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Abrahamsson TR, Sinkiewicz G, Jakobsson T, Fredrikson M, Bjorksten B","title":"Probiotic lactobacilli in breast milk and infant stool in relation to oral intake during the first year of life","original-title":"","source":"Journal of Pediatric Gastroenterology and Nutrition","publication-date":"2009","volume":"49","issue":"3","pages":"349-54","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"2621277"},{"name":"DOI","value":"10.1097\/MPG.0b013e31818f091b"},{"name":"PUBMED","value":"19525871"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Connolly E, Abrahamsson TR, Björkstén B","title":"Safety of D(−)-lactic acid producing bacteria in the human infant","original-title":"","source":"Journal of Pediatric Gastroenterology and Nutrition","publication-date":"2005","volume":"41","issue":"4","pages":"489-92","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958403"},{"name":"DOI","value":"10.1097\/01.mpg.0000176179.81638.45"},{"name":"PUBMED","value":"16205524"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Abrahamsson TR, Sandberg M, Forsberg A, Björkstén B, Jenmalm MC","title":"A Th1\/Th2-associated chemokine imbalance preceding allergic disease is influenced by birth size, breastfeeding, daycare and probiotics","original-title":"","source":"Allergy","publication-date":"2009","volume":"64","issue":"Suppl 1","pages":"56","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958402"},{"name":"DOI","value":"10.1111\/j.1398-9995.2009.02074.x"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Bottcher MF, Abrahamsson TR, Fredriksson M, Jakobsson T, Björkstén B","title":"Low breast milk TGF-beta2 is induced by Lactobacillus reuteri supplementation and associates with reduced risk of sensitization during infancy","original-title":"","source":"Pediatric Allergy and Immunology","publication-date":"2008","volume":"19","issue":"6","pages":"497-504","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"2621278"},{"name":"DOI","value":"10.1111\/j.1399-3038.2007.00687.x"},{"name":"PUBMED","value":"18221472"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Abrahamsson TR, Jakobsson HE, Andersson AF, Björkstén B, Engstrand L, Jenmalm MC","title":"Low diversity of the gut microbiota in infants with atopic eczema","original-title":"","source":"Journal of Allergy and Clinical Immunology","publication-date":"2012","volume":"129","issue":"2","pages":"434-40","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958397"},{"name":"DOI","value":"10.1016\/j.jaci.2011.10.025"},{"name":"PUBMED","value":"22153774"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Abrahamsson TR, Jakobsson T, Bottcher MF, Fredrikson M, Jenmalm MC, Björkstén B, et al","title":"Probiotics in the prevention of IgE-associated eczema: a double blind randomised placebo-controlled trial","original-title":"","source":"Journal of Allergy and Clinical Immunology","publication-date":"2007","volume":"119","issue":"5","pages":"1174-80","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958400"},{"name":"PUBMED","value":"17349686"},{"name":"DOI","value":"10.1016\/j.jaci.2007.01.007"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Abrahamsson TR, Sanberg Abelius M, Forsberg A, Björkstén B, Jenmalm MC","title":"A Th1\/Th2-associated chemokine imbalance during infancy in children developing eczema, wheeze and sensitization","original-title":"","source":"Clinical and Experimental Allergy","publication-date":"2011","volume":"41","issue":"12","pages":"1729-39","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958401"},{"name":"DOI","value":"10.1111\/j.1365-2222.2011.03827.x"},{"name":"PUBMED","value":"21801246"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Abrahamsson TR, Jakobsson T, Björkstén B, Oldaeus G, Jenmalm MC","title":"No effect of probiotics on respiratory allergies: a seven-year follow-up of a randomized controlled trial in infancy","original-title":"","source":"Pediatric Allergy and Immunology","publication-date":"2013","volume":"24","issue":"6","pages":"556-61","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958398"},{"name":"DOI","value":"10.1111\/pai.12104"},{"name":"PUBMED","value":"23902407"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Abrahamsson TR, Jakobsson HE, Andersson AF, Björkstén B, Engstrand L, Jenmalm MC","title":"Low gut microbiota diversity in early infancy precedes asthma at school age","original-title":"","source":"Clinical and Experimental Allergy","publication-date":"2014","volume":"44","issue":"6","pages":"842-50","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958396"},{"name":"DOI","value":"10.1111\/cea.12253"},{"name":"PUBMED","value":"24330256"}]}],"characteristics":[{"name":"Notes","value":"<p><b>Sponsor: <\/b>Grants from BioGaia AB, Stockholm, Sweden, the Ekhaga Foundation, the Heart and Lung foundation, the Research Council for the South-East Sweden (grant No. F2000-106), the Swedish Asthma and Allergy Association, the Swedish Research Council and the University Hospital of Linköping, Sweden.<\/p>\n<p>2011 update: Additional publications; no additional allergy or food hypersensitivity data. 2023 update: Additional publications; addition of 7-year follow up data on allergic disease and skin prick test reactivity. Allergic disease at (quote:) \"2 years and\/or 7 years\" included in analysis under childhood incidence. Prevalence of allergic disease (quote:) \"between six and 7 yr of age\" included in analysis under childhood prevalence.&nbsp;<\/p>\n<p><b>Declaration of interests:<\/b> B. Björkstén has consulting arrangements with BioGala Inc. The rest of authors have declared that they have no conflict of interest.<\/p>"},{"name":"Outcomes","value":"<p><b>Primary outcomes:<\/b> eczema and sensitisation in first 2 years conducted by a paediatrician. SPTs were performed at 6, 12 and 24 months of age. Circulating IgE antibodies to common allergens were assessed at 6, 12 and 24 months of age. Follow up study at 7-years, allergic disease and skin prick test reactivity were assessed.Follow up assessment by research nurse and structured telephone interview up to 2 years.&nbsp;<\/p>\n<p><br><b>Other outcomes:<\/b> symptoms of allergic disease, adverse events, infections, use of antibiotics and possible confounding factors and inspection of the skin. SCORAD index was used to assess the severity of eczema. Records from primary care units, private paediatricians and the paedatric clinics were examined if parents reported that child had been examined by physician. Outcomes of the study are assessed as per diagnostic criteria described in the study.<br>\n &nbsp;<\/p>\n<p><b>Definitions: <\/b>eczema is physician confirmed. SCORAD score used. Defined as pruritic, chronic or chronically relapsing non-infectious dermatitis with typical features and distribution.<\/p>\n<p>Gastrointestinal allergy required vomiting, diarrhoea, or systemic reaction after ingestion of a potentially allergenic food and a confirmation by challenge, unless there was a clear history of a severe systemic reaction.&nbsp;<br>\n Infants were regarded as sensitised if they had at least 1 positive SPT or detectable circulating allergen specific-IgE antibodies, or both.<br>\n Allergic disease assessed at 7 years of age (±3 months) included asthma, allergic rhinoconjunctivitis (ARC), allergic urticaria and eczema.&nbsp;<\/p>\n<p><br>\n Asthma diagnosis required at least 1 of following 2 criteria:<\/p>\n<ul>\n <li>doctor diagnosis and asthma symptoms or medication, or both, during the last 12 months; and<\/li>\n <li>wheeze or nocturnal cough and a positive reversibility test or pathological FE<sub>NO<\/sub> value, or both.&nbsp;<\/li>\n<\/ul>\n<p>Diagnosis of ARC based on standard ISAAC question and required watery discharge at least twice in contact with the same allergen and no sign of infection.<br>\n Had symptoms of or has been treated for the actual allergic disease during the last 12 months, or both.&nbsp;<\/p>"},{"name":"Interventions","value":"<p><b>Treatment (n = 117): <\/b>Lactobacillus reuteri 1x10<sup>8<\/sup> cfu daily (freeze-dried, suspended in coconut and peanut oil) given to mother for 4 weeks before delivery, mother and baby daily for 12 months after delivery.<\/p>\n<p><br><b>Control (n = 115): <\/b>placebo (same oil).<br>\n Co-interventions: infants breast-fed. When weaned, given whey hydrolysate formula to 6 months (both groups).<\/p>\n<p>Mothers were encouraged to breastfeed. At weaning, babies were offered a hypoallergenic whey hydrolysate until 6 months of age.&nbsp;<\/p>"},{"name":"Participants","value":"<p><b>Inclusion criteria:<\/b> families with allergic disease (1 or more family members with eczema, asthma, gastrointestinal allergy, allergic urticaria, or allergic rhinoconjunctivitis) recruited at antenatal clinics.<\/p>\n<p><br><b>Exclusion criteria: <\/b>mother reporting peanut allergy. Infants admitted to neonatal unit in first week. Insufficient compliance led to exclusion of participants from the study.<\/p>"},{"name":"Methods","value":"<p>Double-blind, randomised, placebo-controlled trial.<\/p>"}],"covariates":[],"arms":[{"name":"No probiotics","description":"","intervention":"No probiotic"},{"name":"Probiotics","description":"","intervention":"Probiotic"}],"results":[{"outcome":"Allergic rhinitis by 2 years","arm-level-result":{"dichotomous-data-rows":[{"arm":"Probiotics","cases":1,"sample-size":95},{"arm":"No probiotics","cases":4,"sample-size":93}],"risk-of-bias":[{"domain":"Bias due to deviations from intended interventions","judgement":"LOW_RISK","support-for-judgement":"<p>Randomised before delivery. Before the delivery, each bottle was labelled and randomly mixed by an independent contract manufacturer.<\/p><p>Placebo used. Daily intake 5 oil droplets. The placebo consisted of the same oil without any bacteria and was not possible to differentiate from the active product by smell, taste, or visual appearance.<\/p><p>Placebo used. Quote: \"none of the investigators or the pharmacies at the trial sites has access to the code.\"<\/p>"},{"domain":"Bias due to missing outcome data","judgement":"LOW_RISK","support-for-judgement":"<p>Losses to follow up: but excluded if admitted to neonatal ward, declined participation or poor compliance. Exclusions included discontinued before delivery (5), admitted to neonatal ward (18), declined participation after randomisation (19) or non-compliers with treatment (2). Reason for missing data is not related to participant outcomes. Completed study at 2 years: probiotic group 95\/117 (81%); placebo group 93\/115 (81%). 184 (79%) families with allergic disease completed follow-up study at 7 years: probiotic group 94; placebo group 90.<\/p>"},{"domain":"Bias in measurement of the outcome","judgement":"LOW_RISK","support-for-judgement":"<p>The aim of the current study was to assess the effect of oral supplementation with L reuteri in infancy on eczema development and sensitisation during the first 2 years of life. Specific definitions for outcomes described as part of the diagnostic criteria.<\/p>"},{"domain":"Bias in selection of the reported result","judgement":"LOW_RISK","support-for-judgement":"<p>Planned analyses provided, although no specification of whether there were any deviations from the planned analysis. NCT01285830.<\/p>"},{"domain":"Overall bias","judgement":"LOW_RISK","support-for-judgement":"<p>The study is judged to be at low risk of bias for all domains for this result.<\/p>"}]}},{"outcome":"Asthma by 2 years","arm-level-result":{"dichotomous-data-rows":[{"arm":"Probiotics","cases":7,"sample-size":95},{"arm":"No probiotics","cases":10,"sample-size":93}],"risk-of-bias":[{"domain":"Bias due to deviations from intended interventions","judgement":"LOW_RISK","support-for-judgement":"<p>Randomised before delivery. Before the delivery, each bottle was labelled and randomly mixed by an independent contract manufacturer.<\/p><p>Placebo used. Daily intake 5 oil droplets. The placebo consisted of the same oil without any bacteria and was not possible to differentiate from the active product by smell, taste, or visual appearance.<\/p><p>Placebo used. Quote: \"none of the investigators or the pharmacies at the trial sites has access to the code.\"<\/p>"},{"domain":"Bias due to missing outcome data","judgement":"LOW_RISK","support-for-judgement":"<p>Losses to follow up: but excluded if admitted to neonatal ward, declined participation or poor compliance. Exclusions included discontinued before delivery (5), admitted to neonatal ward (18), declined participation after randomisation (19) or non-compliers with treatment (2). Reason for missing data is not related to participant outcomes. Completed study at 2 years: probiotic group 95\/117 (81%); placebo group 93\/115 (81%). 184 (79%) families with allergic disease completed follow-up study at 7 years: probiotic group 94; placebo group 90.<\/p>"},{"domain":"Bias in measurement of the outcome","judgement":"LOW_RISK","support-for-judgement":"<p>The aim of the current study was to assess the effect of oral supplementation with L reuteri in infancy on eczema development and sensitisation during the first 2 years of life. Specific definitions for outcomes described as part of the diagnostic criteria.<\/p>"},{"domain":"Bias in selection of the reported result","judgement":"LOW_RISK","support-for-judgement":"<p>Planned analyses provided, although no specification of whether there were any deviations from the planned analysis. NCT01285830.<\/p>"},{"domain":"Overall bias","judgement":"LOW_RISK","support-for-judgement":"<p>The study is judged to be at low risk of bias for all domains for this result.<\/p>"}]}},{"outcome":"Eczema by 2 years","arm-level-result":{"dichotomous-data-rows":[{"arm":"Probiotics","cases":34,"sample-size":95},{"arm":"No probiotics","cases":32,"sample-size":93}],"risk-of-bias":[{"domain":"Bias due to deviations from intended interventions","judgement":"LOW_RISK","support-for-judgement":"<p>Randomised before delivery. Before the delivery, each bottle was labelled and randomly mixed by an independent contract manufacturer.<\/p><p>Placebo used. Daily intake 5 oil droplets. The placebo consisted of the same oil without any bacteria and was not possible to differentiate from the active product by smell, taste, or visual appearance.<\/p><p>Placebo used. Quote: \"none of the investigators or the pharmacies at the trial sites has access to the code.\"<\/p>"},{"domain":"Bias due to missing outcome data","judgement":"LOW_RISK","support-for-judgement":"<p>Losses to follow up: but excluded if admitted to neonatal ward, declined participation or poor compliance. Exclusions included discontinued before delivery (5), admitted to neonatal ward (18), declined participation after randomisation (19) or non-compliers with treatment (2). Reason for missing data is not related to participant outcomes. Completed study at 2 years: probiotic group 95\/117 (81%); placebo group 93\/115 (81%). 184 (79%) families with allergic disease completed follow-up study at 7 years: probiotic group 94; placebo group 90.<\/p>"},{"domain":"Bias in measurement of the outcome","judgement":"LOW_RISK","support-for-judgement":"<p>The aim of the current study was to assess the effect of oral supplementation with L reuteri in infancy on eczema development and sensitisation during the first 2 years of life. Specific definitions for outcomes described as part of the diagnostic criteria.<\/p>"},{"domain":"Bias in selection of the reported result","judgement":"LOW_RISK","support-for-judgement":"<p>Planned analyses provided, although no specification of whether there were any deviations from the planned analysis. NCT01285830.<\/p>"},{"domain":"Overall bias","judgement":"LOW_RISK","support-for-judgement":"<p>The study is judged to be at low risk of bias for all domains for this result.<\/p>"}]}}],"risk-of-bias":[{"domain":"Bias arising from the randomization process","judgement":"LOW_RISK","support-for-judgement":"<p>Randomisation was stratified for each study centre. Each centre was provided an allocation list with unique identification numbers for each participant. Groups well balanced.<\/p><p>Randomised before delivery. Before the delivery, each bottle was labelled and randomly mixed by an independent contract manufacturer.<\/p>"}]},{"name":"Kim 2010","year":"2010","data-source":"PUB","identifiers":[{"name":"CRS","value":"2621297"}],"references":[{"reference-type":"JOURNAL_ARTICLE","primary":true,"authors":"Kim JY, Kwon JH, Ahn SH, Lee SI, Han YS, Choi YO, et al","title":"Effect of probiotic mix (Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus) in the primary prevention of eczema: a double-blind, randomized, placebo-controlled trial","original-title":"","source":"Pediatric Allergy and Immunology","publication-date":"2010","volume":"21","issue":"2 Pt 2","pages":"e386-93","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"2621299"},{"name":"DOI","value":"10.1111\/j.1399-3038.2009.00958.x"},{"name":"PUBMED","value":"19840300"}]},{"reference-type":"OTHER","primary":false,"authors":"ISRCTN26134979","title":"Effect of probiotics in the primary prevention of atopic eczema","original-title":"Effect of probiotics (Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus) in the primary prevention of atopic dermatitis: a double-blind, randomised, placebo-controlled trial","source":"https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ISRCTN26134979","publication-date":"(first received 27 May 2009)","volume":"","issue":"","pages":"","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958418"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Kim JY, Choi YO, Kwon JH, Ahn KM, Park MS, Ji GE","title":"Clinical effects of probiotics are associated with increased transforming growth factor-B responses in infants with high-risk allergy","original-title":"","source":"Journal of the Korean Society for Applied Biological Chemistry","publication-date":"2011","volume":"54","issue":"6","pages":"944-8","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958419"},{"name":"DOI","value":"10.1007\/BF03253184"}]}],"characteristics":[{"name":"Methods","value":"<p>Randomised, double-blind, placebo-controlled trial.<\/p>"},{"name":"Participants","value":"<p><b>Inclusion criteria: <\/b>pregnant women with a family history of allergic diseases. A family history of allergic diseases defined as:<\/p>\n<ul>\n <li>at least 1 &nbsp;parent or older sibling of the foetus had eczema, as confirmed by a paediatric allergist; or<\/li>\n <li>1 of the parents diagnosed with asthma or allergic rhinitis, or both, by a physician, showing house dust mite-specific IgE &gt; 1.0 kU\/L by CAP-FEIA immunoassay.<\/li>\n<\/ul>\n<p><b>Exclusion criteria:<\/b><\/p>\n<ul>\n <li>premature babies delivered &lt; 36 weeks of gestation;<\/li>\n <li>infants with immune deficiency disease, necrotising enterocolitis, or congenital disorders; or<\/li>\n <li>those requiring anticancer treatment or a central venous catheter.<\/li>\n<\/ul>"},{"name":"Interventions","value":"<p><b>Treatment (n = 57): <\/b>mothers in the probiotic group took a mixture of Bifidobacterium bifidum BGN4 [1.6 x 10<sup>9<\/sup> cfu], Bifidobacterium lactis AD011 (1.6 x 10<sup>9<\/sup> cfu), and Lactobacillus acidophilus AD031 (1.6 x 10<sup>9<\/sup> cfu) in 0.72 g of maltodextrin and 0.8 g of alpha-corn (Bifido Inc., Hongchungun, Korea) once daily from 8 weeks before the expected delivery to 3 months after delivery. Infants were fed the same powder dissolved in breast milk, infant formula, or sterile water from 4 to 6 months of age.<\/p>\n<p><b>Control (n = 55): <\/b>mothers and infants in the placebo group took maltodextrin and alpha-corn without probiotic bacteria.<\/p>\n<p>Mean duration exclusive breastfeeding probiotic group 5.97 months and control group 5.26 months.<\/p>"},{"name":"Outcomes","value":"<p><b>Primary outcomes: <\/b>eczema and sensitisation against common food allergens. Infants were followed up to 1 year of age, involving examinations at 3, 6, and 12 months to assess the occurrence of eczema. Venous blood was obtained at 12 months to measure total IgE and specific IgE against common food allergens<\/p>\n<p><b>Other outcomes:<\/b> clinical histories such as gestational age, birth weight, caesarean section delivery, mothers age, duration of breastfeeding, diet, fever (‡ 38.5C), respiratory tract infection, hospitalisation, acute gastroenteritis, and use of antibiotics.&nbsp;<\/p>\n<p><br><b>Definitions:<\/b><\/p>\n<p>Diagnosis of eczema was confirmed when the skin lesions met the criteria of Hanifin and Rajka (Hanifin 1980).<br>\n The severity of eczema was determined using the 'Six Area Six Sign in Atopic dermatitis (SASSAD) score'.<br>\n 12 months total IgE and specific IgE against common food allergens (egg white, cow's milk, wheat, peanut, soybean, and buckwheat) using CAP-FEIA (Pharmacia, Uppsala, Sweden). Antigen-specific IgE levels &gt; 0.35 kU\/L were considered positive. Probable egg allergy defined when the egg white-specific IgE level ≻ 2 kU\/L. IgE associated eczema reported. However, antigen-specific results not reported for symptomatic infants.<\/p>"},{"name":"Notes","value":"<p><b>Sponsor:<\/b> no commercial sponsor reported. Supported by grants (A060546 and A080664) from the Ministry for Health, Welfare and Family Affairs, Republic of Korea.<\/p>\n<p><b>Declaration of interests: <\/b>not reported.<\/p>"}],"covariates":[],"arms":[{"name":"No probiotics","description":"","intervention":"No probiotic"},{"name":"Probiotics","description":"","intervention":"Probiotic"}],"results":[{"outcome":"Eczema by 2 years","arm-level-result":{"dichotomous-data-rows":[{"arm":"No probiotics","cases":22,"sample-size":35},{"arm":"Probiotics","cases":12,"sample-size":33}],"risk-of-bias":[{"domain":"Bias due to deviations from intended interventions","judgement":"LOW_RISK","support-for-judgement":"<p>Placebo used. The placebo looked, smelled and tasted identical to the probiotic. Participants were blinded.&nbsp;<\/p><p>Diagnosis and clinical assessment of eczema was performed by a paediatric allergist who remained unaware of the actual treatment administered during the entire study period.<\/p>"},{"domain":"Bias due to missing outcome data","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>68\/112 (61%) followed to 12 months. 23 participants dropped out before the 3 month follow-up due to declined participation, non-feeding, administration of other probiotic product outside of study, loss connection; 21 infants discontinued the study after 3 months for declined participation, poor compliance, loss connection, non-administration of probiotic or placebo. High number of drop out is of concern although the reasons were described to be unrelated to study intervention. In the later group, the occurrence of eczema was 20.0% (2\/10) in the probiotic group and 54.5% (6\/11) in the placebo group at their last visit.<\/p>"},{"domain":"Bias in measurement of the outcome","judgement":"LOW_RISK","support-for-judgement":"<p>Primary outcome eczema and sensitisation against common food allergens. Specific definitions for eczema and allergic disease reported.<\/p>"},{"domain":"Bias in selection of the reported result","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>No pre-specified analysis plan. ISRCTN26134979.<\/p>"},{"domain":"Overall bias","judgement":"HIGH_RISK","support-for-judgement":"<p>The study is judged to have some concerns for multiple domains in a way that substantially lowers confidence in the result.<\/p>"}]}}],"risk-of-bias":[{"domain":"Bias arising from the randomization process","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>Allocated by trials co-ordinator according to computerised randomisation. The groups were stratified and block-randomised in accordance with:<\/p><ul><li>maternal allergy (allergy compared with no allergy);<\/li><li>older siblings eczema; and<\/li><li>number of parents affected by allergic disease (1 compared with 2).<\/li><\/ul><p>Potentially clinically significant although not statistically significant differences between groups after randomisation in rates of caesarean delivery and duration of breastfeeding.<\/p><p>Treatment allocated by trials co-ordinator without detailed knowledge of the clinical history. Allocation was not completed by an external personnel.<\/p>"}]},{"name":"Kukkonen 2006","year":"2006","data-source":"PUB","identifiers":[{"name":"CRS","value":"22958420"}],"references":[{"reference-type":"JOURNAL_ARTICLE","primary":true,"authors":"Kukkonen K, Savilahti E, Haahtela T, Juntunen-Backman K, Korpela R, Poussa T, et al","title":"Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial","original-title":"","source":"Journal of Allergy and Clinical Immunology","publication-date":"2007","volume":"119","issue":"1","pages":"192-8","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958433"},{"name":"DOI","value":"10.1016\/j.jaci.2006.09.009"},{"name":"PUBMED","value":"17208601"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Kukkonen A, Haahtela T, Kuitunen M, Savilahti E","title":"Dynamics of intestinal alpha-and beta-defensin secretion in infancy is associated with the emergence of allergy","original-title":"","source":"Allergy","publication-date":"2011","volume":"66","issue":"Suppl 94","pages":"149","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958428"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Kuitunen M, Juntunen-Backman K, Korpela R, Poussa T, Tuure T, Haahtela T, et al","title":"Probiotics prevent IgE-associated allergy until age 5 in cesarean-delivered children but not in the total cohort","original-title":"","source":"Allergy","publication-date":"2009","volume":"64","issue":"Suppl 90","pages":"64","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958425"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Kauppi P, Kuokkanen M, Kukkonen K, Laitinen T, Kuitunen M","title":"Interaction of NPSR1 genotypes and probiotics in the manifestation of atopic eczema in early childhood","original-title":"","source":"Allergologia et Immunopathologia","publication-date":"2014","volume":"42","issue":"6","pages":"560-7","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958424"},{"name":"PUBMED","value":"24439655"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Kukkonen K, Savilahti E, Haahtela T, Juntunen-Backman K, Korpela R, Poussa T, et al","title":"Long-term safety and impact on infection rates of postnatal probiotic and prebiotic (synbiotic) treatment: randomized, double-blind, placebo-controlled trial","original-title":"","source":"Pediatrics","publication-date":"2008","volume":"122","issue":"1","pages":"8-12","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958434"},{"name":"DOI","value":"10.1542\/peds.2007-1192"},{"name":"PUBMED","value":"18595980"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Savilahti E, Harkonen T, Savilahti EM, Kukkonen K, Kuitunen M, Knip M","title":"Probiotic intervention in infancy is not associated with development of beta cell autoimmunity and type 1 diabetes","original-title":"","source":"Diabetologia","publication-date":"2018","volume":"61","issue":"12","pages":"2668-70","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958440"},{"name":"DOI","value":"10.1007\/s00125-018-4738-4"},{"name":"PUBMED","value":"30238182"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Kukkonen AK, Savilahti EM, Haahtela T, Savilahti E, Kuitunen M","title":"Ovalbumin-specific immunoglobulins A and G levels at age 2 years are associated with the occurrence of atopic disorders","original-title":"","source":"Clinical and Experimental Allergy","publication-date":"2011","volume":"41","issue":"10","pages":"1414-21","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958430"},{"name":"DOI","value":"10.1111\/j.1365-2222.2011.03821.x"},{"name":"PUBMED","value":"21771118"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Savilahti EM, Kukkonen AK, Kuitunen M, Savilahti E","title":"Soluble CD14, α-and β-defensins in breast milk: association with the emergence of allergy in a high-risk population","original-title":"","source":"Innate Immunity","publication-date":"2015","volume":"21","issue":"3","pages":"332-7","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958443"},{"name":"DOI","value":"10.1177\/1753425914541560"},{"name":"PUBMED","value":"25432966"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Sandini U, Kukkonen AK, Poussa T, Sandini L, Savilahti E, Kuitunen M","title":"Protective and risk factors for allergic diseases in high-risk children at the ages of two and five years","original-title":"","source":"International Archives of Allergy and Immunology","publication-date":"2011","volume":"156","issue":"3","pages":"339-48","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958439"},{"name":"DOI","value":"10.1159\/000323907"},{"name":"PUBMED","value":"21720181"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Kuitunen M, Kukkonen K, Juntunen-Backman K, Korpela R, Poussa T, Tuure T, et al","title":"Probiotics prevent IgE-associated allergy until age 5 years in cesarean-delivered children but not in the total cohort","original-title":"","source":"Journal of Allergy and Clinical Immunology","publication-date":"2009","volume":"123","issue":"2","pages":"335-41","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958426"},{"name":"PUBMED","value":"19135235"},{"name":"DOI","value":"10.1016\/j.jaci.2008.11.019"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Marschan E, Honkanen J, Kukkonen K, Kuitunen M, Savilahti E, Vaarala O","title":"Increased activation of GATA-3, IL-2 and IL-5 of cord blood mononuclear cells in infants with IgE sensitization","original-title":"","source":"Pediatric Allergy and Immunology","publication-date":"2008","volume":"19","issue":"2","pages":"132-9","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958435"},{"name":"DOI","value":"10.1111\/j.1399-3038.2007.00593.x"},{"name":"PUBMED","value":"17651376"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Kukkonen AK, Kuitunen M, Savilahti E, Pelkonen A, Malmberg P, Makela M","title":"Airway inflammation in probiotic-treated children at 5 years","original-title":"","source":"Pediatric Allergy and Immunology","publication-date":"2011","volume":"22","issue":"2","pages":"249-51","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958429"},{"name":"DOI","value":"10.1111\/j.1399-3038.2010.01079.x"},{"name":"PUBMED","value":"21332798"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Kukkonen K, Nieminen T, Poussa T, Savilahti E, Kuitunen M","title":"Effect of probiotics on vaccine antibody responses in infancy – a randomized placebo-controlled double-blind trial","original-title":"","source":"Pediatric Allergy and Immunology","publication-date":"2006","volume":"17","issue":"6","pages":"416-21","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958432"},{"name":"DOI","value":"10.1111\/j.1399-3038.2006.00420.x"},{"name":"PUBMED","value":"16925686"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Marschan E, Kuitunen M, Kukkonen K, Poussa T, Sarnesto A, Haahtela T, et al","title":"Probiotics in infancy induce protective immune profiles that are characteristic for chronic low-grade inflammation","original-title":"","source":"Clinical and Experimental Allergy","publication-date":"2008","volume":"38","issue":"4","pages":"611-8","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958436"},{"name":"DOI","value":"10.1111\/j.1365-2222.2008.02942.x"},{"name":"PUBMED","value":"18266878"}]},{"reference-type":"OTHER","primary":false,"authors":"NCT00298337","title":"Use of probiotic bacteria in prevention of allergic disease in children 1999–2008","original-title":"","source":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00298337","publication-date":"(first received 2 March 2006)","volume":"","issue":"","pages":"","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958441"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Savilahti EM, Makitie O, Kukkonen AK, Andersson S, Viljakainen H, Savilahti E, et al","title":"Serum 25-hydroxyvitamin D in early childhood is non-linearly associated with allergy","original-title":"","source":"International Archives of Allergy and Immunology","publication-date":"2016","volume":"170","issue":"3","pages":"141-8","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958444"},{"name":"DOI","value":"10.1159\/000447636"},{"name":"PUBMED","value":"27533066"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Sprenger N, Odenwald H, Kukkonen AK, Kuitunen M, Savilahti E, Kunz C","title":"FUT2-dependent breast milk oligosaccharides and allergy at 2 and 5 years of age in infants with high hereditary allergy risk","original-title":"","source":"European Journal of Nutrition","publication-date":"2017","volume":"56","issue":"3","pages":"1293-301","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958445"},{"name":"PUBMED","value":"26907090"},{"name":"DOI","value":"10.1007\/s00394-016-1180-6"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Kukkonen K, Kuitunen M, Haahtela T, Korpela R, Poussa T, Savilahti E","title":"High intestinal IgA associates with reduced risk of IgE-associated allergic diseases","original-title":"","source":"Pediatric Allergy and Immunology","publication-date":"2010","volume":"21","issue":"1 Pt 1","pages":"67-73","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958431"},{"name":"DOI","value":"10.1111\/j.1399-3038.2009.00907.x"},{"name":"PUBMED","value":"19566584"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Peldan PS, Kukkonen AK, Savilahti E, Kuitunen M","title":"Perinatal probiotic mixture and development of allergic sensitization up to 13 years of age","original-title":"","source":"International Archives of Allergy and Immunology","publication-date":"2020","volume":"181","issue":"4","pages":"270-7","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958438"},{"name":"DOI","value":"10.1159\/000504915"},{"name":"PUBMED","value":"32018252"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Kallio S, Kukkonen K, Savilahti E, Kuitunen M","title":"Early probiotic prophylaxis reduces allergic symptoms in 13-year follow-up","original-title":"","source":"Allergy","publication-date":"2017","volume":"72","issue":"Suppl 103","pages":"553","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958423"},{"name":"DOI","value":"10.1111\/all.13252"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Savilahti EM, Kukkonen AK, Haahtela T, Tuure T, Kuitunen M, Savilahti E","title":"Intestinal defensin secretion in infancy is associated with the emergence of sensitization and atopic dermatitis","original-title":"","source":"Clinical and Experimental Allergy","publication-date":"2012","volume":"42","issue":"3","pages":"405-11","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958442"},{"name":"DOI","value":"10.1111\/j.1365-2222.2011.03904.x"},{"name":"PUBMED","value":"22093109"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Peldan P, Kukkonen AK, Savilahti E, Kuitunen M","title":"Perinatal probiotics decreased eczema up to 10 years of age, but at 5–10 years, allergic rhino-conjunctivitis was increased","original-title":"","source":"Clinical and Experimental Allergy","publication-date":"2017","volume":"47","issue":"7","pages":"975-9","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958437"},{"name":"PUBMED","value":"28316095"},{"name":"DOI","value":"10.1111\/cea.12924"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Kallio S, Kukkonen AK, Savilahti E, Kuitunen M","title":"Perinatal probiotic intervention prevented allergic disease in a caesarean-delivered subgroup at 13-year follow-up","original-title":"","source":"Clinical and Experimental Allergy","publication-date":"2019","volume":"49","issue":"4","pages":"506-15","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958422"},{"name":"DOI","value":"10.1111\/cea.13321"},{"name":"PUBMED","value":"30472801"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Kuitunen M, Kukkonen K, Savilahti E","title":"Pro- and prebiotic supplementation induces a transient reduction in hemoglobin concentration in infants","original-title":"","source":"Journal of Pediatric Gastroenterology and Nutrition","publication-date":"2009","volume":"49","issue":"5","pages":"626-30","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958427"},{"name":"DOI","value":"10.1097\/MPG.0b013e31819de849"},{"name":"PUBMED","value":"19644396"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Kallio S, Kaarina K, Savilahti E, Kuitunen M","title":"Early probiotic intervention increases inhalant sensitisation and reduces eczema in cesarean-delivered subgroup in 13-year follow-up","original-title":"","source":"Allergy","publication-date":"2018","volume":"73","issue":"Suppl 105","pages":"334","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958421"},{"name":"DOI","value":"10.1111\/all.13537"}]}],"characteristics":[{"name":"Methods","value":"<p>Randomised, double-blind, placebo-controlled study.<\/p>"},{"name":"Participants","value":"<p><b>Inclusion criteria: <\/b>pregnant women with at least 1 parent of the unborn child had a physician-diagnosed allergic disease.<br><b>Exclusion criteria:<\/b> infants born &lt; 37 weeks' gestation, infants with major malformations, and B-twins.<\/p>"},{"name":"Interventions","value":"<p><b>Treatment (n = 610):<\/b> mothers took 1 capsule for 2 - 4 weeks before delivery containing Lactobacillus rhamnosus GG (ATCC 53103), 5 x 10<sup>9<\/sup> cfu; L rhamnosus LC705 (DSM 7061), 5 x 10<sup>9<\/sup> cfu; Bifidobacterium breve Bb99 (DSM 13692), 2 x 10<sup>8<\/sup> cfu; and Propionibacterium freudenreichii ssp. shermanii JS (DSM 7076), 2 x 10<sup>9<\/sup> cfu. Their newborn infants received 1 opened capsule containing the same probiotic mixed with 20 drops of sugar syrup containing 0.8 g of galacto-oligosaccharides once daily for 6 months after birth.<br><b>Control (n = 613): <\/b>placebo group mothers and infants took capsules containing microcrystalline cellulose, and infants received sugar syrup without galacto-oligosaccharides.<\/p>\n<p><br>\n Exclusive breast-fed treatment group 2.6 months, control group 2.4 months. Standard adapted cow’s milk–based formula replaced breast milk when breast-feeding was insufficient. The use of hypoallergenic formula was restricted to infants allergic to cow’s milk.<\/p>"},{"name":"Outcomes","value":"<p><b>Primary outcomes: <\/b>any allergic disease (food allergy, eczema, asthma, and allergic rhinitis) and IgE-associated (atopic) disease at 2 years.<br><b>Other outcomes:<\/b> eczema and sensitisation. Physician assessment at 3, 6, 24 months and 5 years. At 10 years parents completed questionnaires based on the ISAAC study. At 13 years, follow-up questionnaire was completed.<\/p>\n<p><b>Definitions<\/b><br>\n Food allergy diagnosed with an open food challenge.<br>\n Eczema: according to the UK Working Party’s criteria (an itchy skin condition plus ≥ 3 of atopic disease in the family, dry skin during the last year, history of eczema, or visible eczema involving typical sites), (William 1994).<br>\n Atopic eczema: if IgE associated.<br>\n Severity of eczema evaluated using SCORAD score.<br>\n Asthma: 2 or more physician-diagnosed wheezing episodes accompanied by persistent cough or exercise-induced symptoms.<\/p>"},{"name":"Notes","value":"<p><b>Sponsor: <\/b>grants from Valio Ltd; 2 authors employed by Valio Ltd.<\/p>\n<p>2023 update: Inclusion of results from 5-year, 10-year, and 13-year follow-up studies. Childhood incidence analysis included results from 5-year follow-up. Childhood prevalence analysis included new onset of allergic disease and eczema diagnosed at age 5 - 10 years (ISAAC based). Adolescent allergic disease included allergic disease present at 13 years of age (12 mo ISAAC based). &nbsp;<\/p>\n<p><b>Declaration of interests: <\/b>K. Kukkonen has received grant support from Valio Ltd. R. Korpela and T. Tuure are employed by Valio Ltd and by R&amp;D. T. Poussa has consultant arrangements with Valio Ltd. M. Kuitunen has received grant support from Valio Ltd. The rest of the authors have declared that they have no conflict of interest.<\/p>"}],"covariates":[],"arms":[],"results":[],"risk-of-bias":[{"domain":"Bias arising from the randomization process","judgement":"LOW_RISK","support-for-judgement":"<p>Computer-generated block randomisation. No significant differences at baseline between groups in family history of atopy. Intervention and control group remain well-balanced throughout follow-up studies.<\/p><p>Randomisation to probiotic and placebo groups occurred at 35 gestational weeks, prior to birth of infant. Randomisation code was kept by the database consultant and revealed only to the statistician.<\/p>"}]},{"name":"Hascoët 2011","year":"2011","data-source":"PUB","identifiers":[{"name":"CRS","value":"22958412"}],"references":[{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Hascoët JM, Hubert C, Rochat F, Legagneur H, Gaga S, Emady-Azar S, et al","title":"Effect of formula composition on the development of infant gut microbiota","original-title":"","source":"Journal of Pediatric Gastroenterology and Nutrition","publication-date":"2011","volume":"56","issue":"6","pages":"756-62","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958413"},{"name":"DOI","value":"10.1097\/MPG.0b013e3182105850"},{"name":"PUBMED","value":"21593648"}]}],"characteristics":[{"name":"Methods","value":"<p>Randomised, double-blind, controlled trial.<\/p>"},{"name":"Participants","value":"<p><b>Inclusion criteria: <\/b>healthy, full-term infants whose mothers had chosen to feed their infants exclusively with either breast milk or with formula starting from day 7 of birth until they were 4 months old. Infants had to be ≤ 7 days old at enrollment, weigh between 2500 and 4500 g, and be singletons.&nbsp;<\/p>\n<p><b>Exclusion criteria:<\/b> congenital illnesses or malformations that could affect normal growth; significant prenatal or postnatal disease or both; been rehospitalised for more than 2 days in the first 14 days of life (with the exception of infants that were rehospitalised because of jaundice); received antibiotics prenatally, at the time of enrollment, or during the 5 days preceding enrollment; received probiotic- or prebiotic-containing formulas at the time of enrollment. Caregivers who were not expected to comply with the study requirements. Infants participating in a different study were excluded.<\/p>"},{"name":"Interventions","value":"<p><b>Study formula group (n = 39): <\/b>study formula with low protein and phosphate content, high lactose and contained predominantly whey protein was given to infants from birth to 4 months of age.&nbsp;<\/p>\n<p><b>Study formula + BL999 (n = 40): <\/b>study formula with low protein and phosphate content, high lactose and contained predominantly whey protein supplemented with 2 × 10<sup>7<\/sup> colony-forming units (CFU)\/g of <i>B longum<\/i>, strain BL999 (ATCC: BAA-999 designation BB536, Morinaga, Japan; NCC3001) was given to infants from birth to 4 months of age.&nbsp;<\/p>\n<p><b>Control formula (n = 38):<\/b> control formula was given to infants from birth to 4 months of age.&nbsp;<\/p>\n<p>Breast-fed (n = 73): infants exclusively breastfed from birth to 4 months of age.&nbsp;<\/p>"},{"name":"Outcomes","value":"<p><b>Primary outcome:<\/b> bifidobacterial counts at the 2-month visit.&nbsp;<\/p>\n<p><b>Secondary outcomes: <\/b>non-<i>Bifidobacteria<\/i> bacterial counts, weight, length, head circumference, digestive tolerance, stool IgA, and the occurrence of adverse events.&nbsp;<\/p>\n<p><b>Definitions:<\/b> adverse events were defined as illnesses or signs and symptoms of illnesses that occurred or worsened during the course of the study. Specific definitions for allergy-skin problems not included.&nbsp;<\/p>"},{"name":"Notes","value":"<p><b>Sponsor:<\/b> Nestlé, Konolfingen, Switzerland was the sponsor of the study and also manufactured the formulas.&nbsp;<\/p>\n<p>Only infants in the study formula group and study formula + BL999 group have been included for analysis in this review. (Quote:) \"Allergy-skin problems\" data points included in the analysis as eczema.<\/p>\n<p><b>Declaration of interest:<\/b> PGS is an employee of Nestlé Nutrition, Nestec Ltd. The other authors reported no conflicts of interest.<\/p>"}],"covariates":[],"arms":[{"name":"No probiotics","description":"","intervention":"No probiotic"},{"name":"Probiotics","description":"","intervention":"Probiotic"}],"results":[{"outcome":"Eczema by 2 years","arm-level-result":{"dichotomous-data-rows":[{"arm":"No probiotics","cases":1,"sample-size":39},{"arm":"Probiotics","cases":0,"sample-size":40}],"risk-of-bias":[{"domain":"Bias due to deviations from intended interventions","judgement":"LOW_RISK","support-for-judgement":"<p>Control formula used. All 3 formulas in the study contained proteins, carbohydrates, fats, minerals, and vitamins in quantities that provided full nutritional support for infants from birth up to 4 months of age.<\/p><p>Double-blinded study. Control formula used. Formulas were manufactured and blinded by the sponsor, which was the only party with knowledge of the product codes.<\/p>"},{"domain":"Bias due to missing outcome data","judgement":"LOW_RISK","support-for-judgement":"<p>Loss to follow-up: 27 (17%) were withdrawn before the end of the study, data from these infants were used when available; only reason for discontinuation was non-compliance - i.e. the family did not arrive for the study visit—and rates were similar in both groups. None of the drop-outs had shown signs of atopic disease before discontinuation.<\/p>"},{"domain":"Bias in measurement of the outcome","judgement":"LOW_RISK","support-for-judgement":"<p>The primary aim of the study was to compare the bifidobacterial counts of infants fed different formulas and breastfed. Specific definitions for allergy-skin problems was not included.<\/p>"},{"domain":"Bias in selection of the reported result","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>No pre-specified analysis plan. No clinical trial registry provided.<\/p>"},{"domain":"Overall bias","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.<\/p>"}]}}],"risk-of-bias":[{"domain":"Bias arising from the randomization process","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>Stratified randomisation was performed using SAS version 8.2 (SAS Institute, Cary, NC). Stratification was based on sex and mode of delivery (caesarean section vs vaginal birth). Study formula and study formula groups were well balanced.<br>Double-blind, controlled trial. Stratified randomisation was managed by sponsor - Nestle. Details of allocation concealment not described.<\/p>"}]},{"name":"Dissanayake 2018","year":"2018","data-source":"PUB","identifiers":[{"name":"CRS","value":"22958408"}],"references":[{"reference-type":"JOURNAL_ARTICLE","primary":true,"authors":"Dissanayake E, Tani Y, Nagai K, Sahara M, Mitsuishi C, Togawa Y, et al","title":"Skin care and synbiotics for prevention of atopic dermatitis or food allergy in newborn infants: a 2 × 2 factorial, randomized, non-treatment controlled trial","original-title":"","source":"International Archives of Allergy and Immunology","publication-date":"2019","volume":"180","issue":"3","pages":"202-11","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958409"},{"name":"DOI","value":"10.1159\/000501636"},{"name":"PUBMED","value":"31394530"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Fikri B, Tani Y, Nagai K, Sahara M, Mitsuishi C, Togawa Y, et al","title":"Soluble CD14 in breast milk and its relation to atopic manifestations in early infancy","original-title":"","source":"Nutrients","publication-date":"2019","volume":"11","issue":"9","pages":"2118","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958411"},{"name":"DOI","value":"10.3390\/nu11092118"},{"name":"PUBMED","value":"31492016"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Dissanayake E, Tani Y, Sahara M, Mitsuishi C, Nagai K, Sato Y, et al","title":"Skincare and synbiotics for the prevention of atopic dermatitis or food allergy in newborn infants: a 2 × 2 factorial randomized non-treatment controlled trial","original-title":"","source":"Allergy","publication-date":"2018","volume":"73","issue":"","pages":"692-3","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"24344283"},{"name":"DOI","value":"10.1111\/all.13539"}]}],"characteristics":[{"name":"Methods","value":"<p>&nbsp; 2 × 2 factorial, randomised, non-treatment controlled trial.<\/p>"},{"name":"Participants","value":"<p><b>Inclusion criteria:<\/b> families who attended the antenatal clinic were recruited into the study. Following delivery, the babies were recruited if they were born at term and written informed consent was available from parent(s)\/guardian. A family history of atopy was not required for inclusion.&nbsp;<\/p>\n<p><b>Exclusion criteria: <\/b>infants born pre-term, experience complications due to severe underlying disease were excluded from the study. HBV or HIV positivity of mother at the time of birth or any other inappropriate status as judged by the physician.&nbsp;<\/p>"},{"name":"Interventions","value":"<p><b>Synbiotic and skincare (n = 137): <\/b>combination of 0.5 g (7 × 10<sup>9<\/sup> CFU\/g) of <i>Bifidobacterium bifidum<\/i>OLB6378 (Meiji Holdings Co. Ltd., Japan) combined with 0.5 g of fructo-oligosaccharides (Meiji Food Materia Co., Ltd., Japan) twice a day and Locobase® REPAIR Cream (Daiichi Sankyo, Japan) which contains ceramide, cholesterol, and free fatty acids 2 - 3 times a day. Intervention was carried out from birth to 6 months of age.&nbsp;<\/p>\n<p><b>Synbiotic only (n = 137): <\/b>combination of 0.5 g (7 × 10<sup>9<\/sup> CFU\/g) of <i>Bifidobacterium bifidum<\/i>OLB6378 (Meiji Holdings Co. Ltd., Japan) combined with 0.5 g of fructo-oligosaccharides (Meiji Food Materia Co., Ltd., Japan) 2x a day from birth to 6 months of age.&nbsp;<\/p>\n<p><b>Skincare only (n = 138):<\/b> locobase® REPAIR Cream (Daiichi Sankyo, Japan) which contains ceramide, cholesterol, and free fatty acids 2 - 3 times a day from birth to 6 months.<\/p>\n<p><b>Control (n = 137): <\/b>the control group did not receive any synbiotics. The no treatment group was not prevented from applying emollients due to ethical reasons.&nbsp;<\/p>"},{"name":"Outcomes","value":"<p><b>Primary outcome:<\/b> development of atopic dermatitis by 1 year of age.&nbsp;<\/p>\n<p><b>Secondary outcome:<\/b> prevalence of food allergy. Sensitisation to food or inhalant allergens or both. EASI score examined by a paediatrician.&nbsp;<\/p>\n<p><b>Definitions:<\/b> atopic dermatitis was diagnosed according to the criteria of the Japanese Dermatological Association (Katayama 2017), and using the UK Working Party's Diagnostic Criteria (William 1994), included in the questionnaire at 1 year. Defined as itchy rash lasting 2 or more months was reported in the questionnaires returned at 1, 6, and 9 months and 1 year of the baby’s age.&nbsp;<\/p>\n<p>Food allergy reported in the questionnaire at 1 year. Sensitisation to food or inhalant allergens in total, or both, and allergen-specific IgE levels in blood sampled at 9 months of age.<\/p>"},{"name":"Notes","value":"<p><b>Sponsor: <\/b>supported by the Environmental Restoration and Conservation Agency of Japan in fiscal years 2014 - 2016. Grants from the Japan Agency for Medical Research and Development.<\/p>\n<p>The incidence of AD at 1 year according to the UKWP diagnostic criteria has been used for analysis in this review.<\/p>\n<p><b>Declaration of interest: <\/b>no conflicts of interest to disclose<\/p>"}],"covariates":[],"arms":[],"results":[],"risk-of-bias":[{"domain":"Bias arising from the randomization process","judgement":"LOW_RISK","support-for-judgement":"<p>Babies born at term were randomised into 4 groups according to gender (male or female), mode of delivery (vaginal or caesarean) and family history of allergic diseases (present or absent) using computerised random numbers. Randomisation was performed at a central location.&lt;\/p&gt;&lt;p&gt;Baseline characteristics were similar amongst the groups. Although the number of babies with no family history of allergic disease in the no-intervention group was relatively higher than in the other groups, the investigators found that the difference was not significant.<\/p><p>Intervention group allocation was determined by a randomisation system based on the minimisation technique (Nouvelle Place Inc., Tokyo, Japan).<\/p>"}]},{"name":"Plummer 2020","year":"2020","data-source":"PUB","identifiers":[{"name":"CRS","value":"22958457"}],"references":[{"reference-type":"JOURNAL_ARTICLE","primary":true,"authors":"Plummer EL, Chebar Lozinsky A, Tobin JM, Uebergang JB, Axelrad C, Garland SM, et al; ProPrems Study Group","title":"Postnatal probiotics and allergic disease in very preterm infants: sub-study to the ProPrems randomized trial","original-title":"","source":"Allergy","publication-date":"2020","volume":"75","issue":"1","pages":"127-36","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958461"},{"name":"DOI","value":"10.1111\/all.14088"},{"name":"PUBMED","value":"31608448"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Tobin J","title":"The opportunity of probiotics for infants: responsibility for a lifetime?","original-title":"","source":"Journal of Paediatrics and Child Health","publication-date":"2011","volume":"47","issue":"","pages":"3","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958462"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Tobin JM, Ubergang JB, Jacobs SE, Garland SM, Tang ML","title":"Probiotics for the prevention of allergic diseases in very preterm infants","original-title":"","source":"Journal of Paediatrics and Child Health","publication-date":"2016","volume":"52","issue":"S2","pages":"56","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958463"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Garland SM, Tobin JM, Piortta M, Tabrizi S, Opie G, Donath S, et al; ProPrems Study Group","title":"The ProPrems trial: investigating the effects of probiotics on late onset sepsis in very preterm infants","original-title":"","source":"BMC Infectious Diseases","publication-date":"2011","volume":"11","issue":"","pages":"210","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958458"},{"name":"DOI","value":"10.1186\/1471-2334-11-210"},{"name":"PUBMED","value":"21816056"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Jacobs SE, Hickey L, Donath S, Opie GF, Anderson PJ, Garland SM, et al; ProPremsStudy Groups","title":"Probiotics, prematurity and neurodevelopment: follow-up of a randomised trial","original-title":"","source":"BMJ Paediatrics Open","publication-date":"2017","volume":"1","issue":"1","pages":"e000176","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958459"},{"name":"DOI","value":"10.1136\/bmjpo-2017-000176"},{"name":"PUBMED","value":"29637171"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Plummer EL, Bulach DM, Murray GL, Jacobs SE, Tabrizi SN, Garland SM; ProPrems Study Group","title":"Gut microbiota of preterm infants supplemented with probiotics: sub-study of the ProPrems trial","original-title":"","source":"BMC Microbiology","publication-date":"2018","volume":"18","issue":"1","pages":"184","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958460"},{"name":"PUBMED","value":"30424728"},{"name":"DOI","value":"10.1186\/s12866-018-1326-1"}]}],"characteristics":[{"name":"Methods","value":"<p>Double-blind, placebo-controlled randomised trial.<\/p>"},{"name":"Participants","value":"<p><b>Inclusion criteria:<\/b> preterm infants both below 1500 g and less than 32 weeks' gestational age at birth.&nbsp;<\/p>\n<p><b>Exclusion criteria:<\/b> infants suspected of or has major congenital anomalies, considered likely to die within 72 hours of birth as excluded. Babies of mothers who are already taking supplemental probiotics by capsule (not yogurt, etc) are excluded.&nbsp;<\/p>"},{"name":"Interventions","value":"<p><b>Treatment (n = 548)<\/b>: &nbsp;1 × 10<sup>9<\/sup> total organisms per 1.5 gm <i>Bifidobacterium infantis, Streptococcus thermophilus<\/i> and <i>Bifidobacterium lactis<\/i> (\"ABC Dophilus Probiotic Powder for Infants<sup>®<\/sup>\", Solgar, USA) is given to infants from soon after the start of milk feeds until discharge home or term corrected, whichever comes first.&nbsp;<\/p>\n<p><b>Control (n = 511)<\/b>: placebo. Maltodextrin powder contains 4 kcal\/gram and is dairy free, gluten-free and suitable for vegans. The daily dose is 1.5 g of study powder, irrespective of infant's weight or postnatal age.<\/p>\n<p><b>Substudy<\/b> in Victorian participants (n = 683) at 12 months' corrected age. Of the participants analysed in the substudy, probiotic group n = 127, placebo group n = 154.&nbsp;<\/p>\n<p>The study intervention or placebo was given orally or via gastric tube once daily, unless the feed volume is less than 3 mL when 1 level ProPrems trial measuring spoon of powder is administered in 1.5 mL feed twice daily. Freshly expressed mother's breast milk is the feed of choice, followed by frozen breast milk, if fresh is not available. Banked breast milk is used when mother's milk is not available in centres with established protocols that use breast milk banking. Formula is used only when there is insufficient breast milk or if the mother chooses not to provide breast milk. Tube feeding is commenced as soon as possible in small and increasing amounts according to local protocols and the discretion of the treating neonatalist. Intravenous fluids and nutrition are used until approximately 120 ml\/kg of milk is tolerated per 24-hour period.&nbsp;<\/p>"},{"name":"Outcomes","value":"<p><b>Primary outcome:<\/b> incidence of at least 1 episode of definite late onset sepsis before 40 weeks' corrected age or discharge home.&nbsp;<\/p>\n<p><b>Secondary outcomes:<\/b> incidence of clinically-suspected sepsis, NEC, mortality, duration of primary hospital admission, number of courses of antibiotics, number of days until full enteral feeds established&nbsp;<\/p>\n<p><b>Substudy outcomes: <\/b>growth, infections, hospital admissions and antibiotic courses, cumulative incidence of allergic disease, immunological parameters, allergic sensitisation at 12 months.&nbsp;<\/p>\n<p><b>Definitions:<\/b> eczema was defined as parent report of doctor diagnosis of eczema or fulfillment of the modified UK Working Party's Diagnostic Criteria (William 1994), for atopic dermatitis; a history of itchy skin in the preceeding 12 months, plus &nbsp;≥ 3 of the following visible dermatitis involving the skin creases extensor surfaces or &nbsp;cheeks, or both; a history of generally dry skin in the preceding 12 months; and a history of asthma or allergic rhinitis (or history of atopic disease in a first‐degree relative).&nbsp;<\/p>\n<p>Atopic eczema was defined as eczema together with a positive SPT to 1 &nbsp;or more allergen.&nbsp;<\/p>\n<p>Food allergy was defined as parent report of doctor‐diagnosed cow's milk, soy, egg, wheat, or peanut allergy with or without a positive SPT to the relevant food allergen to capture both IgE and non‐IgE–mediated food allergy phenotypes.&nbsp;<\/p>\n<p>Wheeze was defined as any parental reported wheeze, and number of infections during the first 2 years of life was defined as parent‐reported number of colds with fever lasting at least 3 days to ensure medically significant infections were captured.<\/p>"},{"name":"Notes","value":"<p><b>Sponsor:<\/b> project grant from the National Health and Medical Research Council. Funding has also been provided by The Royal Women's Hospital Foundation, Melbourne and The Angior Family Foundation, Melbourne.<\/p>\n<p><b>Declaration of interest: <\/b>Tang M. was a past member of the Nestle Nutrition Institute Medical Advisory Board (Oceania), was a past member of the global scientific advisory board for Danone Nutricia, received speaker fees for seminars sponsored by Danone Nutricia and Nestle Health Sciences, share options\/interest in Prota Therapeutics, and was a consultant to Bayer. All other authors have no conflicts of interest to disclose.<\/p>"}],"covariates":[],"arms":[{"name":"No probiotics","description":"","intervention":"No probiotic"},{"name":"Probiotics","description":"","intervention":"Probiotic"}],"results":[{"outcome":"Eczema by 2 years","arm-level-result":{"dichotomous-data-rows":[{"arm":"Probiotics","cases":35,"sample-size":118},{"arm":"No probiotics","cases":37,"sample-size":137}],"risk-of-bias":[{"domain":"Bias due to deviations from intended interventions","judgement":"LOW_RISK","support-for-judgement":"<p>All doctors, nurses, research assistants, laboratory staff and parents are blind to the randomised allocation. The probiotic and placebo powders are identically packaged by The Royal Women's Hospital Pharmacy Department, which holds the randomisation code.<\/p><p>The key is held by the Chief Pharmacist at The Royal Women's Hospital and the trial statistician, both of whom are independent of the investigators and not involved in outcome assessment.<\/p>"},{"domain":"Bias due to missing outcome data","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>Loss to follow up: 683 Victorian participants of the parent ProPrems study (n = 1099). 230\/683 excluded, n = 168 declined consent at primary hospitalisation, n = 43 infant died by time of follow up, n = 9 did not receive allocated intervention, n = 7 family not approached for follow up, n = 3 parents withdrew consent. 453 participants were eligible to be approached for follow-up visit. 165\/453 excluded. n = 43 uncontactable, n = 122 declined consent at follow-up. 288\/453 eligible participants recruited to the substudy (40% loss to follow up), 7\/288 excluded due to not completing any study procedures. Probiotic group 127, placebo group 154. High number of drop out, although not described to be related to study intervention.&nbsp;<\/p><p>The sub-study infants are only a representative of the parent study cohort. A larger proportion of sub-study participants had parent-reported family history of allergic disease compared with the infants who did not participate in the sub-study.<\/p>"},{"domain":"Bias in measurement of the outcome","judgement":"LOW_RISK","support-for-judgement":"<p>Predefined definitions of eczema and allergic disease. Questionnaire has been adapted from the Probiotic Eczema Prevention Study (Boyle 2008).<\/p>"},{"domain":"Bias in selection of the reported result","judgement":"LOW_RISK","support-for-judgement":"<p>Pre-specified analyses provided, although no specification of whether there were any deviations from the planned analysis. ANZCTR 12607000144415.<\/p>"},{"domain":"Overall bias","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.<\/p>"}]}},{"outcome":"Food allergy by 2 years","arm-level-result":{"dichotomous-data-rows":[{"arm":"Probiotics","cases":4,"sample-size":124},{"arm":"No probiotics","cases":2,"sample-size":154}],"risk-of-bias":[{"domain":"Bias due to deviations from intended interventions","judgement":"LOW_RISK","support-for-judgement":"<p>All doctors, nurses, research assistants, laboratory staff and parents are blind to the randomised allocation. The probiotic and placebo powders are identically packaged by The Royal Women's Hospital Pharmacy Department, which holds the randomisation code.<\/p><p>The key is held by the Chief Pharmacist at The Royal Women's Hospital and the trial statistician, both of whom are independent of the investigators and not involved in outcome assessment.<\/p>"},{"domain":"Bias due to missing outcome data","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>Loss to follow up: 683 Victorian participants of the parent ProPrems study (n = 1099). 230\/683 excluded, n = 168 declined consent at primary hospitalisation, n = 43 infant died by time of follow up, n = 9 did not receive allocated intervention, n = 7 family not approached for follow up, n = 3 parents withdrew consent. 453 participants were eligible to be approached for follow-up visit. 165\/453 excluded. n = 43 uncontactable, n = 122 declined consent at follow-up. 288\/453 eligible participants recruited to the substudy (40% loss to follow up), 7\/288 excluded due to not completing any study procedures. Probiotic group 127, placebo group 154. High number of drop out, although not described to be related to study intervention.&nbsp;<\/p><p>The sub-study infants are only a representative of the parent study cohort. A larger proportion of sub-study participants had parent-reported family history of allergic disease compared with the infants who did not participate in the sub-study.<\/p>"},{"domain":"Bias in measurement of the outcome","judgement":"LOW_RISK","support-for-judgement":"<p>Predefined definitions of eczema and allergic disease. Questionnaire has been adapted from the Probiotic Eczema Prevention Study (Boyle 2008).<\/p>"},{"domain":"Bias in selection of the reported result","judgement":"LOW_RISK","support-for-judgement":"<p>Pre-specified analyses provided, although no specification of whether there were any deviations from the planned analysis. ANZCTR 12607000144415.<\/p>"},{"domain":"Overall bias","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.<\/p>"}]}}],"risk-of-bias":[{"domain":"Bias arising from the randomization process","judgement":"LOW_RISK","support-for-judgement":"<p>Randomisation was achieved using a variable block design constructed by the Clinical Epidemiology and Biostatistics Unit (CEBU) at the Murdoch Children's Research Institute, who are independent of the study investigators. Each block contains equal numbers of placebo and active allocation. Randomisation is stratified by unit. Each of the participating neonatal units is able to access the next sequentially numbered probiotic or placebo immediately after randomisation.<\/p><p>Demographic variables and possible risk factors for allergy were similar between groups. Larger proportion of infants randomised to placebo were born &lt; 28 weeks' gestation compared with probiotic group (47% compared with 35%), the median gestational age of infants was reported to be similar in both groups.<\/p><p>Block design sequentially numbered randomisation with equal numbers of placebo and active allocations. Each infant is assigned a unique code following randomisation.<\/p>"}]},{"name":"Morisset 2011","year":"2011","data-source":"PUB","identifiers":[{"name":"CRS","value":"22958450"}],"references":[{"reference-type":"JOURNAL_ARTICLE","primary":true,"authors":"Morisset M, Aubert-Jacquin C, Soulaines P, Moneret-Vautrin PA, Dupont C","title":"A non-hydrolyzed, fermented milk formula reduces digestive and respiratory events in infants at high risk of allergy","original-title":"","source":"European Journal of Clinical Nutrition","publication-date":"2011","volume":"65","issue":"2","pages":"175-83","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958451"},{"name":"DOI","value":"10.1038\/ejcn.2010.250"},{"name":"PUBMED","value":"21081959"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Morisset M, Soulaines P, Aubertjacquin C, Codreanu F, Maamri N, Hatahet R, et al","title":"Double blind trial of a fermented infantile formula in cow's milk allergy prevention","original-title":"","source":"Journal of Allergy and Clinical Immunology","publication-date":"2008","volume":"121","issue":"2","pages":"S244","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958452"}]}],"characteristics":[{"name":"Methods","value":"<p>Double-blind, randomised, control trial,<\/p>"},{"name":"Participants","value":"<p><b>Inclusion criteria: <\/b>less than 6 months of pregnancy and family at risk of atopy defined as at least 2 atopic members including at least 1 of the parents (e.g. mother or father or at least 1 brother or sister).&nbsp;<\/p>\n<p><b>Exclusion criteria: <\/b>children with known or suspected immune deficiency within family are excluded.&nbsp;<\/p>"},{"name":"Interventions","value":"<p><b>Treatment (n = 66): <\/b>infant formula made of milk fermented with B. breve C50 (4.2 x 10<sup>9<\/sup> bacteria per 100 g of powder formula) and S. thermophilus 065 (3.84 x 10<sup>7<\/sup> bacteria per 100 g of powder formula) and heated to kill ferments (heat-killed Bifidobacterium breve C50 and Streptococcus thermophilus 065 (HKBBST)). Formula was to be given every day, from birth to the end of breastfeeding.<\/p>\n<p><b>Control (n = 63): <\/b>standard infant formula.&nbsp;<\/p>\n<p>Co-intervention: &nbsp;from the 5th month of pregnancy, calcium supplement was included and avoid peanut, nut, egg and fermented milk products or prebiotic- or probiotic-containing food (commercially available milk was allowed).&nbsp;<\/p>\n<p>Mothers who wished to breastfeed were encouraged to do so up to the 6th month after birth. From the 5th month of pregnancy, the mother was required to use calcium supplementation and avoid peanut, nut, egg and fermented milk products or pre-biotic- or probiotic-containing food.&nbsp;<\/p>"},{"name":"Outcomes","value":"<p><b>Primary outcome:<\/b> incidence of cow's milk allergy and cow's milk sensitisation at 2 years.&nbsp;<\/p>\n<p><b>Secondary outcome:<\/b> incidence of sensitisation or allergy to other allergens than cow's milk, or both, and the incidence of allergic symptoms during the study period.&nbsp;<\/p>\n<p><b>Definitions: <\/b>children were considered allergic to cow's milk or to another food allergen, or both, when oral food challenge was positive. Children were considered sensitised to a food allergen in case of positive skin test (SPT or APT) or positive specific IgE independently of allergy-like symptoms.&nbsp;<\/p>"},{"name":"Notes","value":"<p><b>Sponsor: <\/b>study was supported by Blédina, France (Danone group).<\/p>\n<p><b>Declaration of interests: <\/b>C. Aubert-Jacquin was the Danone employee. M. Morisset, D. Moneret-Vautrin and C. Dupont have received honoraria or compensation with regards to the study, as an investigator, coordinator or expert, in relation with the time spent on the study. The authors declared no conflict of interest.<\/p>"}],"covariates":[],"arms":[{"name":"No probiotics","description":"","intervention":"No probiotic"},{"name":"Probiotics","description":"","intervention":"Probiotic"}],"results":[{"outcome":"Cow's milk protein allergy by 2 years","arm-level-result":{"dichotomous-data-rows":[{"arm":"No probiotics","cases":15,"sample-size":16},{"arm":"Probiotics","cases":13,"sample-size":14}],"risk-of-bias":[{"domain":"Bias due to deviations from intended interventions","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>Control, standard infant formula used. The appearance, taste and smell of the 2 products were similar. Mothers were blinded to the products allocated. Study personnel, allergist and dietitian were blinded during all the study.<\/p><p>Control, standard infant formula used. Allergist, dietitian and mothers were blinded to the products allocated during all the study, until the analysis of last result data.<\/p><p>Results presented were from Per-Protocol populations, which were described to showed no substantial difference as compared with ITT populations.<\/p>"},{"domain":"Bias due to missing outcome data","judgement":"LOW_RISK","support-for-judgement":"<p>Loss to follow-up: 21\/129 (16%). Reasons for loss to follow-up include: excluded for non-compliance n = 1, product cross-over n = 4, unknown date of weaning n = 3, loss to follow-up n = 10. Control group n = 55, HKBBST group n = 53 completed 24 months follow-up.<\/p>"},{"domain":"Bias in measurement of the outcome","judgement":"LOW_RISK","support-for-judgement":"<p>Predefined definitions for allergic disease. Clinician diagnosed allergic disease. Parents completed a diary collecting data on weaning and use of milk or formula, where dietician checked diet compliance and tolerance by the mothers.<\/p>"},{"domain":"Bias in selection of the reported result","judgement":"LOW_RISK","support-for-judgement":"<p>Planned analyses provided, although no specification of whether there were any deviations from the planned analysis. NCT00792090.<\/p>"},{"domain":"Overall bias","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>The study is judged to be at low risk of bias for all domains for this result.<\/p>"}]}}],"risk-of-bias":[{"domain":"Bias arising from the randomization process","judgement":"LOW_RISK","support-for-judgement":"<p>Randomised in sequential ascending order to either SIF or HKBBST milk. The randomisation list was created by an independent statistician (OPTIMED, Grenoble, France) and confidentially maintained until approval was received for the study to be unblinded for analysis. Well-balanced groups. No statistically significant difference observed between control and intervention groups. Use of other milk or formula during the study was low and did not differ between groups.<\/p><p>Randomisation occurred after selection; before the end of the 5th month of pregnancy. Women wishing to breastfeed were randomly balanced between groups.<\/p>"}]},{"name":"Lau 2012","year":"2012","data-source":"PUB","identifiers":[{"name":"CRS","value":"22958446"}],"references":[{"reference-type":"JOURNAL_ARTICLE","primary":true,"authors":"Lau S, Gerhold K, Zimmermann K, Ockeloen CW, Rossberg S, Wagner P, et al","title":"Oral application of bacterial lysate in infancy decreases the risk of atopic dermatitis in children with 1 atopic parent in a randomized, placebo-controlled trial","original-title":"","source":"Journal of Allergy and Clinical Immunology","publication-date":"2012","volume":"129","issue":"4","pages":"1040-7","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958447"},{"name":"DOI","value":"10.1016\/j.jaci.2012.02.005"},{"name":"PUBMED","value":"22464674"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Penders J, Gerhold K, Rossberg S, Witt I, Zimmermann K, Wahn U, et al","title":"Establishment and role of the gastrointestinal microbiota in infantile eczema: a randomised trial with bacterial lysates","original-title":"","source":"Allergy","publication-date":"2012","volume":"67","issue":"Suppl 96","pages":"100-1","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958448"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Penders J, Gerhold K, Stobberingh EE, Thijs C, Zimmermann K, Lau S, et al","title":"Establishment of the intestinal microbiota and its role for atopic dermatitis in early childhood","original-title":"","source":"Journal of Allergy and Clinical Immunology","publication-date":"2013","volume":"132","issue":"3","pages":"601-7.e8","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958449"},{"name":"PUBMED","value":"23900058"},{"name":"DOI","value":"10.1016\/j.jaci.2013.05.043"}]}],"characteristics":[{"name":"Methods","value":"<p>Blinded, randomised, placebo-controlled trial.<\/p>"},{"name":"Participants","value":"<p><b>Inclusion criteria: <\/b>healthy newborns at term, birth weight of 2500 g or greater, 1 or 2 parents with atopic disease (atopic dermatitis, allergic rhinitis, or asthma), and informed consent. Families were informed of the study within the first week after the infant's birth through the obstetric department.<\/p>\n<p><b>Exclusion criteria: <\/b>antibiotic treatment or other medication after birth, lymphocytopenia or thrombocytopenia, intensive care after birth, lack of German-language knowledge, and no informed consent.&nbsp;<\/p>"},{"name":"Interventions","value":"<p><b>Treatment (n = 303):<\/b> from week 5 until the end of month 7, infants had daily dose of 3 x 0.7mL of &nbsp;oral bacterial lysate (Pro-Symbioflor; SymbioPharm, Herborn, Germany) containing heat-killed non-pathogenic gram-negative E coli Symbio DSM 17252 and non-pathogenic gram-positive E faecalis Symbio DSM 16440 (1.5-4.5 3 107 bacteria\/mL). 10 drops of the solution were administered to the infants with a spoon 3 times a day.&nbsp;<\/p>\n<p><b>Control (n = 303):<\/b> placebo contained lactose monohydrate (4.9 mg\/mL), sodium chloride (8.8 mg\/mL), magnesium chloride (0.608 mg\/ mL), calcium chloride (0.076 mg\/mL), potassium chloride (0.133 mg\/mL), magnesium sulfate (0.779 mg\/mL), and aqua destillata (998.2 mg\/mL).<\/p>"},{"name":"Outcomes","value":"<p><b>Primary outcomes: <\/b>the prevalence of atopic dermatitis at the end of the prophylactic treatment period at 7 months of age.&nbsp;<\/p>\n<p><b>Other outcomes: <\/b>specific serum IgE levels to 6 food allergens (cow's milk, hen's egg, wheat, peanut, soya, and cod fish) and 7 inhalant allergens (cat dander, dog dander, , Dermatophagoides pteronyssinus, birch, grass, mugwort, and Cladosporium herbarum; fx5, sx1; Phadia, Freiburg, Germany) and total IgE levels were measured at the ages of 5 and 31 weeks and 1, 2, and 3 years. Stool samples for analyses of gut flora.&nbsp;<\/p>\n<p><b>Definitions: <\/b>Atopic dermatitis was clinically assessed by using a score according to the method of Hanifin and Rajka (Hanifin 1980) adapted for infants. Diagnosis for atopic dermatitis was made if infants showed a typical itchy rash at flexural\/extensor sites, in the face, or both and dryness of the skin for more than 6 weeks.&nbsp;<\/p>"},{"name":"Notes","value":"<p><b>Sponsor: <\/b>funding from SymbioPharm. SymbioPharm was involved in the study plan but had no influence on the analyses and interpretation of data.&nbsp;<\/p>\n<p><b>Declaration of interests: <\/b>U. Wahn has received research support from SymbioPharm. The rest of the authors declared that they have no relevant conflicts of interest.<\/p>"}],"covariates":[],"arms":[{"name":"No probiotics","description":"","intervention":"No probiotic"},{"name":"Probiotics","description":"","intervention":"Probiotic"}],"results":[{"outcome":"Eczema by 2 years","arm-level-result":{"dichotomous-data-rows":[{"arm":"Probiotics","cases":84,"sample-size":303},{"arm":"No probiotics","cases":87,"sample-size":303}],"risk-of-bias":[{"domain":"Bias due to deviations from intended interventions","judgement":"LOW_RISK","support-for-judgement":"<p>Placebo used. Participants were blinded. Bottles were filled in fully randomised order, and blinding was complete for the study personnel. Unblinding was performed in November 2010.<\/p>"},{"domain":"Bias due to missing outcome data","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>Lost to follow-up: 119\/606 (20%). Discontinued due to adverse events n = 24 but no details of whether adverse events were related to study outcomes or not, failure to return during intervention phase n = 8, at parent's request during intervention phase n = 48. 39 participants lost to follow-up during follow-up phase.<\/p><p>526\/606 (13% loss to follow-up) participants completed the study to 7 months of age. 487\/606 participants completed the study to 3 years of age.<\/p>"},{"domain":"Bias in measurement of the outcome","judgement":"LOW_RISK","support-for-judgement":"<p>Specific definitions for outcomes described as part of the diagnostic criteria. Primary outcomes were measured with validated and appropriate methods.&nbsp;<\/p>"},{"domain":"Bias in selection of the reported result","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>No description of pre-specified analysis. ISRCTN60475069.<\/p>"},{"domain":"Overall bias","judgement":"HIGH_RISK","support-for-judgement":"<p>The study is judged to have some concerns for multiple domains in a way that substantially lowers confidence in the result.<\/p>"}]}}],"risk-of-bias":[{"domain":"Bias arising from the randomization process","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>Study randomisation was assigned by simple randomisation done centrally at SymbioPharm. Every participant was given a randomisation number in ascending order according to the date of appearance at the study site.<\/p><p>Well-balanced groups, similar baseline characteristics.<\/p><p>Quote: \"Allocation concealment was provided\". Details of allocation concealment were not specified.<\/p>"}]},{"name":"Cabana 2007","year":"2007","data-source":"MIX","identifiers":[{"name":"CRS","value":"22958592"}],"references":[{"reference-type":"JOURNAL_ARTICLE","primary":true,"authors":"Cabana MD, McKean M, Caughey AB, Fong L, Lynch S, Wong A, et al","title":"Early probiotic supplementation for eczema and asthma prevention: a randomized controlled trial","original-title":"","source":"Pediatrics","publication-date":"2017","volume":"140","issue":"3","pages":"e20163000","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958596"},{"name":"PUBMED","value":"28784701"},{"name":"DOI","value":"10.1542\/peds.2016-3000"}]},{"reference-type":"OTHER","primary":false,"authors":"NCT00113659","title":"Use of a probiotic supplement to prevent asthma in infants","original-title":"Trial of infant probiotic supplementation to prevent asthma","source":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00113659","publication-date":"(first received 10 June 2005)","volume":"","issue":"","pages":"","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958598"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Cabana MD, KcKean M, Caughey AB, Fong L, Lynch S, et al","title":"Early probiotic supplementation for eczema and asthma prevention: a randomized controlled trial","original-title":"","source":"Pediatrics","publication-date":"2017","volume":"140","issue":"3","pages":"e20163000","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958594"},{"name":"DOI","value":"10.1542\/peds.2016-3000"},{"name":"PUBMED","value":"28784701"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Cabana MD, McKean M, Wong AR, Chao C, Caughey AB","title":"Examining the hygiene hypothesis: the trial of infant probiotic supplementation","original-title":"","source":"Paediatric and Perinatal Epidemiology","publication-date":"2007","volume":"21","issue":"Suppl 3","pages":"23-8","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958597"},{"name":"DOI","value":"10.1111\/j.1365-3016.2007.00881.x"},{"name":"PUBMED","value":"17935572"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Cabana MD, LeCroy MN, Menard-Livingston A, Rodggers CR, McKean M, Caughey AB, et al","title":"Effect of early infant probiotic supplementation on eczema, asthma, and rhinitis at 7 years of age","original-title":"","source":"Pediatrics","publication-date":"2022","volume":"149","issue":"5","pages":"e2021052483","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958595"},{"name":"PUBMED","value":"35419605"},{"name":"DOI","value":"10.1542\/peds.2021-052483"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Cabana M, McKean M, Caughey A, Leong R, Wong A, Hilton J, et al","title":"Late-breaking abstract: a randomized controlled trial of early probiotic supplementation to prevent early markers of asthma for high-risk infants","original-title":"","source":"European Respiratory Journal","publication-date":"2015","volume":"46","issue":"Suppl 59","pages":"OA4770","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958593"},{"name":"DOI","value":"10.1183\/13993003.congress-2015.OA4770"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Cox MJ, Huang YJ, Fujimura KE, Liu JT, McKean M, Boushey HA, et al","title":"Lactobacillus casei abundance is associated with profound shifts in the infant gut microbiome","original-title":"","source":"PLOS One","publication-date":"2010","volume":"5","issue":"1","pages":"e8745","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"22958599"},{"name":"DOI","value":"10.1371\/journal.pone.0008745"},{"name":"PUBMED","value":"20090909"}]}],"characteristics":[{"name":"Methods","value":"<p>Randomised, double-blind, placebo-controlled trial.<\/p>"},{"name":"Participants","value":"<p><b>Inclusion criteria: <\/b>newborns at increased risk of atopy, defined as at least 1 biological parent with a history of asthma. Parents had to speak and read English or Spanish. Recruitment occurred during the third trimester of pregnancy, with random assignment of infants occurring within 4 days after birth.<\/p>\n<p><b>Exclusion criteria: <\/b>any major congenital birth deformities, acute illness at enrolment (within 4 days after the newborn infant's birth), or any condition affecting food intake or metabolism.<\/p>"},{"name":"Interventions","value":"<p><b>Treatment (n = 92):<\/b> daily capsule of 10 billion colony-forming units of LGG and 225 mg of inulin for the first 6 months of life.<\/p>\n<p><b>Control (n = 92):<\/b> daily capsule of 325 mg of inulin for the first 6 months of life.<\/p>\n<p>The intervention started within the first 4 days of life. The supplement was dissolved in 2mL of pumped breast milk, infant formula or sterile water and fed to the infant. To promote breast-feeding, all participating families were encouraged to use breast-feeding and were provided with a breast pump.<\/p>"},{"name":"Outcomes","value":"<p><b>Primary outcome:<\/b> incidence of eczema within 2 years of birth. This was assessed at 5 timepoints (1, 2, 6, 12 and 24 months) by a clinical examination performed by a study clinician.<\/p>\n<p><b>Other outcomes:<\/b> incidences of asthma and allergic rhinitis within 5 years of birth. This was assessed by a parental telephone survey conducted monthly during the first year of life, then semiannually thereafter. Questions included: any diagnoses of asthma, allergic rhinitis or eczema by a health care professional.<\/p>\n<p><b>Definition:<\/b> the diagnosis of asthma is difficult to establish at a young age, therefore the study focusses on early markers of asthma including a history of frequent wheezing, wheezing without colds, atopic dermatitis and rhinitis using a standard history assessment developed by&nbsp;Castro-Rodriguez 2000.<\/p>"},{"name":"Notes","value":"<p><b>Sponsor: <\/b>funded by the Clinical and Translational Science Institute (UL1 RR024131) at the University of California, San Francisco, and by the National Institutes of<br>\n Health, HL 080074. Funded by the National Institutes of Health (NIH).Parental telephone survey-Additional question regarding feeding practices (breast milk only\/formula only\/combination\/other\/does not apply) were asked to assess for potential confounding.<\/p>\n<p><b>Declaration of interests: <\/b>Dr Lynch was a co-founder and served on the board of directors for Siolta Therapeutics, a microbiome therapeutics company. Dr Cabana has served as a paid scientific consultant to BioGaia, Mead Johnson Nutrition, Nestle, and Wyeth (unrelated to the study), has received grant funding from Nestec (unrelated to study), and has served on the Merck Speakers Bureau for topics focused on medication adherence (unrelated to study); and other authors have indicated they have no potential conflicts of interest to disclose.<\/p>"}],"covariates":[],"arms":[{"name":"No probiotics","description":"","intervention":"No probiotic"},{"name":"Probiotics","description":"","intervention":"Probiotic"}],"results":[{"outcome":"Eczema by 2 years","arm-level-result":{"dichotomous-data-rows":[{"arm":"No probiotics","cases":29,"sample-size":92},{"arm":"Probiotics","cases":26,"sample-size":92}],"risk-of-bias":[{"domain":"Bias due to deviations from intended interventions","judgement":"LOW_RISK","support-for-judgement":"<p>Participants, parents, study staff, and investigators were blinded to group assignment. The control capsule did not differ from the active capsule in terms of appearance, taste, smell or texture. After the end of the intervention period at 6 months, parents were surveyed to determine if they could correctly identify whether they received the active or control capsule.<\/p><p>Participants who were accrued earlier had more assessments, bias was avoided by using survival analysis methods that account for variable lengths of follow-up.&nbsp;<\/p>"},{"domain":"Bias due to missing outcome data","judgement":"LOW_RISK","support-for-judgement":"<p>Loss to follow up: 10% of mothers per arm discontinued participation before treatment initiation, leaving 184 infants who were randomly assigned and initiated treatment. 95% of infants followed for at least 2 years. 77% for at least 3 years, 46% for at least 5 years. Reason for loss to follow-up at 2 years, 3 years and at least 5 years has not been reported. Small number of loss to follow up at 2 years, although reasons for loss to follow-up were not specified.&nbsp;<\/p>"},{"domain":"Bias in measurement of the outcome","judgement":"LOW_RISK","support-for-judgement":"<p>The objective of the study was to determine if probiotic administration during the first 6 months of life affects childhood asthma and eczema. Specific definitions for outcomes described and assessment of outcome was clearly defined.<\/p>"},{"domain":"Bias in selection of the reported result","judgement":"LOW_RISK","support-for-judgement":"<p>Pre-planned analyses provided, although no specification of whether there were any deviations from the planned analysis. NCT00113659.<\/p>"},{"domain":"Overall bias","judgement":"LOW_RISK","support-for-judgement":"<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.<\/p>"}]}}],"risk-of-bias":[{"domain":"Bias arising from the randomization process","judgement":"LOW_RISK","support-for-judgement":"<p>Group assignment was based on the output from a computer-generated randomisation program that was accessed by the study coordinator once eligibility and consent was obtained.<\/p><p>Group allocation and the randomisation sequence were concealed from the study staff and investigators to further eliminate conscious or unconscious selection bias. Participants were randomly assigned after enrolment in the nursery.<\/p><p>Groups are balanced and similar in characteristics.<\/p>"}]},{"name":"Allen 2014","year":"2014","data-source":"PUB","identifiers":[{"name":"CRS","value":"23696192"}],"references":[{"reference-type":"JOURNAL_ARTICLE","primary":true,"authors":"Allen SJ, Jordan S, Storey M, Thorton CA, Gravenor MB, Garaiova I, et al","title":"Probiotics in the prevention of eczema: a randomised controlled trial","original-title":"","source":"Archives of Disease in Childhood","publication-date":"2014","volume":"99","issue":"11","pages":"1014-9","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"23696195"},{"name":"DOI","value":"10.1136\/archdischild-2013-305799"},{"name":"PUBMED","value":"24947281"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Allen SJ, Jordan S, Storey M, Thornton CA, Gravenor M, Garaiova I, et al","title":"Dietary supplementation with lactobacilli and bifidobacteria is well tolerated and not associated with adverse events during late pregnancy and early infancy","original-title":"","source":"Journal of Nutrition","publication-date":"2010","volume":"140","issue":"3","pages":"483-8","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"23696194"},{"name":"DOI","value":"10.3945\/jn.109.117093"},{"name":"PUBMED","value":"20089774"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Allen S, Jordan S, Storey M, Thornton C, Gravenor M, Garaiova I, et al","title":"Probiotics and atopic eczema: a double-blind randomised controlled trial","original-title":"","source":"Archives of Disease in Childhood","publication-date":"2012","volume":"97","issue":"Suppl 1","pages":"A2","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"23696193"},{"name":"DOI","value":"10.1136\/archdischild-2012-301885.5"}]}],"characteristics":[{"name":"Methods","value":"<p>Randomised, double-blind, placebo-controlled, parallel group trial.<\/p>"},{"name":"Participants","value":"<p><b>Inclusion criteria: <\/b>women 16 years or older with a normal singleton pregnancy. The intention was to recruit infants at high risk of developing atopy; however, sufficient details of atopy in first-degree relatives were often difficult to obtain at recruitment. Therefore, infants with and without increased risk of atopy were recruited.<\/p>\n<p><b>Exclusion criteria: <\/b>any known adverse condition affecting the woman, foetus, or the likely outcome of the pregnancy; if a member of the foetus’s sibship or household was already recruited to the study; or if the woman was unwilling to discontinue use of other live bacterial dietary supplements<\/p>"},{"name":"Interventions","value":"<p><b>Treatment (n = 220): <\/b>probiotic supplement Lactobacillus salivarius LS33 6.25x10<sup>9<\/sup> cfu, Lactobacillus paracasei CUL08 1.25x10<sup>9<\/sup> cfu, Bifidobacterium infantis Bi07 1.25x10<sup>9<\/sup> cfu and Bifidobacterium bifidum CUL20 1.25 x 10<sup>9<\/sup> cfu.&nbsp;<\/p>\n<p><br><b>Control (n = 234): <\/b>maltodextrin 100 mg.<br>\n Mother from 36 weeks' gestation until delivery. Infant from birth to 6 months.<br>\n Weeks (median (range)) exclusively breast-fed, treatment group (n = 167): 2 (0 – 8); control (n = 161): 3 (0 – 8).<\/p>\n<p>Both arms received 1 capsule daily from 36 weeks' gestation until delivery. Infants received the same capsules as their mother 1x daily from birth to age 6 months. Contents of the capsule were sprinkled directly into the infant's open mouth or mixed with expressed breast milk or formula feed.<\/p>"},{"name":"Outcomes","value":"<p><b>Primary outcomes<\/b>: the cumulative frequency of diagnosed eczema (assessed by the SCORAD system) at the 2-year follow up (reported by a parent to have been diagnosed by a clinician or assessed by a study clinician or trained research personnel). Changes to symptoms and adverse effects related to atopy.<\/p>\n<p><b>Other outcomes:<\/b> responses to SPTs, atopic eczema defined as eczema with 1 or more positive SPTs, eczema of any duration and whether or not diagnosed by health professional, severity of eczema, treatment with topical steroid preparations, respiratory symptoms with asthma and allergic rhinitis and reported food allergies.<\/p>\n<p><b>Definition:<\/b> eczema defined as an itchy rash affecting the face, scalp or extensor surfaces of the limbs in infants and flexures in older children and of duration ≥ 4 weeks and with ≥ 1 exacerbation by age 24 months.<\/p>"},{"name":"Notes","value":"<p><b>Sponsor:<\/b> knowledge exploitation fund, Collaborative Industrial Research Project number: HE 09 COL 1002, Welsh Assembly Government (UK)<\/p>\n<p><b>Declaration of interests: <\/b>SFP is a director of Cultech. IG reports grants from Cultect UK, during the conduct of the study. SJA reports a grant from Yakult UK outside the submitted work. The remaining authors declared that they have no competing interests.&nbsp;<\/p>"}],"covariates":[],"arms":[{"name":"No probiotics","description":"","intervention":"No probiotic"},{"name":"Probiotics","description":"","intervention":"Probiotic"}],"results":[{"outcome":"Allergic rhinitis by 2 years","arm-level-result":{"dichotomous-data-rows":[{"arm":"Probiotics","cases":10,"sample-size":190},{"arm":"No probiotics","cases":10,"sample-size":201}]}},{"outcome":"Asthma by 2 years","arm-level-result":{"dichotomous-data-rows":[{"arm":"Probiotics","cases":23,"sample-size":171},{"arm":"No probiotics","cases":20,"sample-size":179}],"risk-of-bias":[{"domain":"Bias due to deviations from intended interventions","judgement":"LOW_RISK","support-for-judgement":"<p>Placebo used. The placebo capsules containing maltodextrin were of identical appearance as the active product.<\/p><p>Strict blinding of research personnel. The databases were locked following data collection.<\/p>"},{"domain":"Bias due to missing outcome data","judgement":"LOW_RISK","support-for-judgement":"<p>~ 15% overall loss to follow up. Failure to participate include: lost contact with research team (288), not sufficiently interested or disliked tests (184), concern that trial was (quote:) \"too much to take on\" (129), unwillingness to take the investigation products (85), not prepared to be allocated to the placebo arm (21), developed a medical condition (16), language difficulties (10), not willing for this child to be treated differently from previous child (7), bereavement (2). Exclusions included pregnancy complications (110), presented after 36 weeks' gestation or at the end of the recruitment period and before 36 weeks' gestation (83), multiple pregnancy (14), contacted again after recruitment terminated (9), previous infant participated in trial (6), unwilling to stop current probiotic (1). Completed study at 2 years: probiotic group 187\/220 (85%); placebo group 191\/234 (82%).<\/p><p>Reasons for drop out were noted and not related to study intervention.&nbsp;<\/p>"},{"domain":"Bias in measurement of the outcome","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>Prespecified allergy outcomes. Specific definitions for allergy. Definition for respiratory symptoms with asthma and allergic rhinitis was not specified and included (quote:) \"whether or not diagnosed by a health professional\".<\/p><p>Parental report of a clinician's diagnosis of allergy (recall bias). Follow-up was often delayed; includes children seen up to, but not including, age 3 years.<\/p>"},{"domain":"Bias in selection of the reported result","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>No pre-specified analyses. ISRCTN26287422<\/p>"},{"domain":"Overall bias","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.<\/p>"}]}},{"outcome":"Eczema by 2 years","arm-level-result":{"dichotomous-data-rows":[{"arm":"Probiotics","cases":119,"sample-size":214},{"arm":"No probiotics","cases":132,"sample-size":226}],"risk-of-bias":[{"domain":"Bias due to deviations from intended interventions","judgement":"LOW_RISK","support-for-judgement":"<p>Placebo used. The placebo capsules containing maltodextrin were of identical appearance as the active product.<\/p><p>Strict blinding of research personnel. The databases were locked following data collection.<\/p>"},{"domain":"Bias due to missing outcome data","judgement":"LOW_RISK","support-for-judgement":"<p>~ 15% overall loss to follow up. Failure to participate include: lost contact with research team (288), not sufficiently interested or disliked tests (184), concern that trial was (quote:) \"too much to take on\" (129), unwillingness to take the investigation products (85), not prepared to be allocated to the placebo arm (21), developed a medical condition (16), language difficulties (10), not willing for this child to be treated differently from previous child (7), bereavement (2). Exclusions included pregnancy complications (110), presented after 36 weeks' gestation or at the end of the recruitment period and before 36 weeks' gestation (83), multiple pregnancy (14), contacted again after recruitment terminated (9), previous infant participated in trial (6), unwilling to stop current probiotic (1). Completed study at 2 years: probiotic group 187\/220 (85%); placebo group 191\/234 (82%).<\/p><p>Reasons for drop out were noted and not related to study intervention.&nbsp;<\/p>"},{"domain":"Bias in measurement of the outcome","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>Prespecified allergy outcomes. Specific definitions for allergy. Definition for respiratory symptoms with asthma and allergic rhinitis was not specified and included (quote:) \"whether or not diagnosed by a health professional\".<\/p><p>Parental report of a clinician's diagnosis of allergy (recall bias). Follow-up was often delayed; includes children seen up to, but not including, age 3 years.<\/p>"},{"domain":"Bias in selection of the reported result","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>No pre-specified analyses. ISRCTN26287422<\/p>"},{"domain":"Overall bias","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.<\/p>"}]}},{"outcome":"Food allergy by 2 years","arm-level-result":{"dichotomous-data-rows":[{"arm":"Probiotics","cases":22,"sample-size":200},{"arm":"No probiotics","cases":31,"sample-size":204}],"risk-of-bias":[{"domain":"Bias due to deviations from intended interventions","judgement":"LOW_RISK","support-for-judgement":"<p>Placebo used. The placebo capsules containing maltodextrin were of identical appearance as the active product.<\/p><p>Strict blinding of research personnel. The databases were locked following data collection.<\/p>"},{"domain":"Bias due to missing outcome data","judgement":"LOW_RISK","support-for-judgement":"<p>~ 15% overall loss to follow up. Failure to participate include: lost contact with research team (288), not sufficiently interested or disliked tests (184), concern that trial was (quote:) \"too much to take on\" (129), unwillingness to take the investigation products (85), not prepared to be allocated to the placebo arm (21), developed a medical condition (16), language difficulties (10), not willing for this child to be treated differently from previous child (7), bereavement (2). Exclusions included pregnancy complications (110), presented after 36 weeks' gestation or at the end of the recruitment period and before 36 weeks' gestation (83), multiple pregnancy (14), contacted again after recruitment terminated (9), previous infant participated in trial (6), unwilling to stop current probiotic (1). Completed study at 2 years: probiotic group 187\/220 (85%); placebo group 191\/234 (82%).<\/p><p>Reasons for drop out were noted and not related to study intervention.&nbsp;<\/p>"},{"domain":"Bias in measurement of the outcome","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>Prespecified allergy outcomes. Specific definitions for allergy. Definition for respiratory symptoms with asthma and allergic rhinitis was not specified and included (quote:) \"whether or not diagnosed by a health professional\".<\/p><p>Parental report of a clinician's diagnosis of allergy (recall bias). Follow-up was often delayed; includes children seen up to, but not including, age 3 years.<\/p>"},{"domain":"Bias in selection of the reported result","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>No pre-specified analyses. ISRCTN26287422<\/p>"},{"domain":"Overall bias","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.<\/p>"}]}}],"risk-of-bias":[{"domain":"Bias arising from the randomization process","judgement":"LOW_RISK","support-for-judgement":"<p>A computer-generated, random allocation sequence without blocks allocated the mother-infant dyad at 36 weeks of gestation to either the treatment or placebo arm of the study on a 1:1 basis.<\/p><p>The allocation sequence was generated by the independent statistician and was held in sealed, opaque envelopes at the trial site for emergency access but was not available to any member of the research team.<\/p><p>Research staff allocated dyads sequentially to the next number in the sequence.<\/p>"}]},{"name":"Kalliomaki 2001","year":"2001","data-source":"PUB","identifiers":[{"name":"CRS","value":"24344284"}],"references":[{"reference-type":"JOURNAL_ARTICLE","primary":true,"authors":"Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E","title":"Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial","original-title":"","source":"Lancet","publication-date":"2001","volume":"357","issue":"9262","pages":"1076-9","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"24344287"},{"name":"DOI","value":"10.1016\/S0140-6736(00)04259-8"},{"name":"PUBMED","value":"11297958"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Kalliomäki M, Isolauri E","title":"Role of intestinal flora in the development of allergy","original-title":"","source":"Current Opinion in Allergy and Clinical Immunology","publication-date":"2003","volume":"3","issue":"1","pages":"15-20","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"24344291"},{"name":"DOI","value":"10.1097\/00130832-200302000-00003"},{"name":"PUBMED","value":"12582309"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Luoto R, Kalliomaki M, Laitinen K, Isolauri E","title":"The impact of perinatal probiotic intervention on the development of overweight and obesity: follow-up study from birth to 10 years","original-title":"","source":"International Journal of Obesity : Journal of the International Association for the Study of Obesity","publication-date":"2010","volume":"34","issue":"10","pages":"1531-7","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"24344294"},{"name":"DOI","value":"10.1038\/ijo.2010.50"},{"name":"PUBMED","value":"20231842"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Kalliomaki M, Collado MC, Salminen S, Isolauri E","title":"Early differences in fecal microbiota composition in children may predict overweight","original-title":"","source":"American Journal of Clinical Nutrition","publication-date":"2008","volume":"87","issue":"3","pages":"534-8","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"24344286"},{"name":"DOI","value":"10.1093\/ajcn\/87.3.534"},{"name":"PUBMED","value":"18326589"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Laitinen K, Kalliomaki M, Poussa T, Lagstrom H, Isolauri E","title":"Evaluation of diet and growth in children with and without atopic eczema: follow-up study from birth to 4 years","original-title":"","source":"British Journal of Nutrition","publication-date":"2005","volume":"94","issue":"4","pages":"565-74","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"24344292"},{"name":"DOI","value":"10.1079\/bjn20051503"},{"name":"PUBMED","value":"16197582"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Rautava S, Kalliomaki M, Isolauri E","title":"Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant","original-title":"","source":"Journal of Allergy and Clinical Immunology","publication-date":"2002","volume":"109","issue":"1","pages":"119-21","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"24344295"},{"name":"PUBMED","value":"11799376"},{"name":"DOI","value":"10.1067\/mai.2002.120273"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Rinne M, Kalliomaki M, Arvilommi H, Salminen S, Isolauri E","title":"Effect of probiotics and breastfeeding on the bifidobacterium and lactobacillus\/enterococcus microbiota and humoral immune responses","original-title":"","source":"Journal of Pediatrics","publication-date":"2005","volume":"147","issue":"2","pages":"186-91","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"24344296"},{"name":"DOI","value":"10.1016\/j.jpeds.2005.03.053"},{"name":"PUBMED","value":"16126047"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Rinne M, Kalliomaki M, Salminen S, Isolauri E","title":"Probiotic intervention in the first months of life: short-term effects on gastrointestinal symptoms and long-term effects on gut microbiota","original-title":"","source":"Journal of Pediatric Gastroenterology and Nutrition","publication-date":"2006","volume":"43","issue":"2","pages":"200-5","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"24344297"},{"name":"DOI","value":"10.1097\/01.mpg.0000228106.91240.5b"},{"name":"PUBMED","value":"16877985"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Kalliomaki M, Salminen S, Arvilommi H","title":"Prenatal and postnatal administration of Lactobacillus GG reduced the occurence of atopic disease in offspring","original-title":"","source":"BMJ Evidence-Based Medicine","publication-date":"2001","volume":"6","issue":"6","pages":"178","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"24344288"},{"name":"DOI","value":"10.1136\/ebm.6.6.178"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Luoto R, Kalliomaki M, Laitinen K, Delzenne NM, Cani PD, Salminen S, et al","title":"Initial dietary and microbiological environments deviate in normal-weight compared to overweight children at 10 years of age","original-title":"","source":"Journal of Pediatric Gastroenterology and Nutrition","publication-date":"2011","volume":"52","issue":"1","pages":"90-5","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"24344293"},{"name":"DOI","value":"10.1097\/MPG.0b013e3181f3457f"},{"name":"PUBMED","value":"21150648"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Kalliomaki M, Salminen S, Poussa T, Isolauri E","title":"Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial","original-title":"","source":"Journal of Allergy and Clinical Immunology","publication-date":"2007","volume":"119","issue":"4","pages":"1019-21","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"24344290"},{"name":"PUBMED","value":"17289135"},{"name":"DOI","value":"10.1016\/j.jaci.2006.12.608"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Kalliomaki M, Salminen S, Poussa T, Arvilommi H, Isolauri E","title":"Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial","original-title":"","source":"Lancet","publication-date":"2003","volume":"361","issue":"9372","pages":"1869-71","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"24344289"},{"name":"DOI","value":"10.1016\/S0140-6736(03)13490-3Abstract"},{"name":"PUBMED","value":"12788576"}]},{"reference-type":"JOURNAL_ARTICLE","primary":false,"authors":"Gueimonde M, Kalliomaki M, Isolauri E, Salminen S","title":"Probiotic intervention in neonates – will permanent colonization ensue?","original-title":"","source":"Journal of Pediatric Gastroenterology and Nutrition","publication-date":"2006","volume":"42","issue":"5","pages":"604-6","edition":"","editors":"","publisher":"","city":"","medium":"","identifiers":[{"name":"CRS","value":"24344285"},{"name":"DOI","value":"10.1097\/01.mpg.0000221897.45910.d3"},{"name":"PUBMED","value":"16707993"}]}],"characteristics":[{"name":"Notes","value":"<p><b>Sponsor: <\/b>Finnish Foundation for Paediatric Research, the National Technology Agency of Finland, and the Allergy Research Foundation in Finland. 2023 update:&nbsp; Additional publications; addition of 4-year and 7-year follow-up data on allergic disease. Allergic disease persisted up to the age of 4 years included in analysis under childhood incidence. Skin prick test reactivity and allergic disease at 7-years of age included in analysis under childhood prevalence.<\/p>\n<p><b>Declaration of interests:<\/b> not reported.<\/p>"},{"name":"Outcomes","value":"<p><b>Primary outcomes:<\/b> atopic disease at 2 and 4 years.<\/p>\n<p><b>Other outcomes:<\/b> blinded physician assessment for atopy.<\/p>\n<p><b>Definitions: <\/b>eczema: pruritis, facial or extensor involvement, or both, and chronic relapsing course (for 1 month or longer at the 24-month visit and on at least 1 &nbsp;previous visit. The SCORAD index used to assess eczema severity.&nbsp;<br>\n Allergic rhinitis: most days 2 or more of: nasal discharge, blockage, sneezing, and itching.<br>\n Asthma: based on an algorithm created by an international paediatric asthma consensus group. Diagnosed if infant had chronic or recurrent cough, wheeze or shortness of breath, or both, suggestive of asthma, and if other diagnoses were excluded and trial antiasthma treatment was effective.<br>\n Sensitisation measured by: skin-prick tests at 6, 12, and 24 months; and total and specific IgE assays on cord blood and at 3, 12, and 24 months.<\/p>\n<p>4 years reported prevalence of eczema, asthma, allergic rhinitis (DBPCFC).<\/p>\n<p>7 years reported cumulative incidence of eczema and prevalence of allergic rhinitis and asthma. Cumulative incidence eczema calculated from percentages reported.<\/p>"},{"name":"Interventions","value":"<p><b>Treatment (n = 77): <\/b>Lactobacillus rhamnosus GG 1 x 10<sup>10<\/sup> cfu prenatally to mothers and postnatally whilst breastfeeding up to 6 months; if not breast-fed given to infants mixed with water on spoon.<\/p>\n<p><br><b>Control (n = 82): <\/b>placebo (microcrystalline cellulose).<\/p>\n<p>Mean time exclusive and total time of breastfeeding children given placebo 2 to 7 months and 6·4 months, respectively, and those on Lactobacillus GG 3·0 months and 7·2 months, respectively.<\/p>"},{"name":"Participants","value":"<p><b>Inclusion criteria: <\/b>family history of atopic disease: ≥ 1 family member (mother, father, or older sibling) with atopic eczema, allergic rhinitis, or asthma. Families were recruited in antenatal clinics.<br><b>Exclusion criteria:<\/b> none reported.<\/p>"},{"name":"Methods","value":"<p>Randomised, double-blind, placebo-controlled trial.<\/p>"}],"covariates":[],"arms":[{"name":"No probiotics","description":"","intervention":"No probiotic"},{"name":"Probiotics","description":"","intervention":"Probiotic"}],"results":[{"outcome":"Eczema by 2 years","arm-level-result":{"dichotomous-data-rows":[{"arm":"Probiotics","cases":15,"sample-size":64},{"arm":"No probiotics","cases":31,"sample-size":68}],"risk-of-bias":[{"domain":"Bias due to deviations from intended interventions","judgement":"LOW_RISK","support-for-judgement":"<p>Placebo used. Lactobacillus GG and placebo capsules and contents looked, smelled, and tasted identical.<\/p><p>Quote: \"The physician who did the physical examinations, diagnoses of atopic disease, and antiasthma treatments was unaware of the contents of the capsules\".<\/p>"},{"domain":"Bias due to missing outcome data","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>Losses to follow up: 27\/159 (17%) lost; at 2 years, probiotic group n = 64, placebo group n = 68. Losses at 1 year reported to be due to non-compliance. 107\/159 (67%), 33% loss to follow up completed follow up at 4 years. Followed up at 7 years: 116\/159 (73%); probiotic group n = 53, placebo group n = 62. Does not report whether dropouts were related to specific outcomes nor the reason for missing data.<\/p>"},{"domain":"Bias in measurement of the outcome","judgement":"LOW_RISK","support-for-judgement":"<p>Reported primary outcome measure was atopic disease at 2 years. Specific definitions for allergy reported. Reporting of outcomes at multiple time points. Primary outcomes were measured using validated methods.&nbsp;<\/p>"},{"domain":"Bias in selection of the reported result","judgement":"LOW_RISK","support-for-judgement":"<p>Pre-planned analyses provided, although no specification of whether there were any deviations from the planned analysis. NCT06035835.<\/p>"},{"domain":"Overall bias","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.<\/p>"}]}}],"risk-of-bias":[{"domain":"Bias arising from the randomization process","judgement":"UNCLEAR_RISK","support-for-judgement":"<p>Computer-generated, random assignment. Details of allocation concealment are not specified.<\/p><p>Potentially clinically significant although not statistically significant differences between groups after randomisation (placebo compared with probiotic): Parental smoking 21% compared with 12%; Furry pet at home 11% compared with 21%; boys 52% compared with 64%; Cord blood IgE &gt; 0.5 kU\/L 30% compared with 40%. Groups were otherwise well balanced.<\/p>"}]}]}